Control	O
of	O
cell	O
cycle	O
entry	O
and	O
apoptosis	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
infected	O
by	O
Epstein-Barr	O
virus	O
.	O

Infection	O
of	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
with	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
results	O
in	O
activation	O
of	O
the	O
cell	O
cycle	O
and	O
cell	O
growth	O
.	O

To	O
interpret	O
the	O
mechanisms	O
by	O
which	O
EBV	O
activates	O
the	O
cell	O
,	O
we	O
have	O
assayed	O
many	O
proteins	O
involved	O
in	O
control	O
of	O
the	O
G0	O
and	O
G1	O
phases	O
of	O
the	O
cell	O
cycle	O
and	O
regulation	O
of	O
apoptosis	O
.	O

In	O
EBV	O
infection	O
most	O
of	O
the	O
changes	O
,	O
including	O
the	O
early	O
induction	O
of	O
cyclin	B-protein
D2	I-protein
,	O
are	O
dependent	O
on	O
expression	O
of	O
EBV	B-DNA
genes	I-DNA
,	O
but	O
an	O
alteration	O
in	O
the	O
E2F-4	B-protein
profile	O
was	O
partly	O
independent	O
of	O
viral	O
gene	O
expression	O
,	O
presumably	O
occurring	O
in	O
response	O
to	O
signal	O
transduction	O
activated	O
when	O
the	O
virus	O
binds	O
to	O
its	O
receptor	O
,	O
CD21	B-protein
.	O

By	O
comparing	O
the	O
expression	O
of	O
genes	O
controlling	O
apoptosis	O
,	O
including	O
those	O
encoding	O
several	O
members	O
of	O
the	O
BCL-2	B-protein
family	I-protein
of	O
proteins	O
,	O
the	O
known	O
relative	O
resistance	O
of	O
EBV-immortalized	B-cell_line
B-cell	I-cell_line
lines	I-cell_line
to	O
apoptosis	O
induced	O
by	O
low	O
serum	O
was	O
found	O
to	O
correlate	O
with	O
expression	O
of	O
both	O
BCL-2	B-protein
and	O
A20	B-protein
.	O

A20	O
can	O
be	O
regulated	O
by	O
the	O
NF-kappaB	B-protein
transcription	B-protein
factor	I-protein
,	O
which	O
is	O
known	O
to	O
be	O
activated	O
by	O
the	O
EBV	B-protein
LMP-1	I-protein
protein	I-protein
.	O

Quantitative	O
assays	O
demonstrated	O
a	O
direct	O
temporal	O
relationship	O
between	O
LMP-1	B-protein
protein	I-protein
levels	O
and	O
active	O
NF-kappaB	B-protein
during	O
the	O
time	O
course	O
of	O
infection	O
.	O

JOURNAL	NULL
or	NULL
ViRoLOGY	NULL
,	NULL
June	NULL
1999	NULL
,	NULL
p.	NULL
4678-4688	NULL
0022-538	NULL
X/99/	NULL
$	NULL
04.00+0	NULL
Vol	NULL
.	NULL

73	NULL
,	NULL
No	NULL
.	NULL

6	NULL
Copyright	NULL
©	NULL
1999	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
.	NULL

All	NULL
Rights	NULL
Reserved	NULL
.	NULL

Control	NULL
of	NULL
Cell	NULL
Cycle	NULL
Entry	NULL
and	NULL
Apoptosis	NULL
in	NULL
B	NULL
Lymphocytes	NULL
Infected	NULL
by	NULL
Epstein-Barr	NULL
Virus	NULL
LINDSAY	NULL
C.	NULL
SPENDER	NULL
,	NULL
``	NULL
EMMA	NULL
J.	NULL
CANNELL	NULL
,	NULL
'¢	NULL
MARTINE	NULL
HOLLYOAKE	NULL
,	NULL
``	NULL
'	NULL
BARBARA	NULL
WENSING	NULL
,	NULL
!	NULL

JONATHAN	NULL
M.	NULL
GAWN	NULL
,	NULL
'	NULL
MATTHEW	NULL
BRIMMELL	NULL
,	NULL
'	NULL
GRAHAM	NULL
PACKHAM	NULL
,	NULL
**	NULL
AND	NULL
PAUL	NULL
J.	NULL
FARRELL®**	NULL
Ludwig	NULL
Institute	NULL
for	NULL
Cancer	NULL
Research	NULL
and	NULL
Virology	NULL
and	NULL
Cell	NULL
Biology	NULL
Section	NULL
,	NULL
``	NULL
Imperial	NULL
College	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
St.	NULL
Mary	NULL
's	NULL
Campus	NULL
,	NULL
London	NULL
W2	NULL
1PG	NULL
,	NULL
United	NULL
Kingdom	NULL
Received	NULL
23	NULL
October	NULL
1998/Accepted	NULL
23	NULL
February	NULL
1999	NULL
Infection	NULL
of	NULL
human	NULL
B	NULL
cells	NULL
with	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
results	NULL
in	NULL
activation	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
and	NULL
cell	NULL
growth	NULL
.	NULL

To	NULL
interpret	NULL
the	NULL
mechanisms	NULL
by	NULL
which	NULL
EBV	NULL
activates	NULL
the	NULL
cell	NULL
,	NULL
we	NULL
have	NULL
assayed	NULL
many	NULL
proteins	NULL
involved	NULL
in	NULL
control	NULL
of	NULL
the	NULL
G	NULL
,	NULL
and	NULL
G	NULL
,	NULL
phases	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
and	NULL
regulation	NULL
of	NULL
apoptosis	NULL
.	NULL

In	NULL
EBV	NULL
infection	NULL
most	NULL
of	NULL
the	NULL
changes	NULL
,	NULL
including	NULL
the	NULL
early	NULL
induction	NULL
of	NULL
cyclin	NULL
D2	NULL
,	NULL
are	NULL
dependent	NULL
on	NULL
expression	NULL
of	NULL
EBV	NULL
genes	NULL
,	NULL
but	NULL
an	NULL
alteration	NULL
in	NULL
the	NULL
E2F-4	NULL
profile	NULL
was	NULL
partly	NULL
independent	NULL
of	NULL
viral	NULL
gene	NULL
expression	NULL
,	NULL
presumably	NULL
occurring	NULL
in	NULL
response	NULL
to	NULL
signal	NULL
transduction	NULL
activated	NULL
when	NULL
the	NULL
virus	NULL
binds	NULL
to	NULL
its	NULL
receptor	NULL
,	NULL
CD21	NULL
.	NULL

By	NULL
comparing	NULL
the	NULL
expression	NULL
of	NULL
genes	NULL
controlling	NULL
apoptosis	NULL
,	NULL
including	NULL
those	NULL
encoding	NULL
several	NULL
members	NULL
of	NULL
the	NULL
BCL-2	NULL
family	NULL
of	NULL
proteins	NULL
,	NULL
the	NULL
known	NULL
relative	NULL
resistance	NULL
of	NULL
EBV-immortalized	NULL
B-cell	NULL
lines	NULL
to	NULL
apoptosis	NULL
induced	NULL
by	NULL
low	NULL
serum	NULL
was	NULL
found	NULL
to	NULL
correlate	NULL
with	NULL
expression	NULL
of	NULL
both	NULL
BCL-2	NULL
and	NULL
A20	NULL
.	NULL

A20	NULL
can	NULL
be	NULL
regulated	NULL
by	NULL
the	NULL
NF-KB	NULL
transcription	NULL
factor	NULL
,	NULL
which	NULL
is	NULL
known	NULL
to	NULL
be	NULL
activated	NULL
by	NULL
the	NULL
EBV	NULL
LMP-1	NULL
protein	NULL
.	NULL

Quantitative	NULL
assays	NULL
demonstrated	NULL
a	NULL
direct	NULL
temporal	NULL
relationship	NULL
between	NULL
LMP-1	NULL
protein	NULL
levels	NULL
and	NULL
active	NULL
NF-B	NULL
during	NULL
the	NULL
time	NULL
course	NULL
of	NULL
infection	NULL
.	NULL

When	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
infects	NULL
resting	NULL
human	NULL
B	NULL
lymphocytes	NULL
,	NULL
it	NULL
drives	NULL
the	NULL
cells	NULL
into	NULL
the	NULL
cell	NULL
cycle	NULL
and	NULL
maintains	NULL
cell	NULL
division	NULL
.	NULL

The	NULL
lymphoblastoid	NULL
cell	NULL
lines	NULL
(	NULL
LCLs	NULL
)	NULL
that	NULL
arise	NULL
from	NULL
this	NULL
type	NULL
of	NULL
EBV	NULL
infection	NULL
are	NULL
relatively	NULL
resistant	NULL
to	NULL
apoptosis	NULL
caused	NULL
by	NULL
deprivation	NULL
of	NULL
serum	NULL
growth	NULL
factors	NULL
.	NULL

Cells	NULL
of	NULL
this	NULL
LCL	NULL
type	NULL
are	NULL
produced	NULL
in	NULL
vivo	NULL
upon	NULL
primary	NULL
infection	NULL
of	NULL
humans	NULL
but	NULL
are	NULL
then	NULL
eliminated	NULL
by	NULL
the	NULL
immune	NULL
response	NULL
,	NULL
asymptomatically	NULL
in	NULL
infants	NULL
but	NULL
in	NULL
adults	NULL
in	NULL
the	NULL
course	NULL
of	NULL
the	NULL
disease	NULL
known	NULL
as	NULL
infectious	NULL
mononucleosis	NULL
.	NULL

In	NULL
the	NULL
absence	NULL
of	NULL
normal	NULL
immune	NULL
surveillance	NULL
,	NULL
cells	NULL
of	NULL
the	NULL
LCL	NULL
type	NULL
can	NULL
develop	NULL
into	NULL
lymphomas	NULL
(	NULL
reviewed	NULL
in	NULL
reference	NULL
61	NULL
)	NULL
.	NULL

Genetic	NULL
analysis	NULL
of	NULL
EBV	NULL
has	NULL
demonstrated	NULL
several	NULL
viral	NULL
genes	NULL
that	NULL
are	NULL
required	NULL
for	NULL
initiation	NULL
and	NULL
maintenance	NULL
of	NULL
growth	NULL
.	NULL

These	NULL
include	NULL
the	NULL
genes	NULL
that	NULL
encode	NULL
the	NULL
nuclear	NULL
proteins	NULL
EBNA-1	NULL
,	NULL
EBNA-2	NULL
,	NULL
EBNA-LP	NULL
,	NULL
EBNA-3A	NULL
,	NULL
and	NULL
EBNA-3C	NULL
and	NULL
the	NULL
plasma	NULL
membrane	NULL
protein	NULL
LMP	NULL
-1	NULL
(	NULL
reviewed	NULL
in	NULL
references	NULL
22	NULL
and	NULL
23	NULL
)	NULL
.	NULL

Some	NULL
of	NULL
the	NULL
biochemical	NULL
functions	NULL
of	NULL
these	NULL
proteins	NULL
are	NULL
now	NULL
becoming	NULL
clear	NULL
.	NULL

EBNA-1	NULL
is	NULL
required	NULL
for	NULL
EBV	NULL
plasmid	NULL
maintenance	NULL
,	NULL
EBNA-2	NULL
causes	NULL
transcription	NULL
activation	NULL
through	NULL
several	NULL
interactions	NULL
(	NULL
including	NULL
the	NULL
Notch	NULL
pathway	NULL
)	NULL
,	NULL
and	NULL
EBNA-LP	NULL
is	NULL
able	NULL
to	NULL
cooperate	NULL
with	NULL
EBNA-2	NULL
in	NULL
regulation	NULL
of	NULL
some	NULL
genes	NULL
.	NULL

EBNA-3C	NULL
causes	NULL
cells	NULL
to	NULL
progress	NULL
through	NULL
cell	NULL
cycle	NULL
check	NULL
points	NULL
in	NULL
both	NULL
G	NULL
,	NULL
and	NULL
G	NULL
;	NULL
,	NULL
/M	NULL
by	NULL
an	NULL
unknown	NULL
mechanism	NULL
,	NULL
and	NULL
the	NULL
partly	NULL
related	NULL
EBNA-3A	NULL
protein	NULL
has	NULL
effects	NULL
on	NULL
gene	NULL
regulation	NULL
(	NULL
15	NULL
)	NULL
.	NULL

The	NULL
LMP-1	NULL
protein	NULL
activates	NULL
signalling	NULL
through	NULL
several	NULL
transduction	NULL
pathways	NULL
,	NULL
including	NULL
TRAF-	NULL
and	NULL
TRADD-mediated	NULL
activation	NULL
of	NULL
NF-kB	NULL
(	NULL
10	NULL
,	NULL
19	NULL
,	NULL
30	NULL
,	NULL
47	NULL
,	NULL
64	NULL
)	NULL
and	NULL
activation	NULL
of	NULL
SAP/JNK1	NULL
kinase	NULL
,	NULL
leading	NULL
to	NULL
c-Jun	NULL
phosphorylation	NULL
(	NULL
20	NULL
,	NULL
34	NULL
)	NULL
.	NULL

The	NULL
EBV	NULL
immortalization	NULL
genes	NULL
are	NULL
not	NULL
all	NULL
expressed	NULL
simultaneously	NULL
upon	NULL
infection	NULL
;	NULL
EBNA-LP	NULL
and	NULL
EBNA-2	NULL
are	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
Ludwig	NULL
Institute	NULL
for	NULL
Cancer	NULL
Research	NULL
,	NULL
Imperial	NULL
College	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
St.	NULL
Mary	NULL
's	NULL
Campus	NULL
,	NULL
Norfolk	NULL
Place	NULL
,	NULL
London	NULL
W2	NULL
1PG	NULL
,	NULL
United	NULL
Kingdom	NULL
.	NULL

Phone	NULL
:	NULL
44	NULL
171	NULL
724	NULL
5522	NULL
.	NULL

Fax	NULL
:	NULL
44	NULL
171	NULL
724	NULL
8586	NULL
.	NULL

E-mail	NULL
:	NULL
pfarrell	NULL
@	NULL
ic.ac.uk	NULL
.	NULL

¢	NULL
Present	NULL
address	NULL
:	NULL
Institute	NULL
for	NULL
Cancer	NULL
Research	NULL
,	NULL
Chester	NULL
Beatty	NULL
Laboratories	NULL
,	NULL
London	NULL
SW3	NULL
6JB	NULL
,	NULL
United	NULL
Kingdom	NULL
.	NULL

4678	NULL
the	NULL
first	NULL
to	NULL
be	NULL
expressed	NULL
,	NULL
followed	NULL
by	NULL
the	NULL
remaining	NULL
EBNA	NULL
proteins	NULL
and	NULL
then	NULL
LMP	NULL
We	NULL
have	NULL
studied	NULL
the	NULL
mechanism	NULL
by	NULL
which	NULL
the	NULL
resting	NULL
B	NULL
cells	NULL
which	NULL
EBV	NULL
infects	NULL
are	NULL
driven	NULL
into	NULL
the	NULL
cell	NULL
cycle	NULL
and	NULL
the	NULL
expression	NULL
of	NULL
genes	NULL
that	NULL
may	NULL
control	NULL
apoptosis	NULL
during	NULL
the	NULL
infection	NULL
of	NULL
B	NULL
cells	NULL
We	NULL
and	NULL
others	NULL
have	NULL
shown	NULL
previously	NULL
that	NULL
binding	NULL
of	NULL
the	NULL
virus	NULL
to	NULL
its	NULL
receptor	NULL
on	NULL
the	NULL
B-cell	NULL
surface	NULL
(	NULL
CD21	NULL
)	NULL
not	NULL
only	NULL
mediates	NULL
uptake	NULL
of	NULL
the	NULL
virus	NULL
but	NULL
also	NULL
results	NULL
in	NULL
signal	NULL
transduction	NULL
(	NULL
71	NULL
,	NULL
72	NULL
)	NULL
,	NULL
which	NULL
preactivates	NULL
the	NULL
cell	NULL
,	NULL
enabling	NULL
expression	NULL
of	NULL
transfected	NULL
genes	NULL
and	NULL
giving	NULL
an	NULL
early	NULL
transient	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
75	NULL
)	NULL
.	NULL

In	NULL
B	NULL
cells	NULL
preactivated	NULL
by	NULL
exposure	NULL
to	NULL
purified	NULL
gp340	NULL
(	NULL
a	NULL
form	NULL
of	NULL
the	NULL
EBV	NULL
surface	NULL
glycoprotein	NULL
which	NULL
mediates	NULL
virus	NULL
binding	NULL
to	NULL
CD21	NULL
)	NULL
,	NULL
we	NULL
showed	NULL
that	NULL
transfection	NULL
of	NULL
the	NULL
first	NULL
two	NULL
viral	NULL
genes	NULL
known	NULL
to	NULL
be	NULL
expressed	NULL
during	NULL
infection	NULL
(	NULL
EBNA-LP	NULL
and	NULL
EBNA-2	NULL
)	NULL
resulted	NULL
in	NULL
induction	NULL
of	NULL
the	NULL
RNA	NULL
encoding	NULL
an	NULL
early	NULL
marker	NULL
of	NULL
cell	NULL
cycle	NULL
entry	NULL
,	NULL
cyclin	NULL
D2	NULL
(	NULL
72	NULL
)	NULL
.	NULL

Cyclin-dependent	NULL
kinases	NULL
(	NULL
ecdks	NULL
)	NULL
control	NULL
cell	NULL
cycle	NULL
progression	NULL
partly	NULL
through	NULL
the	NULL
E2F	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
and	NULL
the	NULL
pocket	NULL
proteins	NULL
,	NULL
Rb	NULL
,	NULL
p107	NULL
,	NULL
and	NULL
p130	NULL
,	NULL
that	NULL
can	NULL
bind	NULL
the	NULL
various	NULL
E2F	NULL
complexes	NULL
(	NULL
65	NULL
)	NULL
.	NULL

Here	NULL
we	NULL
study	NULL
the	NULL
expression	NULL
of	NULL
these	NULL
proteins	NULL
during	NULL
the	NULL
time	NULL
course	NULL
of	NULL
EBV	NULL
infection	NULL
,	NULL
when	NULL
EBV	NULL
drives	NULL
the	NULL
cells	NULL
into	NULL
cycle	NULL
,	NULL
and	NULL
describe	NULL
modifications	NULL
to	NULL
the	NULL
E2F	NULL
profile	NULL
that	NULL
are	NULL
dependent	NULL
upon	NULL
virus	NULL
infection	NULL
,	NULL
some	NULL
of	NULL
which	NULL
require	NULL
viral	NULL
protein	NULL
synthesis	NULL
.	NULL

Current	NULL
models	NULL
for	NULL
entry	NULL
of	NULL
resting	NULL
cells	NULL
into	NULL
the	NULL
cell	NULL
cycle	NULL
in	NULL
response	NULL
to	NULL
serum	NULL
stimulation	NULL
imply	NULL
a	NULL
key	NULL
early	NULL
role	NULL
for	NULL
E2F4	NULL
and	NULL
p130	NULL
proteins	NULL
in	NULL
governing	NULL
the	NULL
G	NULL
,	NULL
-to-G	NULL
,	NULL
transition	NULL
(	NULL
45	NULL
,	NULL
73	NULL
,	NULL
78	NULL
)	NULL
;	NULL
it	NULL
has	NULL
so	NULL
far	NULL
been	NULL
unclear	NULL
whether	NULL
activation	NULL
of	NULL
the	NULL
cells	NULL
by	NULL
EBNA-LP	NULL
and	NULL
EBNA-2	NULL
is	NULL
mediated	NULL
through	NULL
a	NULL
direct	NULL
effect	NULL
on	NULL
E2F-pocket	NULL
protein	NULL
complexes	NULL
or	NULL
through	NULL
activation	NULL
of	NULL
cyclin	NULL
expression	NULL
.	NULL

Here	NULL
we	NULL
show	NULL
that	NULL
the	NULL
timing	NULL
of	NULL
changes	NULL
we	NULL
have	NULL
detected	NULL
in	NULL
E2F	NULL
and	NULL
pocket	NULL
proteins	NULL
and	NULL
the	NULL
induction	NULL
of	NULL
cyclin	NULL
D2	NULL
protein	NULL
upon	NULL
EBV	NULL
infection	NULL
are	NULL
consistent	NULL
with	NULL
a	NULL
cyclin	NULL
D2-cdk	NULL
complex	NULL
mediating	NULL
activation	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

Once	NULL
the	NULL
cells	NULL
are	NULL
established	NULL
in	NULL
cycle	NULL
,	NULL
the	NULL
EBNA-2	NULL
,	NULL
EBNA-3C	NULL
,	NULL
and	NULL
LMP-1	NULL
proteins	NULL
are	NULL
thought	NULL
to	NULL
control	NULL
cell	NULL
growth	NULL
(	NULL
32	NULL
,	NULL
35	NULL
,	NULL
56	NULL
)	NULL
.	NULL

Prevention	NULL
of	NULL
apoptosis	NULL
is	NULL
now	NULL
recognized	NULL
to	NULL
be	NULL
as	NULL
important	NULL
as	NULL
proliferation	NULL
in	NULL
determining	NULL
the	NULL
overall	NULL
increase	NULL
in	NULL
cell	NULL
num-	NULL
voL	NULL
.	NULL

73	NULL
,	NULL
1999	NULL
ber	NULL
in	NULL
various	NULL
cell	NULL
types	NULL
.	NULL

In	NULL
certain	NULL
circumstances	NULL
B	NULL
lymphocytes	NULL
are	NULL
particularly	NULL
prone	NULL
to	NULL
apoptosis	NULL
,	NULL
which	NULL
is	NULL
the	NULL
main	NULL
mechanism	NULL
by	NULL
which	NULL
cells	NULL
bearing	NULL
self-reactive	NULL
and	NULL
low-affinity	NULL
immunoglobulins	NULL
are	NULL
eliminated	NULL
,	NULL
particularly	NULL
through	NULL
Fas-mediated	NULL
apoptosis	NULL
(	NULL
3	NULL
)	NULL
.	NULL

EBV-immortalized	NULL
B	NULL
cells	NULL
are	NULL
relatively	NULL
resistant	NULL
to	NULL
apoptosis	NULL
induced	NULL
by	NULL
low	NULL
serum	NULL
.	NULL

Resting	NULL
B	NULL
cells	NULL
contain	NULL
relatively	NULL
high	NULL
levels	NULL
of	NULL
BCL-2	NULL
protein	NULL
,	NULL
similar	NULL
to	NULL
LCL	NULL
cells	NULL
,	NULL
and	NULL
BCL-2	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
protect	NULL
B	NULL
cells	NULL
against	NULL
apoptosis	NULL
.	NULL

BCL-2	NULL
expression	NULL
can	NULL
also	NULL
be	NULL
induced	NULL
by	NULL
the	NULL
EBV	NULL
LMP	NULL
-1	NULL
protein	NULL
(	NULL
28	NULL
)	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
BCL-2	NULL
is	NULL
merely	NULL
the	NULL
prototypical	NULL
member	NULL
of	NULL
a	NULL
family	NULL
of	NULL
related	NULL
proteins	NULL
which	NULL
are	NULL
key	NULL
regulators	NULL
of	NULL
apoptosis	NULL
(	NULL
16	NULL
,	NULL
17	NULL
,	NULL
48	NULL
,	NULL
58	NULL
,	NULL
59	NULL
,	NULL
83	NULL
)	NULL
.	NULL

The	NULL
family	NULL
also	NULL
includes	NULL
BCL-X	NULL
;	NULL
,	NULL
,	NULL
and	NULL
MCL-1	NULL
(	NULL
which	NULL
,	NULL
like	NULL
BCL-2	NULL
,	NULL
suppress	NULL
apoptosis	NULL
)	NULL
and	NULL
BAX	NULL
,	NULL
BAD	NULL
,	NULL
and	NULL
BAK	NULL
,	NULL
which	NULL
promote	NULL
cell	NULL
death	NULL
(	NULL
7	NULL
,	NULL
13	NULL
,	NULL
24	NULL
,	NULL
33	NULL
,	NULL
49	NULL
,	NULL
60	NULL
,	NULL
84	NULL
)	NULL
.	NULL

These	NULL
proteins	NULL
form	NULL
various	NULL
heterodimers	NULL
and	NULL
homodimers	NULL
,	NULL
and	NULL
it	NULL
is	NULL
likely	NULL
that	NULL
the	NULL
interactions	NULL
among	NULL
them	NULL
are	NULL
critical	NULL
to	NULL
BCL-2	NULL
family	NULL
functions	NULL
(	NULL
58	NULL
,	NULL
67	NULL
,	NULL
68	NULL
)	NULL
.	NULL

BAX	NULL
is	NULL
central	NULL
to	NULL
the	NULL
BCL-2	NULL
family	NULL
of	NULL
proteins	NULL
,	NULL
since	NULL
it	NULL
interacts	NULL
with	NULL
several	NULL
antiapoptotic	NULL
family	NULL
members	NULL
,	NULL
including	NULL
BCL-2	NULL
,	NULL
BCL-X	NULL
;	NULL
,	NULL
and	NULL
MCL-1	NULL
.	NULL

The	NULL
BCL-2	NULL
homology	NULL
(	NULL
BH	NULL
)	NULL
domains	NULL
1	NULL
and	NULL
2	NULL
define	NULL
the	NULL
family	NULL
,	NULL
and	NULL
BHI1	NULL
and	NULL
BH2	NULL
of	NULL
BCL-2	NULL
are	NULL
required	NULL
for	NULL
interaction	NULL
with	NULL
BAX	NULL
and	NULL
for	NULL
suppression	NULL
of	NULL
apoptosis	NULL
(	NULL
85	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
BAX	NULL
BH3	NULL
domain	NULL
is	NULL
required	NULL
for	NULL
association	NULL
with	NULL
BCL-2	NULL
and	NULL
promotion	NULL
of	NULL
apoptosis	NULL
(	NULL
86	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
dimerization	NULL
,	NULL
further	NULL
complexity	NULL
is	NULL
present	NULL
,	NULL
since	NULL
multiple	NULL
isoforms	NULL
of	NULL
some	NULL
family	NULL
members	NULL
are	NULL
generated	NULL
via	NULL
alternate	NULL
splicing	NULL
,	NULL
and	NULL
these	NULL
may	NULL
be	NULL
functionally	NULL
distinct	NULL
.	NULL

For	NULL
example	NULL
,	NULL
the	NULL
alternate	NULL
BCL-X	NULL
form	NULL
,	NULL
lacks	NULL
BHI1	NULL
and	NULL
BH2	NULL
and	NULL
promotes	NULL
apoptosis	NULL
(	NULL
7	NULL
)	NULL
.	NULL

The	NULL
balance	NULL
of	NULL
the	NULL
levels	NULL
of	NULL
these	NULL
various	NULL
proteins	NULL
,	NULL
rather	NULL
than	NULL
the	NULL
simple	NULL
expression	NULL
of	NULL
BCL-2	NULL
,	NULL
is	NULL
a	NULL
key	NULL
aspect	NULL
of	NULL
the	NULL
regulation	NULL
of	NULL
apoptosis	NULL
,	NULL
but	NULL
there	NULL
is	NULL
little	NULL
knowledge	NULL
of	NULL
their	NULL
levels	NULL
in	NULL
EBV-immortalized	NULL
B	NULL
cells	NULL
and	NULL
their	NULL
relative	NULL
importance	NULL
.	NULL

A	NULL
further	NULL
regulator	NULL
of	NULL
apoptosis	NULL
present	NULL
in	NULL
LCLs	NULL
is	NULL
the	NULL
A20	NULL
protein	NULL
.	NULL

A20	NULL
is	NULL
a	NULL
ring	NULL
finger	NULL
protein	NULL
which	NULL
suppresses	NULL
apoptosis	NULL
and	NULL
can	NULL
be	NULL
induced	NULL
by	NULL
LMP	NULL
(	NULL
26	NULL
,	NULL
39	NULL
,	NULL
50	NULL
,	NULL
51	NULL
,	NULL
66	NULL
)	NULL
.	NULL

We	NULL
have	NULL
measured	NULL
the	NULL
levels	NULL
of	NULL
these	NULL
apoptosis-regulatory	NULL
gene	NULL
products	NULL
in	NULL
a	NULL
panel	NULL
of	NULL
cell	NULL
lines	NULL
,	NULL
including	NULL
LCLs	NULL
and	NULL
Burkitt	NULL
's	NULL
lymphomas	NULL
(	NULL
BLs	NULL
)	NULL
,	NULL
with	NULL
or	NULL
without	NULL
EBV	NULL
immortalizing-gene	NULL
expression	NULL
.	NULL

The	NULL
results	NULL
suggest	NULL
that	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
BCL-2	NULL
,	NULL
the	NULL
A20	NULL
antiapoptotic	NULL
protein	NULL
may	NULL
also	NULL
have	NULL
a	NULL
role	NULL
in	NULL
preventing	NULL
the	NULL
sensitivity	NULL
of	NULL
LCLs	NULL
to	NULL
apoptosis	NULL
induced	NULL
by	NULL
low	NULL
serum	NULL
.	NULL

The	NULL
A20	NULL
promoter	NULL
can	NULL
be	NULL
regulated	NULL
by	NULL
LMP	NULL
-1	NULL
through	NULL
its	NULL
NF-KB	NULL
site	NULL
(	NULL
39	NULL
)	NULL
,	NULL
and	NULL
we	NULL
have	NULL
directly	NULL
measured	NULL
the	NULL
induction	NULL
of	NULL
active	NULL
nuclear	NULL
NF-kB	NULL
during	NULL
primary	NULL
infection	NULL
,	NULL
showing	NULL
that	NULL
it	NULL
correlates	NULL
with	NULL
LMP-1	NULL
expression	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Purification	NULL
of	NULL
B	NULL
cells	NULL
,	NULL
EBV	NULL
,	NULL
and	NULL
virus	NULL
infections	NULL
.	NULL

Primary	NULL
B	NULL
cells	NULL
from	NULL
peripheral	NULL
blood	NULL
were	NULL
isolated	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
12	NULL
,	NULL
72	NULL
)	NULL
.	NULL

Buffy	NULL
coats	NULL
were	NULL
centrifuged	NULL
over	NULL
Ficoll-Pague	NULL
(	NULL
Pharmacia	NULL
LKB	NULL
)	NULL
gradients	NULL
,	NULL
and	NULL
CD19-positive	NULL
lymphocytes	NULL
were	NULL
immunoselected	NULL
with	NULL
pan-B	NULL
Dynabeads	NULL
M450	NULL
(	NULL
Dynal	NULL
)	NULL
.	NULL

The	NULL
beads	NULL
were	NULL
removed	NULL
by	NULL
competition	NULL
with	NULL
Detachabeads	NULL
(	NULL
Dynal	NULL
)	NULL
,	NULL
and	NULL
the	NULL
cells	NULL
were	NULL
resuspended	NULL
at	NULL
10	NULL
%	NULL
/ml	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
penicillin	NULL
,	NULL
streptomycin	NULL
,	NULL
and	NULL
15	NULL
%	NULL
heat-inactivated	NULL
fetal	NULL
calf	NULL
serum	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
incubated	NULL
for	NULL
40	NULL
h	NULL
prior	NULL
to	NULL
infection	NULL
with	NULL
EBV	NULL
or	NULL
treatment	NULL
with	NULL
30	NULL
ng	NULL
of	NULL
PMA	NULL
(	NULL
phorbol-12-myristate-13-acetate	NULL
)	NULL
as	NULL
indicated	NULL
.	NULL

UV	NULL
radiation	NULL
inactivation	NULL
of	NULL
EBV	NULL
prior	NULL
to	NULL
infection	NULL
was	NULL
performed	NULL
in	NULL
a	NULL
Stratalinker	NULL
with	NULL
9	NULL
J	NULL
of	NULL
UV	NULL
radiation	NULL
.	NULL

Tonsil	NULL
B	NULL
cells	NULL
were	NULL
purified	NULL
by	NULL
negative	NULL
selection	NULL
.	NULL

Single-cell	NULL
suspensions	NULL
prepared	NULL
from	NULL
fresh	NULL
tonsils	NULL
were	NULL
centrifuged	NULL
over	NULL
Ficoll-Paque	NULL
.	NULL

T	NULL
cells	NULL
were	NULL
removed	NULL
by	NULL
rosetting	NULL
with	NULL
5-2-aminoethylisothiouronium	NULL
bromide	NULL
(	NULL
AET	NULL
'	NULL
)	NULL
-treated	NULL
sheep	NULL
erythrocytes	NULL
followed	NULL
by	NULL
centrifugation	NULL
over	NULL
Percoll	NULL
(	NULL
specific	NULL
gravity	NULL
,	NULL
1.08	NULL
;	NULL
Pharmacia	NULL
Bio-tech	NULL
)	NULL
.	NULL

The	NULL
dense	NULL
resting	NULL
B	NULL
cells	NULL
were	NULL
further	NULL
isolated	NULL
by	NULL
centrifugation	NULL
over	NULL
Percoll	NULL
at	NULL
a	NULL
specific	NULL
gravity	NULL
of	NULL
1.074	NULL
and	NULL
resuspended	NULL
at	NULL
10	NULL
%	NULL
/ml	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
penicillin	NULL
,	NULL
streptomycin	NULL
,	NULL
and	NULL
15	NULL
%	NULL
heat-inactivated	NULL
fetal	NULL
calf	NULL
serum	NULL
.	NULL

The	NULL
isolated	NULL
cells	NULL
were	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
for	NULL
purity	NULL
and	NULL
DNA	NULL
content	NULL
with	NULL
fluorescein	NULL
isothiocyanate	NULL
(	NULL
FITC	NULL
)	NULL
-conjugated	NULL
anti-CD20	NULL
and	NULL
propidium	NULL
iodide	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
infected	NULL
with	NULL
the	NULL
B95-8	NULL
strain	NULL
of	NULL
EBV	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
28a	NULL
)	NULL
.	NULL

Cell	NULL
lines	NULL
and	NULL
apoptosis	NULL
assay	NULL
.	NULL

BL41	NULL
,	NULL
DG75	NULL
(	NULL
6	NULL
)	NULL
,	NULL
BL40	NULL
,	NULL
and	NULL
BL2	NULL
(	NULL
40	NULL
)	NULL
are	NULL
EBV-negative	NULL
BL	NULL
cell	NULL
lines	NULL
.	NULL

Akata	NULL
(	NULL
76	NULL
)	NULL
and	NULL
Elijah	NULL
are	NULL
EBV-positive	NULL
BL	NULL
cell	NULL
lines	NULL
CELL	NULL
CYCLE	NULL
AND	NULL
APOPTOSIS	NULL
IN	NULL
EBV	NULL
INFECTION	NULL
-	NULL
4679	NULL
that	NULL
have	NULL
retained	NULL
a	NULL
group	NULL
I	NULL
phenotype	NULL
(	NULL
62	NULL
)	NULL
.	NULL

Mutu	NULL
III	NULL
clone	NULL
148	NULL
,	NULL
BL72	NULL
(	NULL
40	NULL
)	NULL
,	NULL
and	NULL
WewakI	NULL
(	NULL
62	NULL
)	NULL
are	NULL
EBV-positive	NULL
BL	NULL
cell	NULL
lines	NULL
that	NULL
have	NULL
acquired	NULL
a	NULL
group	NULL
III	NULL
phenotype	NULL
.	NULL

Namalwa	NULL
(	NULL
37	NULL
)	NULL
,	NULL
Raji	NULL
(	NULL
57	NULL
)	NULL
,	NULL
and	NULL
BL74	NULL
(	NULL
40	NULL
)	NULL
are	NULL
EBV-positive	NULL
BL	NULL
cell	NULL
lines	NULL
with	NULL
the	NULL
intermediate	NULL
group	NULL
II	NULL
phenotype	NULL
.	NULL

BL36-LCL	NULL
,	NULL
PF-LCL	NULL
,	NULL
LCL3	NULL
,	NULL
IB4	NULL
(	NULL
36	NULL
)	NULL
,	NULL
and	NULL
X50-7	NULL
(	NULL
82	NULL
)	NULL
are	NULL
in	NULL
vitro	NULL
EBV-immortalized	NULL
LCLs	NULL
.	NULL

The	NULL
cell	NULL
lines	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
Gibco-BRL	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
to	NULL
15	NULL
%	NULL
(	NULL
vol/vol	NULL
)	NULL
fetal	NULL
calf	NULL
serum	NULL
and	NULL
antibiotics	NULL
.	NULL

To	NULL
test	NULL
the	NULL
sensitivity	NULL
of	NULL
cell	NULL
lines	NULL
to	NULL
Fas-induced	NULL
apoptosis	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
diluted	NULL
to	NULL
10°	NULL
per	NULL
ml	NULL
and	NULL
treated	NULL
with	NULL
100	NULL
or	NULL
500	NULL
ng	NULL
of	NULL
an	NULL
anti-Fas	NULL
immunoglobulin	NULL
M	NULL
(	NULL
IgM	NULL
)	NULL
class	NULL
antibody	NULL
(	NULL
no	NULL
.	NULL

05-201	NULL
;	NULL
Upstate	NULL
Biotechnology	NULL
Inc.	NULL
)	NULL
/ml	NULL
or	NULL
were	NULL
left	NULL
untreated	NULL
as	NULL
a	NULL
control	NULL
.	NULL

The	NULL
anti-Fas	NULL
antibody	NULL
had	NULL
x	NULL
light	NULL
chains	NULL
so	NULL
,	NULL
as	NULL
an	NULL
additional	NULL
control	NULL
,	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
equivalent	NULL
concentrations	NULL
of	NULL
an	NULL
unrelated	NULL
Ig	NULL
M	NULL
(	NULL
x	NULL
)	NULL
antibody	NULL
(	NULL
Pharmingen	NULL
03081D	NULL
)	NULL
that	NULL
had	NULL
been	NULL
dialyzed	NULL
to	NULL
remove	NULL
azide	NULL
.	NULL

After	NULL
24	NULL
h	NULL
,	NULL
cell	NULL
viability	NULL
was	NULL
determined	NULL
by	NULL
trypan	NULL
blue	NULL
exclusion	NULL
as	NULL
a	NULL
measure	NULL
of	NULL
cell	NULL
membrane	NULL
permeability	NULL
.	NULL

Cell	NULL
genomic	NULL
DNA	NULL
was	NULL
analyzed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
4	NULL
)	NULL
.	NULL

Cell	NULL
proliferation	NULL
measured	NULL
by	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
.	NULL

Uninfected	NULL
or	NULL
EBV-infected	NULL
cells	NULL
(	NULL
2	NULL
x	NULL
10°	NULL
)	NULL
were	NULL
pulse	NULL
labelled	NULL
for	NULL
2	NULL
h	NULL
with	NULL
1	NULL
wCi	NULL
of	NULL
midine	NULL
per	NULL
well	NULL
and	NULL
harvested	NULL
onto	NULL
glass	NULL
fiber	NULL
filters	NULL
with	NULL
a	NULL
cell	NULL
harvester	NULL
(	NULL
Ska-tron	NULL
Ltd.	NULL
,	NULL
Lier	NULL
,	NULL
Norway	NULL
)	NULL
.	NULL

The	NULL
filters	NULL
were	NULL
air	NULL
dried	NULL
,	NULL
and	NULL
scintillations	NULL
were	NULL
counted	NULL
.	NULL

Immunoblotting	NULL
,	NULL
immunofluorescence	NULL
,	NULL
and	NULL
antibodies	NULL
.	NULL

Radicimmunoprecipi-tation	NULL
assay	NULL
lysates	NULL
were	NULL
prepared	NULL
and	NULL
quantitated	NULL
,	NULL
and	NULL
immunoblotting	NULL
was	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
9	NULL
)	NULL
.	NULL

Proteins	NULL
were	NULL
fractionated	NULL
by	NULL
sodium	NULL
dodecyl	NULL
sulfate-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
and	NULL
transferred	NULL
to	NULL
nitrocel-lulose	NULL
membranes	NULL
.	NULL

After	NULL
being	NULL
blocked	NULL
with	NULL
10	NULL
%	NULL
milk	NULL
powder	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
,	NULL
the	NULL
membranes	NULL
were	NULL
probed	NULL
with	NULL
the	NULL
following	NULL
antibodies	NULL
(	NULL
all	NULL
antibodies	NULL
were	NULL
mouse	NULL
monoclonal	NULL
antibodies	NULL
unless	NULL
otherwise	NULL
indicated	NULL
)	NULL
.	NULL

The	NULL
antibodies	NULL
used	NULL
were	NULL
a	NULL
1/10	NULL
dilution	NULL
of	NULL
anti-EBNA-LP	NULL
monoclonal	NULL
JF	NULL
186	NULL
(	NULL
25	NULL
)	NULL
,	NULL
1/500	NULL
dilution	NULL
of	NULL
anti-EBNA-2	NULL
monoclonal	NULL
antibody	NULL
PE2	NULL
(	NULL
Dako	NULL
)	NULL
,	NULL
1/10	NULL
dilution	NULL
of	NULL
anti-LMP-1	NULL
monoclonal	NULL
$	NULL
12	NULL
(	NULL
41	NULL
)	NULL
,	NULL
1/1,000	NULL
dilution	NULL
of	NULL
rabbit	NULL
polyclonal	NULL
anti-p107	NULL
(	NULL
C-18	NULL
;	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
,	NULL
1/1,000	NULL
dilution	NULL
of	NULL
rabbit	NULL
polyclonal	NULL
anti-pRB	NULL
(	NULL
C-15	NULL
;	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
,	NULL
1/1,000	NULL
dilution	NULL
of	NULL
rabbit	NULL
polyclonal	NULL
anti-p130	NULL
(	NULL
C-20	NULL
;	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
,	NULL
1/80	NULL
dilution	NULL
of	NULL
anti-cyclin	NULL
D2	NULL
(	NULL
G132-43	NULL
;	NULL
Pharmingen	NULL
)	NULL
,	NULL
1/500	NULL
dilution	NULL
of	NULL
anti-cyclin	NULL
E	NULL
(	NULL
HE12	NULL
;	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
,	NULL
1/700	NULL
dilution	NULL
of	NULL
anti-E2F-1	NULL
(	NULL
KH-95	NULL
;	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
,	NULL
1/1,000	NULL
dilution	NULL
of	NULL
rabbit	NULL
polyclonal	NULL
anti-E2F-4	NULL
(	NULL
C-108	NULL
;	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
,	NULL
1/1,000	NULL
dilution	NULL
of	NULL
rabbit	NULL
polyclonal	NULL
anti-p27	NULL
(	NULL
C-19	NULL
;	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
,	NULL
1/1,000	NULL
dilution	NULL
of	NULL
rabbit	NULL
polyclonal	NULL
anti-edk2	NULL
(	NULL
M2	NULL
;	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
,	NULL
1/500	NULL
dilution	NULL
of	NULL
rabbit	NULL
polyclonal	NULL
anti-cdk4	NULL
(	NULL
C-22	NULL
;	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
,	NULL
and	NULL
1/1,000	NULL
dilution	NULL
of	NULL
rabbit	NULL
polyclonal	NULL
anti-edk6	NULL
(	NULL
C-21	NULL
;	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
.	NULL

Three	NULL
rabbit	NULL
BAX	NULL
antibodies	NULL
were	NULL
used	NULL
.	NULL

BAX	NULL
N-20	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
was	NULL
used	NULL
at	NULL
0.4	NULL
pg/ml	NULL
,	NULL
BAX	NULL
P-19	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
was	NULL
used	NULL
at	NULL
0.5	NULL
ug/ml	NULL
,	NULL
and	NULL
BAX	NULL
13666E	NULL
(	NULL
Pharmingen	NULL
)	NULL
was	NULL
used	NULL
at	NULL
a	NULL
dilution	NULL
of	NULL
1:1,000	NULL
.	NULL

The	NULL
-specific	NULL
rabbit	NULL
antibody	NULL
S-18	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
was	NULL
used	NULL
at	NULL
0.4	NULL
ug/ml	NULL
,	NULL
the	NULL
BCL-2	NULL
antibody	NULL
C124	NULL
(	NULL
Dako	NULL
)	NULL
was	NULL
used	NULL
at	NULL
1	NULL
pg/ml	NULL
,	NULL
the	NULL
BAK-specific	NULL
goat	NULL
antibody	NULL
G-23	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
was	NULL
used	NULL
at	NULL
0.5	NULL
pg/ml	NULL
,	NULL
and	NULL
the	NULL
BAG-1-specific	NULL
rabbit	NULL
antibody	NULL
C-16	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
was	NULL
used	NULL
at	NULL
0.5	NULL
ug/ral	NULL
.	NULL

The	NULL
secondary	NULL
antibodies	NULL
were	NULL
horseradish	NULL
peroxidase-conjugated	NULL
donkey	NULL
anti-rabbit	NULL
Ig	NULL
or	NULL
sheep	NULL
anti-mouse	NULL
Ig	NULL
(	NULL
both	NULL
Amersham	NULL
)	NULL
or	NULL
horseradish	NULL
peroxidase-conjugated	NULL
rabbit	NULL
anti-goat	NULL
Ig	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
.	NULL

Bound	NULL
immu-nocomplexes	NULL
were	NULL
detected	NULL
by	NULL
enhanced	NULL
chemiluminescence	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

For	NULL
immunofluorescent	NULL
detection	NULL
of	NULL
EBNA-LP	NULL
,	NULL
cytospins	NULL
were	NULL
prepared	NULL
from	NULL
uninfected	NULL
and	NULL
EBV-infected	NULL
cells	NULL
30	NULL
h	NULL
after	NULL
infection	NULL
and	NULL
fixed	NULL
in	NULL
1:1	NULL
methanol-acetone	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
stained	NULL
with	NULL
JF186	NULL
(	NULL
1:10	NULL
dilution	NULL
)	NULL
followed	NULL
by	NULL
FITC-conjugated	NULL
sheep	NULL
anti-mouse	NULL
IgG	NULL
(	NULL
Sigma	NULL
)	NULL
or	NULL
the	NULL
secondary	NULL
antibody	NULL
alone	NULL
.	NULL

Positive	NULL
cells	NULL
were	NULL
counted	NULL
by	NULL
fluorescent	NULL
microscopy	NULL
.	NULL

RNase	NULL
protection	NULL
assay	NULL
and	NULL
Northern	NULL
blotting	NULL
.	NULL

Northern	NULL
blotting	NULL
and	NULL
RNase	NULL
protection	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
4	NULL
,	NULL
71	NULL
,	NULL
72	NULL
)	NULL
with	NULL
cytoplasmic	NULL
RNA	NULL
.	NULL

The	NULL
A20	NULL
probe	NULL
for	NULL
Northern	NULL
blotting	NULL
contained	NULL
nucleotides	NULL
337	NULL
to	NULL
1614	NULL
of	NULL
the	NULL
cDNA	NULL
(	NULL
50	NULL
)	NULL
,	NULL
kindly	NULL
provided	NULL
by	NULL
V.	NULL
M.	NULL
Dixit	NULL
.	NULL

For	NULL
the	NULL
A20	NULL
RNAse	NULL
protection	NULL
assay	NULL
,	NULL
nucleotides	NULL
2218	NULL
to	NULL
1705	NULL
of	NULL
the	NULL
cDNA	NULL
were	NULL
subcloned	NULL
to	NULL
make	NULL
the	NULL
probe	NULL
.	NULL

The	NULL
E2F-4	NULL
RNAse	NULL
protection	NULL
probe	NULL
contained	NULL
nucleotides	NULL
531	NULL
to	NULL
246	NULL
of	NULL
the	NULL
E2F-4	NULL
cDNA	NULL
(	NULL
5	NULL
)	NULL
and	NULL
was	NULL
made	NULL
by	NULL
in	NULL
vitro	NULL
transcription	NULL
with	NULL
SP6	NULL
RNA	NULL
polymerase	NULL
from	NULL
the	NULL
plasmid	NULL
peDNA3-E2F4AApal	NULL
(	NULL
a	NULL
kind	NULL
gift	NULL
of	NULL
E.	NULL
Lam	NULL
)	NULL
lin-earized	NULL
with	NULL
BstXL	NULL
.	NULL

Gel	NULL
retardation	NULL
assay	NULL
.	NULL

A	NULL
double-stranded	NULL
oligonucleotide	NULL
,	NULL
AGTTGAGGGG	NULL
ACTITCCCAGGC	NULL
,	NULL
was	NULL
end-labelled	NULL
with	NULL
T4	NULL
polynucleotide	NULL
kinase	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
54	NULL
)	NULL
.	NULL

For	NULL
each	NULL
assay	NULL
,	NULL
5	NULL
mg	NULL
of	NULL
LCL3	NULL
extract	NULL
protein	NULL
or	NULL
an	NULL
equivalent	NULL
amount	NULL
of	NULL
extract	NULL
(	NULL
primary	NULL
B-cell	NULL
infec-tions	NULL
)	NULL
was	NULL
incubated	NULL
in	NULL
a	NULL
final	NULL
reaction	NULL
volume	NULL
of	NULL
20	NULL
l	NULL
containing	NULL
40	NULL
mM	NULL
NaCl	NULL
,	NULL
10	NULL
mM	NULL
Tris-Cl	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
1	NULL
mM	NULL
2-mercaptocthanol	NULL
,	NULL
4	NULL
%	NULL
(	NULL
vol/vol	NULL
)	NULL
glycerol	NULL
,	NULL
1	NULL
mg	NULL
of	NULL
bovine	NULL
serum	NULL
albumin/ml	NULL
,	NULL
0.1	NULL
mg	NULL
of	NULL
poly	NULL
(	NULL
dIC	NULL
)	NULL
/ml	NULL
,	NULL
and	NULL
50	NULL
ng	NULL
of	NULL
*°P-labelled	NULL
oligonucleotide	NULL
for	NULL
30	NULL
min	NULL
at	NULL
25°C	NULL
.	NULL

Samples	NULL
were	NULL
electrophoresed	NULL
on	NULL
4	NULL
%	NULL
polyacrylamide	NULL
gels	NULL
in	NULL
0.5	NULL
%	NULL
Tris-borate-EDTA	NULL
.	NULL

RESULTS	NULL
In	NULL
the	NULL
experiments	NULL
we	NULL
have	NULL
published	NULL
previously	NULL
on	NULL
the	NULL
early	NULL
events	NULL
after	NULL
EBV	NULL
infection	NULL
of	NULL
B	NULL
cells	NULL
,	NULL
the	NULL
B	NULL
cells	NULL
were	NULL
purified	NULL
4680	NULL
SPENDER	NULL
ET	NULL
AL	NULL
.	NULL

by	NULL
positive	NULL
selection	NULL
of	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
on	NULL
CD19	NULL
beads	NULL
(	NULL
12	NULL
,	NULL
72	NULL
)	NULL
.	NULL

CD19	NULL
is	NULL
part	NULL
of	NULL
the	NULL
membrane	NULL
complex	NULL
containing	NULL
the	NULL
EBV	NULL
receptor	NULL
(	NULL
CD21	NULL
)	NULL
.	NULL

There	NULL
was	NULL
,	NULL
therefore	NULL
,	NULL
the	NULL
possibility	NULL
that	NULL
the	NULL
selection	NULL
process	NULL
might	NULL
have	NULL
affected	NULL
the	NULL
signal	NULL
transduction	NULL
and	NULL
G	NULL
,	NULL
,	NULL
status	NULL
of	NULL
the	NULL
purified	NULL
B	NULL
cells	NULL
,	NULL
even	NULL
though	NULL
our	NULL
standard	NULL
procedure	NULL
involved	NULL
an	NULL
overnight	NULL
incubation	NULL
in	NULL
medium	NULL
after	NULL
the	NULL
purification	NULL
to	NULL
allow	NULL
any	NULL
transduction	NULL
effects	NULL
of	NULL
the	NULL
purification	NULL
process	NULL
to	NULL
dissipate	NULL
.	NULL

Although	NULL
most	NULL
parameters	NULL
(	NULL
very	NULL
low	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
,	NULL
2	NULL
N	NULL
DNA	NULL
content	NULL
,	NULL
and	NULL
cell	NULL
surface	NULL
and	NULL
intracellular	NULL
markers	NULL
)	NULL
were	NULL
as	NULL
expected	NULL
for	NULL
resting	NULL
cells	NULL
(	NULL
12	NULL
,	NULL
72	NULL
)	NULL
,	NULL
we	NULL
have	NULL
found	NULL
some	NULL
variation	NULL
in	NULL
the	NULL
level	NULL
of	NULL
hypophosphorylated	NULL
p130	NULL
in	NULL
the	NULL
purified	NULL
B	NULL
cells	NULL
.	NULL

This	NULL
seemed	NULL
to	NULL
be	NULL
more	NULL
a	NULL
consequence	NULL
of	NULL
variation	NULL
in	NULL
the	NULL
batches	NULL
of	NULL
buffy	NULL
coats	NULL
used	NULL
for	NULL
B-cell	NULL
purification	NULL
than	NULL
a	NULL
result	NULL
of	NULL
the	NULL
positive	NULL
selection	NULL
protocol	NULL
.	NULL

Nevertheless	NULL
,	NULL
the	NULL
purification	NULL
procedure	NULL
was	NULL
modified	NULL
,	NULL
increasing	NULL
the	NULL
recovery	NULL
period	NULL
to	NULL
40	NULL
h.	NULL
With	NULL
this	NULL
revised	NULL
purification	NULL
procedure	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
confirmed	NULL
as	NULL
predominately	NULL
resting	NULL
B	NULL
cells	NULL
,	NULL
since	NULL
they	NULL
were	NULL
CD20	NULL
positive	NULL
and	NULL
CD23	NULL
negative	NULL
,	NULL
lacked	NULL
measurable	NULL
[	NULL
°HJthy-midine	NULL
incorporation	NULL
,	NULL
and	NULL
lacked	NULL
G-	NULL
or	NULL
S-phase	NULL
cells	NULL
in	NULL
fluorescence-activated	NULL
cell	NULL
sorter	NULL
analysis	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
p130	NULL
levels	NULL
in	NULL
the	NULL
purified-B-cell	NULL
population	NULL
were	NULL
consistently	NULL
normal	NULL
and	NULL
similar	NULL
to	NULL
those	NULL
of	NULL
resting	NULL
B	NULL
cells	NULL
purified	NULL
from	NULL
tonsils	NULL
by	NULL
a	NULL
negative	NULL
selection	NULL
protocol	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Other	NULL
types	NULL
of	NULL
resting	NULL
(	NULL
G	NULL
,	NULL
)	NULL
cells	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
contain	NULL
an	NULL
E2F	NULL
factor	NULL
made	NULL
up	NULL
of	NULL
E2F-4	NULL
complexed	NULL
with	NULL
a	NULL
DP	NULL
protein	NULL
bound	NULL
to	NULL
the	NULL
transcriptionally	NULL
repressive	NULL
pocket	NULL
protein	NULL
p130	NULL
(	NULL
45	NULL
,	NULL
73	NULL
,	NULL
78	NULL
)	NULL
.	NULL

The	NULL
resting	NULL
B	NULL
cells	NULL
were	NULL
shown	NULL
also	NULL
to	NULL
express	NULL
E2F-4	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

The	NULL
purified	NULL
B	NULL
cells	NULL
are	NULL
thus	NULL
in	NULL
G	NULL
,	NULL
by	NULL
all	NULL
criteria	NULL
that	NULL
we	NULL
have	NULL
been	NULL
able	NULL
to	NULL
measure	NULL
.	NULL

Purified	NULL
resting	NULL
cells	NULL
were	NULL
infected	NULL
with	NULL
EBV	NULL
,	NULL
and	NULL
the	NULL
expression	NULL
of	NULL
viral	NULL
and	NULL
cell	NULL
proteins	NULL
at	NULL
various	NULL
times	NULL
after	NULL
infection	NULL
was	NULL
monitored	NULL
by	NULL
Western	NULL
blotting	NULL
extracts	NULL
of	NULL
the	NULL
cells	NULL
.	NULL

As	NULL
we	NULL
have	NULL
shown	NULL
previously	NULL
(	NULL
72	NULL
)	NULL
,	NULL
the	NULL
cells	NULL
begin	NULL
to	NULL
enter	NULL
S	NULL
phase	NULL
about	NULL
48	NULL
to	NULL
72	NULL
h	NULL
after	NULL
infection	NULL
under	NULL
these	NULL
conditions	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Cell	NULL
death	NULL
in	NULL
the	NULL
cultures	NULL
was	NULL
found	NULL
to	NULL
be	NULL
relatively	NULL
low	NULL
:	NULL
about	NULL
70	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
remained	NULL
viable	NULL
by	NULL
trypan	NULL
blue	NULL
exclusion	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
,	NULL
consistent	NULL
with	NULL
the	NULL
fluorescence-activated	NULL
cell	NULL
sorter	NULL
analysis	NULL
of	NULL
propidium	NULL
iodide-stained	NULL
cells	NULL
,	NULL
which	NULL
showed	NULL
about	NULL
30	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
with	NULL
a	NULL
sub-G	NULL
,	NULL
DNA	NULL
content	NULL
at	NULL
72	NULL
h	NULL
after	NULL
the	NULL
addition	NULL
of	NULL
virus	NULL
.	NULL

The	NULL
viral	NULL
proteins	NULL
EBNA-LP	NULL
,	NULL
EBNA-2	NULL
,	NULL
and	NULL
LMP	NULL
-1	NULL
were	NULL
assayed	NULL
.	NULL

As	NULL
shown	NULL
previously	NULL
(	NULL
72	NULL
)	NULL
,	NULL
EBNA-LP	NULL
and	NULL
EBNA-2	NULL
are	NULL
the	NULL
earliest	NULL
viral	NULL
proteins	NULL
that	NULL
can	NULL
be	NULL
detected	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

These	NULL
transcription	NULL
factors	NULL
are	NULL
assumed	NULL
to	NULL
modify	NULL
the	NULL
activity	NULL
of	NULL
cell	NULL
genes	NULL
or	NULL
proteins	NULL
,	NULL
but	NULL
the	NULL
relevant	NULL
early	NULL
cell	NULL
targets	NULL
have	NULL
not	NULL
yet	NULL
been	NULL
identified	NULL
.	NULL

Across	NULL
the	NULL
same	NULL
time	NULL
course	NULL
of	NULL
infection	NULL
,	NULL
the	NULL
E2F-1	NULL
and	NULL
E2F-4	NULL
proteins	NULL
were	NULL
in-duced	NULL
,	NULL
with	NULL
E2F-1	NULL
being	NULL
undetectable	NULL
or	NULL
present	NULL
at	NULL
only	NULL
a	NULL
very	NULL
low	NULL
level	NULL
in	NULL
the	NULL
uninfected	NULL
cells	NULL
at	NULL
the	NULL
start	NULL
of	NULL
the	NULL
experiments	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

E2F-4	NULL
was	NULL
present	NULL
as	NULL
multiple	NULL
bands	NULL
;	NULL
the	NULL
slower-migrating	NULL
forms	NULL
are	NULL
thought	NULL
perhaps	NULL
to	NULL
represent	NULL
phosphorylated	NULL
forms	NULL
of	NULL
the	NULL
protein	NULL
(	NULL
78	NULL
,	NULL
79	NULL
)	NULL
.	NULL

The	NULL
level	NULL
of	NULL
the	NULL
slower-migrating	NULL
forms	NULL
of	NULL
E2F-4	NULL
was	NULL
reduced	NULL
during	NULL
the	NULL
infection	NULL
time	NULL
course	NULL
,	NULL
but	NULL
the	NULL
overall	NULL
level	NULL
of	NULL
E2F-4	NULL
detected	NULL
by	NULL
Western	NULL
blotting	NULL
was	NULL
increased	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
the	NULL
pRb	NULL
and	NULL
p107	NULL
pocket	NULL
proteins	NULL
were	NULL
very	NULL
low	NULL
or	NULL
undetectable	NULL
in	NULL
the	NULL
uninfected	NULL
cells	NULL
,	NULL
but	NULL
both	NULL
p107	NULL
and	NULL
pRb	NULL
were	NULL
induced	NULL
upon	NULL
infection	NULL
,	NULL
with	NULL
phosphorylated	NULL
forms	NULL
of	NULL
pRb	NULL
appearing	NULL
about	NULL
30	NULL
h	NULL
after	NULL
infection	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
p130	NULL
levels	NULL
did	NULL
not	NULL
increase	NULL
,	NULL
but	NULL
slower-migrating	NULL
forms	NULL
,	NULL
presumably	NULL
with	NULL
different	NULL
phosphorylation	NULL
states	NULL
,	NULL
appeared	NULL
later	NULL
,	NULL
about	NULL
48	NULL
h	NULL
after	NULL
the	NULL
addition	NULL
of	NULL
virus	NULL
.	NULL

PMA	NULL
treatment	NULL
of	NULL
the	NULL
B	NULL
cells	NULL
(	NULL
which	NULL
drives	NULL
the	NULL
cells	NULL
into	NULL
division	NULL
)	NULL
induced	NULL
changes	NULL
in	NULL
E2F-1	NULL
,	NULL
E2F-4	NULL
,	NULL
and	NULL
the	NULL
pocket	NULL
proteins	NULL
similar	NULL
to	NULL
those	NULL
of	NULL
EBV	NULL
infection	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

We	NULL
demonstrated	NULL
previously	NULL
that	NULL
cyclin	NULL
D2	NULL
RNA	NULL
was	NULL
induced	NULL
by	NULL
EBV	NULL
as	NULL
early	NULL
as	NULL
24	NULL
h	NULL
after	NULL
infection	NULL
in	NULL
our	NULL
system	NULL
J.	NULL
Virou	NULL
.	NULL

(	NULL
72	NULL
)	NULL
,	NULL
and	NULL
this	NULL
has	NULL
now	NULL
been	NULL
confirmed	NULL
at	NULL
the	NULL
protein	NULL
level	NULL
by	NULL
Western	NULL
blotting	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Cyclin	NULL
E	NULL
was	NULL
found	NULL
to	NULL
be	NULL
induced	NULL
at	NULL
about	NULL
the	NULL
same	NULL
time	NULL
the	NULL
level	NULL
of	NULL
p27	NULL
protein	NULL
declined	NULL
abruptly	NULL
,	NULL
perhaps	NULL
consistent	NULL
with	NULL
targeted	NULL
degradation	NULL
of	NULL
p27	NULL
,	NULL
as	NULL
has	NULL
been	NULL
reported	NULL
in	NULL
other	NULL
systems	NULL
of	NULL
cell	NULL
cycle	NULL
entry	NULL
(	NULL
55	NULL
,	NULL
69	NULL
,	NULL
80	NULL
)	NULL
.	NULL

Although	NULL
we	NULL
previously	NULL
reported	NULL
induction	NULL
of	NULL
edk-2	NULL
,	NULL
-4	NULL
,	NULL
and	NULL
-6	NULL
proteins	NULL
from	NULL
very	NULL
low	NULL
levels	NULL
upon	NULL
EBV	NULL
infection	NULL
(	NULL
12	NULL
)	NULL
,	NULL
it	NULL
is	NULL
now	NULL
clear	NULL
with	NULL
improved	NULL
detection	NULL
methods	NULL
that	NULL
there	NULL
is	NULL
detectable	NULL
cdk-2	NULL
,	NULL
-4	NULL
,	NULL
and	NULL
-6	NULL
in	NULL
the	NULL
uninfected	NULL
cells	NULL
but	NULL
that	NULL
all	NULL
these	NULL
edks	NULL
are	NULL
induced	NULL
further	NULL
upon	NULL
EBV	NULL
infection	NULL
.	NULL

Some	NULL
of	NULL
the	NULL
induction	NULL
of	NULL
edk-2	NULL
also	NULL
occurred	NULL
when	NULL
the	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
EBV	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Again	NULL
,	NULL
PMA	NULL
treatment	NULL
of	NULL
the	NULL
B	NULL
cells	NULL
resulted	NULL
in	NULL
changes	NULL
to	NULL
the	NULL
profile	NULL
of	NULL
cyclin	NULL
D2	NULL
,	NULL
p27	NULL
,	NULL
and	NULL
edks	NULL
similar	NULL
to	NULL
those	NULL
in	NULL
EBV	NULL
infection	NULL
.	NULL

To	NULL
distinguish	NULL
which	NULL
of	NULL
these	NULL
effects	NULL
was	NULL
dependent	NULL
on	NULL
viral	NULL
gene	NULL
expression	NULL
,	NULL
the	NULL
levels	NULL
of	NULL
cyclin	NULL
D2	NULL
,	NULL
p130	NULL
,	NULL
E2F-4	NULL
,	NULL
and	NULL
p27	NULL
proteins	NULL
were	NULL
measured	NULL
at	NULL
24	NULL
and	NULL
48	NULL
h	NULL
after	NULL
infection	NULL
with	NULL
EBV	NULL
or	NULL
UV	NULL
-inactivated	NULL
EBV	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
.	NULL

After	NULL
UV	NULL
inactivation	NULL
,	NULL
the	NULL
virus	NULL
particles	NULL
remain	NULL
but	NULL
viral	NULL
gene	NULL
expression	NULL
is	NULL
prevented	NULL
(	NULL
the	NULL
effectiveness	NULL
of	NULL
the	NULL
UV	NULL
inactivation	NULL
was	NULL
verified	NULL
by	NULL
monitoring	NULL
expression	NULL
of	NULL
EBNA-LP	NULL
,	NULL
which	NULL
was	NULL
prevented	NULL
by	NULL
the	NULL
UV	NULL
treatment	NULL
)	NULL
.	NULL

The	NULL
results	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
show	NULL
that	NULL
the	NULL
induction	NULL
of	NULL
cyclin	NULL
D2	NULL
protein	NULL
,	NULL
the	NULL
altered	NULL
gel	NULL
mobility	NULL
(	NULL
presumed	NULL
hyperphosphorylation	NULL
)	NULL
of	NULL
p130	NULL
,	NULL
and	NULL
the	NULL
reduction	NULL
in	NULL
p27	NULL
levels	NULL
were	NULL
all	NULL
dependent	NULL
on	NULL
viral	NULL
gene	NULL
expression	NULL
,	NULL
since	NULL
the	NULL
effects	NULL
were	NULL
prevented	NULL
by	NULL
UV	NULL
inactivation	NULL
of	NULL
the	NULL
virus	NULL
.	NULL

The	NULL
changes	NULL
in	NULL
the	NULL
migration	NULL
pattern	NULL
of	NULL
E2F-4	NULL
upon	NULL
EBV	NULL
infection	NULL
were	NULL
also	NULL
analyzed	NULL
,	NULL
comparing	NULL
the	NULL
effects	NULL
of	NULL
UV-inactivated	NULL
EBV	NULL
with	NULL
those	NULL
of	NULL
wild-type	NULL
virus	NULL
.	NULL

An	NULL
increase	NULL
in	NULL
the	NULL
level	NULL
of	NULL
E2F-4	NULL
protein	NULL
was	NULL
prevented	NULL
by	NULL
UV	NULL
inactivation	NULL
of	NULL
the	NULL
virus	NULL
,	NULL
but	NULL
the	NULL
reduction	NULL
in	NULL
amount	NULL
of	NULL
the	NULL
slower-migrating	NULL
forms	NULL
of	NULL
E2F-4	NULL
was	NULL
only	NULL
partly	NULL
affected	NULL
by	NULL
the	NULL
UV	NULL
treatment	NULL
of	NULL
the	NULL
virus	NULL
,	NULL
indicating	NULL
that	NULL
part	NULL
of	NULL
that	NULL
change	NULL
in	NULL
E2F-4	NULL
might	NULL
be	NULL
in	NULL
response	NULL
to	NULL
the	NULL
signal	NULL
transduction	NULL
occurring	NULL
when	NULL
virus	NULL
binds	NULL
to	NULL
the	NULL
B	NULL
cell	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
previously	NULL
for	NULL
cyclin	NULL
D2	NULL
(	NULL
72	NULL
)	NULL
,	NULL
the	NULL
induction	NULL
of	NULL
E2F-4	NULL
expression	NULL
also	NULL
occurred	NULL
at	NULL
the	NULL
RNA	NULL
level	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
,	NULL
at	NULL
a	NULL
time	NULL
consistent	NULL
with	NULL
its	NULL
being	NULL
a	NULL
consequence	NULL
of	NULL
EBNA-2	NULL
and	NULL
EBNA-LP	NULL
expression	NULL
from	NULL
the	NULL
EBV	NULL
genome	NULL
.	NULL

Regulation	NULL
of	NULL
apoptosis	NULL
during	NULL
EBV	NULL
infection	NULL
is	NULL
another	NULL
important	NULL
aspect	NULL
of	NULL
the	NULL
transition	NULL
from	NULL
the	NULL
resting	NULL
state	NULL
to	NULL
immortalized	NULL
LCL	NULL
.	NULL

There	NULL
are	NULL
likely	NULL
to	NULL
be	NULL
changing	NULL
apoptotic	NULL
signals	NULL
during	NULL
the	NULL
process	NULL
of	NULL
infection	NULL
,	NULL
since	NULL
there	NULL
is	NULL
induction	NULL
of	NULL
cell	NULL
proteins	NULL
that	NULL
are	NULL
able	NULL
to	NULL
cause	NULL
apoptosis	NULL
,	NULL
such	NULL
as	NULL
E2F-1	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
and	NULL
c-Myc	NULL
(	NULL
1	NULL
)	NULL
,	NULL
as	NULL
growth	NULL
is	NULL
activated	NULL
.	NULL

BCL-2	NULL
(	NULL
perhaps	NULL
induced	NULL
by	NULL
LMP-1	NULL
)	NULL
has	NULL
already	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
control	NULL
of	NULL
apoptosis	NULL
in	NULL
LCLs	NULL
and	NULL
group	NULL
III	NULL
BL	NULL
cells	NULL
(	NULL
27	NULL
,	NULL
28	NULL
)	NULL
,	NULL
but	NULL
the	NULL
involvement	NULL
of	NULL
other	NULL
pathways	NULL
has	NULL
been	NULL
suggested	NULL
(	NULL
44	NULL
)	NULL
.	NULL

It	NULL
is	NULL
the	NULL
balance	NULL
of	NULL
pro-	NULL
and	NULL
antiapoptotic	NULL
proteins	NULL
that	NULL
is	NULL
impor-tant	NULL
,	NULL
so	NULL
we	NULL
examined	NULL
the	NULL
levels	NULL
of	NULL
several	NULL
proteins	NULL
that	NULL
regulate	NULL
apoptosis	NULL
in	NULL
LCLs	NULL
.	NULL

To	NULL
provide	NULL
a	NULL
framework	NULL
in	NULL
which	NULL
the	NULL
relationship	NULL
between	NULL
the	NULL
EBV	NULL
gene	NULL
expression	NULL
in	NULL
EBV-immortalized	NULL
LCLs	NULL
and	NULL
sensitivity	NULL
to	NULL
apoptosis	NULL
might	NULL
be	NULL
interpreted	NULL
,	NULL
the	NULL
protein	NULL
levels	NULL
in	NULL
LCLs	NULL
were	NULL
compared	NULL
to	NULL
those	NULL
in	NULL
other	NULL
B-cell	NULL
lines	NULL
with	NULL
and	NULL
without	NULL
EBV	NULL
gene	NULL
expression	NULL
.	NULL

The	NULL
most	NULL
suitable	NULL
lines	NULL
for	NULL
comparison	NULL
were	NULL
BL	NULL
cells	NULL
,	NULL
since	NULL
there	NULL
are	NULL
examples	NULL
of	NULL
these	NULL
cell	NULL
lines	NULL
both	NULL
containing	NULL
and	NULL
lacking	NULL
EBV	NULL
and	NULL
there	NULL
is	NULL
also	NULL
the	NULL
opportunity	NULL
to	NULL
compare	NULL
group	NULL
I	NULL
EBV-positive	NULL
BL	NULL
cells	NULL
(	NULL
which	NULL
express	NULL
only	NULL
EBNA-1	NULL
of	NULL
the	NULL
six	NULL
viral	NULL
proteins	NULL
shown	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
LCL	NULL
immortalization	NULL
)	NULL
to	NULL
group	NULL
III	NULL
EBV-positive	NULL
BL	NULL
cells	NULL
,	NULL
which	NULL
have	NULL
a	NULL
pattern	NULL
of	NULL
EBV	NULL
gene	NULL
expression	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
the	NULL
LCLs	NULL
.	NULL

EBV-negative	NULL
and	NULL
group	NULL
I	NULL
EBV-positive	NULL
BL	NULL
cell	NULL
lines	NULL
are	NULL
relatively	NULL
sensitive	NULL
to	NULL
apoptosis	NULL
induced	NULL
by	NULL
ionomycin	NULL
,	NULL
stimulation	NULL
via	NULL
cell	NULL
surface	NULL
Ig	NULL
molecules	NULL
,	NULL
or	NULL
serum	NULL
deprivation	NULL
compared	NULL
to	NULL
group	NULL
III	NULL
BL	NULL
lines	NULL
(	NULL
8	NULL
,	NULL
27	NULL
,	NULL
28	NULL
,	NULL
31	NULL
,	NULL
81	NULL
)	NULL
.	NULL

Additionally	NULL
,	NULL
although	NULL
both	NULL
group	NULL
III	NULL
BL	NULL
cell	NULL
lines	NULL
and	NULL
LCL	NULL
s	NULL
express	NULL
the	NULL
Fas	NULL
voL	NULL
.	NULL

73	NULL
,	NULL
1999	NULL
CELL	NULL
CYCLE	NULL
AND	NULL
APOPTOSIS	NULL
IN	NULL
EBV	NULL
INFECTION	NULL
-	NULL
4681	NULL
A	NULL
g	NULL
B	NULL
C	NULL
&	NULL
g	NULL
N	NULL
Primary	NULL
B	NULL
cells	NULL
Primary	NULL
B	NULL
cells	NULL
~	NULL
LCL-C	NULL
#	NULL
7	NULL
#	NULL
4	NULL
¢	NULL
L4	NULL
]	NULL
,	NULL
96.2	NULL
%	NULL
7.2	NULL
%	NULL
[	NULL
%	NULL
70.8	NULL
%	NULL
ég	NULL
#	NULL
}	NULL
|	NULL
H	NULL
ﬂ	NULL
.	NULL

“	NULL
57	NULL
I	NULL
;	NULL
H	NULL
’	NULL
n	NULL
'	NULL
87	NULL
1L	NULL
``	NULL
I	NULL
:	NULL
;	NULL
a	NULL
Pu	NULL
Whoa	NULL
,	NULL
s	NULL
f*	NULL
in	NULL
“	NULL
.	NULL

uL-x	NULL
.	NULL

,	NULL
iw	NULL
aa	NULL
)	NULL
ag	NULL
as	NULL
-	NULL
ad	NULL
iw	NULL
o	NULL
ao	NULL
!	NULL

ag	NULL
G	NULL
#	NULL
an	NULL
in	NULL
``	NULL
_	NULL
aol	NULL
as	NULL
_	NULL
im	NULL
_	NULL
as	NULL
``	NULL
anti	NULL
CD20-FITC	NULL
anti	NULL
CD23-FITC	NULL
anti	NULL
CD23-FITC	NULL
D	NULL
E	NULL
100	NULL
50	NULL
€	NULL
>	NULL
€0	NULL
75	NULL
&	NULL
4	NULL
C	NULL
é	NULL
3	NULL
$	NULL
8	NULL
50	NULL
o	NULL
=	NULL
&	NULL
s	NULL
°	NULL
=	NULL
25	NULL
=	NULL
3	NULL
5	NULL
a	NULL
*	NULL
E	NULL
0	NULL
0	NULL
0	NULL
20	NULL
_	NULL
40	NULL
_	NULL
60	NULL
_	NULL
80	NULL
0	NULL
_	NULL
20	NULL
_	NULL
40	NULL
_	NULL
60	NULL
_	NULL
80	NULL
Hours	NULL
Hours	NULL
G	NULL
12	NULL
hrs	NULL
0	NULL
200	NULL
400	NULL
600	NULL
$	NULL
00	NULL
1000	NULL
0	NULL
200	NULL
400	NULL
600	NULL
$	NULL
00	NULL
1006	NULL
I	NULL
72	NULL
hrs	NULL
1	NULL
200	NULL
.-	NULL
400	NULL
.	NULL

600	NULL
.	NULL

$	NULL
00	NULL
.	NULL

1000	NULL
DNA	NULL
content	NULL
[	NULL
200	NULL
400	NULL
.	NULL

600	NULL
.	NULL

$	NULL
00	NULL
..	NULL
1000	NULL
DNA	NULL
content	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Primary	NULL
B	NULL
cells	NULL
isolated	NULL
by	NULL
CD19	NULL
positive	NULL
selection	NULL
were	NULL
stained	NULL
with	NULL
FITC-conjugated	NULL
antibodies	NULL
recognizing	NULL
(	NULL
A	NULL
)	NULL
CD20	NULL
or	NULL
(	NULL
B	NULL
)	NULL
CD23	NULL
and	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

An	NULL
LCL	NULL
immortalized	NULL
with	NULL
B95-8	NULL
EBV	NULL
(	NULL
C	NULL
)	NULL
was	NULL
used	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
for	NULL
CD23	NULL
staining	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
positive	NULL
cells	NULL
was	NULL
determined	NULL
by	NULL
using	NULL
linear	NULL
gates	NULL
set	NULL
to	NULL
include	NULL
1	NULL
%	NULL
positive	NULL
cells	NULL
on	NULL
unstained	NULL
samples	NULL
(	NULL
dotted	NULL
lines	NULL
)	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Numbers	NULL
of	NULL
viable	NULL
(	NULL
squares	NULL
)	NULL
and	NULL
dead	NULL
(	NULL
circles	NULL
)	NULL
cells	NULL
were	NULL
determined	NULL
by	NULL
trypan	NULL
blue	NULL
exclusion	NULL
in	NULL
uninfected	NULL
(	NULL
open	NULL
symbols	NULL
)	NULL
and	NULL
EBV-infected	NULL
(	NULL
filled	NULL
symbols	NULL
)	NULL
cultures	NULL
.	NULL

(	NULL
E	NULL
)	NULL
DNA	NULL
synthesis	NULL
was	NULL
measured	NULL
by	NULL
[	NULL
*H	NULL
}	NULL
thymidine	NULL
incorporation	NULL
in	NULL
uninfected	NULL
(	NULL
open	NULL
squares	NULL
)	NULL
and	NULL
EBV	NULL
infected	NULL
(	NULL
filled	NULL
squares	NULL
)	NULL
cells	NULL
.	NULL

Uninfected	NULL
(	NULL
F	NULL
and	NULL
H	NULL
)	NULL
and	NULL
EBV-infected	NULL
(	NULL
G	NULL
and	NULL
I	NULL
)	NULL
cells	NULL
containing	NULL
less	NULL
than	NULL
2	NULL
N	NULL
DNA	NULL
and	NULL
those	NULL
in	NULL
G	NULL
;	NULL
,	NULL
S	NULL
,	NULL
and	NULL
G	NULL
;	NULL
/M	NULL
phases	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
were	NULL
analyzed	NULL
by	NULL
propidium	NULL
iodide	NULL
staining	NULL
at	NULL
12	NULL
(	NULL
F	NULL
and	NULL
G	NULL
)	NULL
and	NULL
72	NULL
(	NULL
H	NULL
an	NULL
I	NULL
)	NULL
h	NULL
after	NULL
the	NULL
addition	NULL
of	NULL
virus	NULL
.	NULL

receptor	NULL
,	NULL
only	NULL
LCL	NULL
s	NULL
are	NULL
sensitive	NULL
to	NULL
ligation	NULL
of	NULL
the	NULL
Fas	NULL
receptor	NULL
(	NULL
21	NULL
)	NULL
.	NULL

However	NULL
,	NULL
this	NULL
study	NULL
measured	NULL
DNA	NULL
synthesis	NULL
and	NULL
did	NULL
not	NULL
directly	NULL
examine	NULL
effects	NULL
of	NULL
Fas	NULL
on	NULL
apoptosis	NULL
.	NULL

To	NULL
confirm	NULL
that	NULL
decreased	NULL
DNA	NULL
synthesis	NULL
in	NULL
Fas-treated	NULL
LCLs	NULL
was	NULL
due	NULL
to	NULL
induction	NULL
of	NULL
apoptosis	NULL
,	NULL
we	NULL
treated	NULL
Fas	NULL
receptor-positive	NULL
group	NULL
III	NULL
BL	NULL
cell	NULL
lines	NULL
and	NULL
LCLs	NULL
with	NULL
an	NULL
agonistic	NULL
Fas	NULL
antibody	NULL
.	NULL

Consistent	NULL
with	NULL
earlier	NULL
results	NULL
(	NULL
21	NULL
)	NULL
,	NULL
anti-Fas	NULL
induced	NULL
cell	NULL
death	NULL
in	NULL
LCLs	NULL
but	NULL
not	NULL
in	NULL
group	NULL
III	NULL
BL	NULL
cell	NULL
lines	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
,	NULL
and	NULL
analysis	NULL
of	NULL
genomic	NULL
DNA	NULL
demonstrated	NULL
DNA	NULL
degradation	NULL
characteristic	NULL
of	NULL
apoptosis	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

4682	NULL
SPENDER	NULL
ET	NULL
AL	NULL
.	NULL

J.	NULL
Virou	NULL
.	NULL

Time	NULL
-	NULL
12	NULL
24	NULL
48	NULL
96	NULL
30	NULL
-	NULL
12	NULL
24	NULL
48	NULL
9	NULL
%	NULL
-	NULL
48	NULL
9	NULL
%	NULL
30	NULL
-	NULL
12	NULL
24	NULL
9	NULL
%	NULL
0	NULL
12	NULL
9	NULL
%	NULL
(	NULL
hrs	NULL
)	NULL
-	NULL
6	NULL
16	NULL
30	NULL
72	NULL
0	NULL
6	NULL
16	NULL
30	NULL
720	NULL
M	NULL
72	NULL
o	NULL
6	NULL
16	NULL
30	NULL
_	NULL
0	NULL
24	NULL
Ev	NULL
t	NULL
#	NULL
t+++++++	NULL
-o-	NULL
4+4+4+4+4+4+	NULL
#	NULL
4+4	NULL
--	NULL
-	NULL
>	NULL
-o-	NULL
444444	NULL
-	NULL
-~	NULL
~	NULL
>	NULL
PMA	NULL
|	NULL
.	NULL

4	NULL
4	NULL
-	NULL
&	NULL
4	NULL
-	NULL
-	NULL
=o	NULL
&	NULL
-	NULL
<	NULL
e	NULL
e	NULL
<	NULL
-o-	NULL
++++	NULL
«	NULL
0	NULL
%	NULL
0	NULL
<	NULL
_	NULL
-	NULL
-	NULL
o=	NULL
-+++	NULL
-	NULL
«	NULL
os	NULL
as	NULL
p130	NULL
#	NULL
woo	NULL
§BP	NULL
te	NULL
16090	NULL
~	NULL
<	NULL
b	NULL
eer	NULL
on	NULL
<	NULL
e	NULL
EBNA-LP	NULL
o	NULL
ae	NULL
.	NULL

p107	NULL
-	NULL
prFj	NULL
-	NULL
@	NULL
@	NULL
pRb	NULL
s®O	NULL
>	NULL
-	NULL
_sg4t	NULL
EBNA-2	NULL
ons	NULL
.	NULL

«	NULL
ne	NULL
mes	NULL
we	NULL
see	NULL
Me	NULL
I	NULL
“	NULL
*=	NULL
P	NULL
N	NULL
LMP-1	NULL
wk	NULL
|_	NULL
E2F-1	NULL
_	NULL
#	NULL
@	NULL
#	NULL
p130	NULL
-	NULL
@	NULL
w	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Purified	NULL
B	NULL
cells	NULL
positively	NULL
selected	NULL
from	NULL
peripheral	NULL
blood	NULL
were	NULL
infected	NULL
with	NULL
EBV	NULL
or	NULL
treated	NULL
with	NULL
PMA	NULL
(	NULL
30	NULL
ng/m	NULL
!	NULL
)	NULL

in	NULL
a	NULL
time	NULL
course	NULL
,	NULL
and	NULL
aliquots	NULL
were	NULL
assayed	NULL
by	NULL
Western	NULL
blotting	NULL
for	NULL
the	NULL
proteins	NULL
indicated	NULL
.	NULL

Purified	NULL
B	NULL
cells	NULL
negatively	NULL
selected	NULL
from	NULL
tonsils	NULL
(	NULL
N	NULL
)	NULL
were	NULL
also	NULL
compared	NULL
with	NULL
the	NULL
positively	NULL
selected	NULL
B	NULL
cells	NULL
from	NULL
peripheral	NULL
blood	NULL
(	NULL
P	NULL
)	NULL
for	NULL
p130	NULL
expression	NULL
(	NULL
lower	NULL
right	NULL
panel	NULL
)	NULL
.	NULL

To	NULL
relate	NULL
these	NULL
differences	NULL
in	NULL
apoptosis	NULL
sensitivity	NULL
to	NULL
the	NULL
endogenous	NULL
levels	NULL
of	NULL
apoptosis-regulatory	NULL
molecules	NULL
,	NULL
we	NULL
examined	NULL
expression	NULL
of	NULL
BCL-2	NULL
,	NULL
BAX	NULL
,	NULL
BCL-XL	NULL
,	NULL
BAK	NULL
,	NULL
MCL-1	NULL
,	NULL
and	NULL
BAG-1	NULL
isoforms	NULL
by	NULL
immunoblotting	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
)	NULL
,	NULL
and	NULL
the	NULL
results	NULL
are	NULL
summarized	NULL
in	NULL
Fig	NULL
.	NULL

6C	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
antiapoptotic	NULL
A20	NULL
gene	NULL
was	NULL
measured	NULL
by	NULL
Northern	NULL
blotting	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
and	NULL
compared	NULL
to	NULL
the	NULL
protein	NULL
data	NULL
(	NULL
Fig	NULL
.	NULL

6C	NULL
)	NULL
.	NULL

Reactivity	NULL
with	NULL
the	NULL
P-19	NULL
antibody	NULL
was	NULL
also	NULL
determined	NULL
in	NULL
the	NULL
cell	NULL
lines	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
)	NULL
(	NULL
see	NULL
below	NULL
)	NULL
.	NULL

Consistent	NULL
with	NULL
previous	NULL
data	NULL
(	NULL
27	NULL
,	NULL
28	NULL
)	NULL
,	NULL
expression	NULL
of	NULL
BCL-2	NULL
was	NULL
higher	NULL
in	NULL
LCLs	NULL
and	NULL
group	NULL
III	NULL
BL	NULL
cell	NULL
lines	NULL
than	NULL
in	NULL
EBV-negative	NULL
and	NULL
group	NULL
I	NULL
BL	NULL
cell	NULL
lines	NULL
.	NULL

The	NULL
sizes	NULL
of	NULL
the	NULL
proteins	NULL
on	NULL
the	NULL
Western	NULL
blots	NULL
indicated	NULL
that	NULL
BAX	NULL
was	NULL
entirely	NULL
the	NULL
a	NULL
form	NULL
,	NULL
with	NULL
no	NULL
evidence	NULL
of	NULL
B	NULL
,	NULL
y	NULL
,	NULL
or	NULL
8	NULL
splicing	NULL
,	NULL
and	NULL
BCL-X	NULL
was	NULL
entirely	NULL
the	NULL
L	NULL
form	NULL
,	NULL
with	NULL
no	NULL
evidence	NULL
of	NULL
BCL-X4	NULL
.	NULL

We	NULL
have	NULL
recently	NULL
clarified	NULL
the	NULL
nature	NULL
of	NULL
the	NULL
two	NULL
BAG-1	NULL
isoforms	NULL
(	NULL
53	NULL
)	NULL
and	NULL
shown	NULL
that	NULL
the	NULL
absence	NULL
of	NULL
BAX	NULL
protein	NULL
in	NULL
DG75	NULL
cells	NULL
is	NULL
due	NULL
to	NULL
a	NULL
frameshift	NULL
mutation	NULL
in	NULL
the	NULL
BAX	NULL
gene	NULL
(	NULL
9	NULL
)	NULL
.	NULL

Of	NULL
the	NULL
other	NULL
genes	NULL
assayed	NULL
which	NULL
can	NULL
contribute	NULL
to	NULL
the	NULL
overall	NULL
threshold	NULL
of	NULL
apoptosis	NULL
,	NULL
only	NULL
the	NULL
A20	NULL
gene	NULL
showed	NULL
a	NULL
correlation	NULL
with	NULL
the	NULL
resistance	NULL
to	NULL
apoptosis	NULL
induced	NULL
by	NULL
low	NULL
serum	NULL
characteristic	NULL
of	NULL
LCLs	NULL
:	NULL
in	NULL
this	NULL
panel	NULL
of	NULL
cell	NULL
lines	NULL
,	NULL
it	NULL
correlated	NULL
almost	NULL
as	NULL
well	NULL
as	NULL
BCL-2	NULL
expression	NULL
.	NULL

However	NULL
,	NULL
neither	NULL
the	NULL
endogenous	NULL
A20	NULL
nor	NULL
BCL-2	NULL
expressed	NULL
in	NULL
LCLs	NULL
is	NULL
sufficient	NULL
to	NULL
make	NULL
the	NULL
EBV-immortalized	NULL
LCL	NULL
s	NULL
resistant	NULL
to	NULL
Fas-induced	NULL
apoptosis	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
the	NULL
group	NULL
III	NULL
BL	NULL
lines	NULL
,	NULL
which	NULL
have	NULL
EBV	NULL
gene	NULL
expression	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
LCL	NULL
s	NULL
but	NULL
are	NULL
relatively	NULL
resistant	NULL
to	NULL
Fas-induced	NULL
apoptosis	NULL
.	NULL

The	NULL
promoter	NULL
for	NULL
the	NULL
A20	NULL
gene	NULL
can	NULL
be	NULL
regulated	NULL
through	NULL
two	NULL
adjacent	NULL
NF-	NULL
«	NULL
B	NULL
sites	NULL
45	NULL
to	NULL
66	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
transcription	NULL
start	NULL
(	NULL
38	NULL
)	NULL
,	NULL
so	NULL
it	NULL
seemed	NULL
likely	NULL
that	NULL
this	NULL
transcription	NULL
factor	NULL
(	NULL
which	NULL
can	NULL
be	NULL
induced	NULL
by	NULL
LMP	NULL
would	NULL
be	NULL
what	NULL
determines	NULL
A20	NULL
expression	NULL
in	NULL
LCLs	NULL
.	NULL

Recent	NULL
work	NULL
indicates	NULL
that	NULL
during	NULL
the	NULL
time	NULL
course	NULL
of	NULL
early	NULL
EBV	NULL
infection	NULL
there	NULL
is	NULL
a	NULL
very	NULL
early	NULL
induction	NULL
of	NULL
NF-kB	NULL
followed	NULL
by	NULL
a	NULL
later	NULL
,	NULL
larger	NULL
induction	NULL
,	NULL
presumably	NULL
caused	NULL
by	NULL
the	NULL
LMP	NULL
protein	NULL
.	NULL

The	NULL
early	NULL
transient	NULL
induction	NULL
of	NULL
NF-kB	NULL
correlated	NULL
with	NULL
the	NULL
signal	NULL
transduction	NULL
activated	NULL
by	NULL
the	NULL
binding	NULL
of	NULL
EBV	NULL
to	NULL
its	NULL
receptor	NULL
on	NULL
the	NULL
cell	NULL
,	NULL
CD21	NULL
(	NULL
75	NULL
)	NULL
.	NULL

We	NULL
analyzed	NULL
the	NULL
time	NULL
course	NULL
of	NULL
expression	NULL
of	NULL
different	NULL
components	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
complex	NULL
and	NULL
its	NULL
inhibitory	NULL
I-	NULL
<	NULL
B	NULL
proteins	NULL
during	NULL
EBV	NULL
infection	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

LMP-1	NULL
continued	NULL
to	NULL
accumulate	NULL
even	NULL
up	NULL
to	NULL
144	NULL
h	NULL
after	NULL
infection	NULL
,	NULL
but	NULL
the	NULL
p65	NULL
,	NULL
p50	NULL
,	NULL
p52	NULL
,	NULL
c-Rel	NULL
,	NULL
Rel-B	NULL
,	NULL
and	NULL
Ix-Ba	NULL
proteins	NULL
were	NULL
all	NULL
induced	NULL
to	NULL
their	NULL
steady-state	NULL
levels	NULL
by	NULL
48	NULL
h	NULL
after	NULL
infection	NULL
.	NULL

The	NULL
level	NULL
of	NULL
Time	NULL
30	NULL
12	NULL
2M	NULL
48	NULL
%	NULL
48	NULL
-	NULL
96	NULL
(	NULL
hrs	NULL
)	NULL
_	NULL
0	NULL
6	NULL
°	NULL
160	NULL
30	NULL
72	NULL
24	NULL
72	NULL
EBV	NULL
O-	NULL
-	NULL
ot4+++++++4+	NULL
-	NULL
--	NULL
-PMA	NULL
=	NULL
L	NULL
200	NULL
<	NULL
<	NULL
<	NULL
<	NULL
<	NULL
-	NULL
<	NULL
-	NULL
~-	NULL
+++	NULL
+	NULL
we	NULL
ome	NULL
ome	NULL
am	NULL
»	NULL
«	NULL
-	NULL
ape	NULL
-~	NULL
cyclin	NULL
D2	NULL
68	NULL
-	NULL
sees	NULL
«	NULL
p27	NULL
«	NULL
-am	NULL
=	NULL
cok	NULL
2	NULL
``	NULL
~-	NULL
-	NULL
@	NULL
-	NULL
-	NULL
@	NULL
Go*	NULL
edk	NULL
4	NULL
<	NULL
r	NULL
<	NULL
ra	NULL
»	NULL
er	NULL
cdk	NULL
6	NULL
24	NULL
48	NULL
9	NULL
%	NULL
cyclin	NULL
E	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Purified	NULL
B	NULL
cells	NULL
from	NULL
peripheral	NULL
blood	NULL
were	NULL
infected	NULL
with	NULL
EBV	NULL
or	NULL
treated	NULL
with	NULL
PMA	NULL
(	NULL
30	NULL
ng/m	NULL
!	NULL
)	NULL

in	NULL
a	NULL
time	NULL
course	NULL
,	NULL
and	NULL
aliquots	NULL
were	NULL
assayed	NULL
by	NULL
Western	NULL
blotting	NULL
for	NULL
the	NULL
proteins	NULL
indicated	NULL
.	NULL

+	NULL
,	NULL
present	NULL
;	NULL
-	NULL
,	NULL
absent	NULL
.	NULL

Vou	NULL
.	NULL

73	NULL
,	NULL
1999	NULL
A	NULL
1	NULL
2	NULL
3	NULL
4	NULL
500	NULL
Lane	NULL
0	NULL
-	NULL
24	NULL
-	NULL
48	NULL
_	NULL
Time	NULL
(	NULL
hrs	NULL
)	NULL
<	NULL
ol	NULL
>	NULL
4m	NULL
.	NULL

<	NULL
a	NULL
cus	NULL
EBNA-LP	NULL
309	NULL
2441240	NULL
219	NULL
s	NULL
p130	NULL
«	NULL
mee	NULL
cyclin	NULL
D2	NULL
&	NULL
&	NULL
406	NULL
E2F-4	NULL
8-4	NULL
-*	NULL
p27	NULL
CELL	NULL
CYCLE	NULL
AND	NULL
APOPTOSIS	NULL
IN	NULL
EBV	NULL
INFECTION	NULL
_	NULL
4683	NULL
EBV	NULL
U.V	NULL
.	NULL

EBV	NULL
M	NULL
P	NULL
Y	NULL
O	NULL
24	NULL
48	NULL
48	NULL
-	NULL
24	NULL
48	NULL
-	NULL
M	NULL
(	NULL
1	NULL
)	NULL
2	NULL
)	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Purified	NULL
B	NULL
cells	NULL
from	NULL
peripheral	NULL
blood	NULL
were	NULL
infected	NULL
with	NULL
EBV	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
4	NULL
)	NULL
or	NULL
UV-inactivated	NULL
EBV	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
5	NULL
)	NULL
or	NULL
left	NULL
uninfected	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

Extracts	NULL
of	NULL
the	NULL
cells	NULL
were	NULL
prepared	NULL
at	NULL
the	NULL
indicated	NULL
times	NULL
after	NULL
infection	NULL
and	NULL
assayed	NULL
by	NULL
Western	NULL
blotting	NULL
.	NULL

(	NULL
B	NULL
)	NULL
RNA	NULL
was	NULL
extracted	NULL
from	NULL
cells	NULL
infected	NULL
as	NULL
for	NULL
panel	NULL
(	NULL
A	NULL
)	NULL
and	NULL
assayed	NULL
by	NULL
RNase	NULL
protection	NULL
analysis	NULL
for	NULL
E2F-4	NULL
RNA	NULL
.	NULL

The	NULL
undigested	NULL
probe	NULL
(	NULL
1	NULL
%	NULL
of	NULL
the	NULL
input	NULL
)	NULL
is	NULL
shown	NULL
in	NULL
track	NULL
P	NULL
,	NULL
and	NULL
track	NULL
Y	NULL
is	NULL
the	NULL
negative	NULL
control	NULL
RPA	NULL
with	NULL
yeast	NULL
RNA	NULL
.	NULL

The	NULL
band	NULL
at	NULL
286	NULL
nucleotides	NULL
(	NULL
arrowhead	NULL
)	NULL
indicates	NULL
the	NULL
presence	NULL
of	NULL
E2F-4	NULL
RNA	NULL
.	NULL

Samples	NULL
48	NULL
(	NULL
1	NULL
)	NULL
and	NULL
48	NULL
(	NULL
2	NULL
)	NULL
are	NULL
the	NULL
48-h	NULL
time	NULL
points	NULL
from	NULL
two	NULL
parallel	NULL
infections	NULL
.	NULL

Size	NULL
markers	NULL
(	NULL
track	NULL
M	NULL
)	NULL
were	NULL
an	NULL
MspI	NULL
digest	NULL
of	NULL
pBR322	NULL
DNA	NULL
end	NULL
repaired	NULL
with	NULL
Klenow	NULL
DNA	NULL
polymerase	NULL
.	NULL

U.V	NULL
.	NULL

EBV	NULL
,	NULL
UV-inactivated	NULL
EBV	NULL
.	NULL

Ix-BB	NULL
was	NULL
higher	NULL
in	NULL
the	NULL
uninfected	NULL
cells	NULL
than	NULL
in	NULL
the	NULL
EBV-infected	NULL
cells	NULL
but	NULL
also	NULL
achieved	NULL
a	NULL
steady-state	NULL
level	NULL
by	NULL
48	NULL
h	NULL
after	NULL
infection	NULL
.	NULL

LMP-1	NULL
expression	NULL
in	NULL
our	NULL
system	NULL
is	NULL
usually	NULL
detected	NULL
at	NULL
48	NULL
to	NULL
72	NULL
h	NULL
,	NULL
so	NULL
the	NULL
components	NULL
of	NULL
the	NULL
NF-kB	NULL
factor	NULL
were	NULL
therefore	NULL
all	NULL
present	NULL
at	NULL
their	NULL
steady-state	NULL
levels	NULL
by	NULL
the	NULL
time	NULL
LMP	NULL
was	NULL
expressed	NULL
.	NULL

Since	NULL
exists	NULL
as	NULL
an	NULL
inactive	NULL
complex	NULL
with	NULL
in	NULL
the	NULL
cytoplasm	NULL
,	NULL
awaiting	NULL
activation	NULL
in	NULL
response	NULL
to	NULL
signal	NULL
transduc-tion	NULL
,	NULL
we	NULL
wished	NULL
to	NULL
compare	NULL
the	NULL
time	NULL
course	NULL
of	NULL
induction	NULL
of	NULL
the	NULL
LMP	NULL
protein	NULL
and	NULL
the	NULL
level	NULL
of	NULL
activated	NULL
NF-kB	NULL
.	NULL

The	NULL
level	NULL
of	NULL
activated	NULL
NF-	NULL
«	NULL
xB	NULL
was	NULL
determined	NULL
by	NULL
gel	NULL
retardation	NULL
assays	NULL
of	NULL
an	NULL
oligonucleotide	NULL
containing	NULL
a	NULL
consensus	NULL
NF-kB	NULL
binding	NULL
site	NULL
.	NULL

The	NULL
specificity	NULL
of	NULL
the	NULL
assay	NULL
was	NULL
established	NULL
by	NULL
using	NULL
nuclear	NULL
extracts	NULL
of	NULL
LCL3	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

8A	NULL
)	NULL
;	NULL
the	NULL
broad	NULL
band	NULL
of	NULL
retarded	NULL
kB	NULL
complexes	NULL
was	NULL
dependent	NULL
on	NULL
the	NULL
addition	NULL
of	NULL
cell	NULL
extract	NULL
and	NULL
was	NULL
competed	NULL
by	NULL
an	NULL
oligonucleotide	NULL
containing	NULL
a	NULL
xB	NULL
site	NULL
but	NULL
not	NULL
by	NULL
an	NULL
unrelated	NULL
control	NULL
oligonucleotide	NULL
.	NULL

Further	NULL
evidence	NULL
for	NULL
specificity	NULL
was	NULL
provided	NULL
by	NULL
supershifting	NULL
the	NULL
complexes	NULL
with	NULL
antibodies	NULL
to	NULL
components	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
factor	NULL
.	NULL

The	NULL
faster-migrating	NULL
part	NULL
of	NULL
the	NULL
complex	NULL
was	NULL
supershifted	NULL
by	NULL
an	NULL
antibody	NULL
to	NULL
p50	NULL
,	NULL
the	NULL
slower-migrating	NULL
part	NULL
of	NULL
the	NULL
complex	NULL
was	NULL
supershifted	NULL
by	NULL
an	NULL
antibody	NULL
to	NULL
p65	NULL
,	NULL
and	NULL
the	NULL
level	NULL
of	NULL
the	NULL
whole	NULL
complex	NULL
was	NULL
reduced	NULL
by	NULL
an	NULL
antibody	NULL
to	NULL
p52	NULL
.	NULL

Antibodies	NULL
to	NULL
RelB	NULL
and	NULL
cRel	NULL
did	NULL
not	NULL
appear	NULL
to	NULL
affect	NULL
the	NULL
complexes	NULL
,	NULL
and	NULL
major	NULL
components	NULL
of	NULL
the	NULL
two	NULL
complexes	NULL
may	NULL
be	NULL
p50-p50	NULL
and	NULL
p50-p65	NULL
.	NULL

This	NULL
assay	NULL
was	NULL
then	NULL
applied	NULL
to	NULL
the	NULL
time	NULL
course	NULL
of	NULL
EBV	NULL
infection	NULL
by	NULL
using	NULL
nuclear	NULL
extracts	NULL
from	NULL
purified	NULL
B	NULL
cells	NULL
at	NULL
various	NULL
times	NULL
after	NULL
infection	NULL
.	NULL

The	NULL
level	NULL
of	NULL
activated	NULL
NF-kB	NULL
(	NULL
Fig	NULL
.	NULL

8C	NULL
)	NULL
and	NULL
the	NULL
level	NULL
of	NULL
LMP-1	NULL
(	NULL
Fig	NULL
.	NULL

8B	NULL
)	NULL
correlated	NULL
in	NULL
time	NULL
,	NULL
consistent	NULL
with	NULL
LMP-1	NULL
being	NULL
responsible	NULL
for	NULL
the	NULL
major	NULL
increase	NULL
in	NULL
activated	NULL
NF-kB	NULL
observed	NULL
during	NULL
primary	NULL
infection	NULL
.	NULL

The	NULL
NF-KB	NULL
site	NULL
in	NULL
the	NULL
oligonucleotide	NULL
used	NULL
for	NULL
the	NULL
determination	NULL
of	NULL
activated	NULL
NF-kB	NULL
in	NULL
the	NULL
gel	NULL
retardation	NULL
assay	NULL
was	NULL
identical	NULL
to	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
in	NULL
the	NULL
A20	NULL
promoter	NULL
57	NULL
to	NULL
66	NULL
nucleotides	NULL
upstream	NULL
of	NULL
the	NULL
transcription	NULL
start	NULL
in	NULL
the	NULL
published	NULL
A20	NULL
sequence	NULL
(	NULL
38	NULL
)	NULL
.	NULL

The	NULL
induction	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
these	NULL
B	NULL
cells	NULL
A	NULL
1007	NULL
.	NULL

(	NULL
``	NULL
-	NULL
-L	NULL
-	NULL
l	NULL
a	NULL
Ro	NULL
757	NULL
hat	NULL
>	NULL
.	NULL

~	NULL
,	NULL
=	NULL
~	NULL
a	NULL
=	NULL
.	NULL

S	NULL
s.	NULL
o	NULL
*~	NULL
507	NULL
~	NULL
a-	NULL
*	NULL
C	NULL
%	NULL
$	NULL
2	NULL
5	NULL
a	NULL
a	NULL
[	NULL
%	NULL
25	NULL
[	NULL
(	NULL
~	NULL
*	NULL
+	NULL
.	NULL

~	NULL
o	NULL
BL74	NULL
B	NULL
is	NULL
1	NULL
2	NULL
3	NULL
4	NULL
1	NULL
2	NULL
3	NULL
4	NULL
pampered	NULL
@	NULL
LCL3	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Sensitivity	NULL
of	NULL
LCLs	NULL
and	NULL
resistance	NULL
of	NULL
BL	NULL
cells	NULL
to	NULL
Fas-induced	NULL
apoptosis	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Cell	NULL
viability	NULL
was	NULL
assayed	NULL
by	NULL
trypan	NULL
blue	NULL
exclusion	NULL
after	NULL
24	NULL
h	NULL
of	NULL
treatment	NULL
with	NULL
anti-Fas	NULL
antibody	NULL
at	NULL
100	NULL
(	NULL
crosshatch	NULL
)	NULL
or	NULL
500	NULL
(	NULL
solid	NULL
)	NULL
ng/ml	NULL
or	NULL
with	NULL
control	NULL
antibody	NULL
(	NULL
open	NULL
)	NULL
.	NULL

Error	NULL
bars	NULL
indicate	NULL
standard	NULL
deviation	NULL
.	NULL

(	NULL
B	NULL
)	NULL
DNA	NULL
laddering	NULL
was	NULL
assayed	NULL
in	NULL
B4	NULL
and	NULL
LCL3	NULL
cells	NULL
treated	NULL
for	NULL
8	NULL
h	NULL
with	NULL
100	NULL
(	NULL
tracks	NULL
1	NULL
)	NULL
or	NULL
500	NULL
(	NULL
tracks	NULL
2	NULL
)	NULL
ng	NULL
of	NULL
anti-Fas	NULL
antibody	NULL
or	NULL
500	NULL
ng	NULL
of	NULL
control	NULL
antibody	NULL
(	NULL
tracks	NULL
3	NULL
)	NULL
/ml	NULL
or	NULL
with	NULL
no	NULL
additions	NULL
(	NULL
tracks	NULL
4	NULL
)	NULL
.	NULL

4684	NULL
SPENDER	NULL
ET	NULL
AL	NULL
.	NULL

a	NULL
_	NULL
4o=	NULL
%	NULL
9	NULL
a-A	NULL
§	NULL
$	NULL
56	NULL
|	NULL
=	NULL
5	NULL
R	NULL
E	NULL
9	NULL
q	NULL
a	NULL
g	NULL
iid	NULL
ir	NULL
1	NULL
kg	NULL
cds	NULL
BCL-2	NULL
«	NULL
--	NULL
--	NULL
wou	NULL
Bots	NULL
,	NULL
Eo	NULL
»	NULL
fe	NULL
ak	NULL
at	NULL
ham	NULL
Iir	NULL
une	NULL
ms	NULL
coe	NULL
-..	NULL
$	NULL
M	NULL
=	NULL
-	NULL
somc	NULL
o	NULL
P19	NULL
t.	NULL
mas	NULL
:	NULL
mae	NULL
(	NULL
bie	NULL
lng	NULL
toe	NULL
ege	NULL
is	NULL
BAK	NULL
|	NULL
Wit	NULL
meme	NULL
®	NULL
a	NULL
f	NULL
z	NULL
8	NULL
&	NULL
3	NULL
9	NULL
;	NULL
z	NULL
Gl	NULL
=	NULL
ROR	NULL
%	NULL
a	NULL
9	NULL
$	NULL
cjdiibir	NULL
{	NULL
lg	NULL
da	NULL
MCI—	NULL
“	NULL
1	NULL
$	NULL
4	NULL
%	NULL
\o	NULL
cg	NULL
=	NULL
¥	NULL
5	NULL
-	NULL
a	NULL
Eos	NULL
x	NULL
3	NULL
.	NULL

§	NULL
5	NULL
3	NULL
0	NULL
pBOBAGA	NULL
|	NULL
-o-	NULL
LR	NULL
_	NULL
_-pMBAG-	NULL
!	NULL

|	NULL
-	NULL
us	NULL
us	NULL
purified	NULL
from	NULL
peripheral	NULL
blood	NULL
would	NULL
thus	NULL
account	NULL
for	NULL
the	NULL
expression	NULL
of	NULL
A20	NULL
in	NULL
the	NULL
LCLs	NULL
.	NULL

DISCUSSION	NULL
We	NULL
have	NULL
assayed	NULL
many	NULL
proteins	NULL
involved	NULL
in	NULL
regulation	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
and	NULL
apoptosis	NULL
during	NULL
EBV	NULL
infection	NULL
.	NULL

The	NULL
most	NULL
straightforward	NULL
interpretation	NULL
of	NULL
our	NULL
data	NULL
is	NULL
that	NULL
the	NULL
changes	NULL
represent	NULL
the	NULL
consequences	NULL
of	NULL
EBV	NULL
infection	NULL
leading	NULL
to	NULL
cell	NULL
proliferation	NULL
,	NULL
but	NULL
it	NULL
is	NULL
important	NULL
to	NULL
appreciate	NULL
that	NULL
there	NULL
is	NULL
a	NULL
heterogeneity	NULL
of	NULL
response	NULL
at	NULL
the	NULL
cellular	NULL
level	NULL
to	NULL
the	NULL
addition	NULL
of	NULL
virus	NULL
to	NULL
the	NULL
B	NULL
lymphocytes	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
cells	NULL
showed	NULL
a	NULL
high	NULL
degree	NULL
of	NULL
homogeneity	NULL
.	NULL

For	NULL
example	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
selected	NULL
with	NULL
the	NULL
B-cell	NULL
marker	NULL
CD19	NULL
and	NULL
then	NULL
also	NULL
verified	NULL
to	NULL
be	NULL
96	NULL
%	NULL
positive	NULL
for	NULL
the	NULL
B-cell	NULL
marker	NULL
CD20	NULL
;	NULL
they	NULL
were	NULL
a	NULL
resting	NULL
population	NULL
,	NULL
as	NULL
shown	NULL
by	NULL
the	NULL
lack	NULL
of	NULL
dine	NULL
incorporation	NULL
and	NULL
lack	NULL
of	NULL
CD23	NULL
activation	NULL
marker	NULL
.	NULL

It	NULL
is	NULL
J.	NULL
Virou	NULL
.	NULL

B	NULL
$	NULL
a	NULL
=	NULL
£	NULL
w	NULL
20	NULL
_	NULL
oc	NULL
s	NULL
e	NULL
1	NULL
o	NULL
na	NULL
moa	NULL
$	NULL
5	NULL
£	NULL
0	NULL
%	NULL
8	NULL
#	NULL
s	NULL
N	NULL
5	NULL
4	NULL
£	NULL
1	NULL
5	NULL
0	NULL
2a	NULL
a	NULL
a	NULL
$	NULL
s	NULL
©	NULL
%	NULL
a	NULL
8	NULL
2	NULL
s	NULL
0	NULL
»	NULL
o	NULL
a	NULL
a	NULL
a	NULL
£	NULL
£	NULL
ii	NULL
<	NULL
m	NULL
5	NULL
2	NULL
2	NULL
1	NULL
x	NULL
«	NULL
ae	NULL
f	NULL
<	NULL
4	NULL
N-20	NULL
BCL-2	NULL
BAX	NULL
BCL-Xp	NULL
BAG-1	NULL
BAK	NULL
MCL-1	NULL
A20	NULL
EBV	NULL
negative	NULL
BL	NULL
BL4L	NULL
-	NULL
+	NULL
+	NULL
++	NULL
ND	NULL
++	NULL
_	NULL
DG75	NULL
-	NULL
-	NULL
++	NULL
++	NULL
ND	NULL
++	NULL
BL40	NULL
-	NULL
+	NULL
++	NULL
++	NULL
+	NULL
+	NULL
BL2	NULL
+	NULL
+	NULL
++	NULL
++	NULL
+	NULL
+	NULL
Ramos	NULL
Rael	NULL
EBV	NULL
positive	NULL
BL	NULL
-	NULL
Group	NULL
I	NULL
Akata	NULL
-	NULL
+	NULL
++	NULL
++	NULL
+	NULL
+	NULL
+/-Elijah	NULL
-	NULL
+	NULL
+	NULL
++	NULL
+	NULL
+	NULL
EBV	NULL
positive	NULL
BL	NULL
-	NULL
Group	NULL
II/III	NULL
Namalwa	NULL
+	NULL
+	NULL
+	NULL
++	NULL
+	NULL
ND	NULL
Mutu	NULL
III	NULL
++	NULL
+	NULL
++	NULL
++	NULL
+/-	NULL
+	NULL
++	NULL
Raji	NULL
+	NULL
+	NULL
++	NULL
++	NULL
+	NULL
++	NULL
+	NULL
BL72	NULL
++	NULL
++	NULL
+	NULL
++	NULL
+	NULL
+	NULL
+	NULL
BL74	NULL
+	NULL
+	NULL
++	NULL
++	NULL
+/-	NULL
+	NULL
Wewak	NULL
I	NULL
t+	NULL
+	NULL
++	NULL
++	NULL
+	NULL
+	NULL
++	NULL
Jijoye	NULL
+	NULL
LCLs	NULL
BL36	NULL
LCL	NULL
+4	NULL
++	NULL
++	NULL
++	NULL
+	NULL
+	NULL
++	NULL
PF	NULL
LCL	NULL
++	NULL
++	NULL
++	NULL
++	NULL
+	NULL
+	NULL
++	NULL
LCL3	NULL
++	NULL
++	NULL
++	NULL
++	NULL
+	NULL
+	NULL
++	NULL
1B4	NULL
++	NULL
+	NULL
+	NULL
4+	NULL
+	NULL
+/-	NULL
++	NULL
X50-7	NULL
++	NULL
++	NULL
++	NULL
t+	NULL
+	NULL
+/-	NULL
+	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Expression	NULL
of	NULL
BCL-2	NULL
family	NULL
proteins	NULL
in	NULL
BL	NULL
cell	NULL
lines	NULL
and	NULL
LCLs	NULL
.	NULL

Lysates	NULL
were	NULL
prepared	NULL
from	NULL
the	NULL
indicated	NULL
cell	NULL
lines	NULL
,	NULL
and	NULL
equal	NULL
amounts	NULL
of	NULL
protein	NULL
were	NULL
analyzed	NULL
for	NULL
expression	NULL
of	NULL
BCL-2	NULL
family	NULL
proteins	NULL
by	NULL
immunoblot-ting	NULL
.	NULL

The	NULL
position	NULL
of	NULL
migration	NULL
of	NULL
each	NULL
protein	NULL
is	NULL
indicated	NULL
.	NULL

N20	NULL
data	NULL
for	NULL
BAX	NULL
expression	NULL
in	NULL
these	NULL
cell	NULL
lines	NULL
is	NULL
shown	NULL
in	NULL
reference	NULL
9	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Analysis	NULL
of	NULL
A20	NULL
RNA	NULL
expression	NULL
in	NULL
BL	NULL
cell	NULL
lines	NULL
and	NULL
LCLs	NULL
.	NULL

Cytoplasmic	NULL
RNA	NULL
isolated	NULL
from	NULL
the	NULL
indicated	NULL
cell	NULL
lines	NULL
was	NULL
analyzed	NULL
by	NULL
Northern	NULL
blotting	NULL
with	NULL
the	NULL
A20	NULL
cDNA	NULL
as	NULL
a	NULL
probe	NULL
.	NULL

Equal	NULL
loading	NULL
of	NULL
the	NULL
gel	NULL
tracks	NULL
was	NULL
confirmed	NULL
by	NULL
ethidium	NULL
bromide	NULL
staining	NULL
of	NULL
the	NULL
rRNA	NULL
bands	NULL
on	NULL
the	NULL
gel	NULL
before	NULL
transfer	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Summary	NULL
of	NULL
BCL-2	NULL
family	NULL
protein	NULL
expression	NULL
and	NULL
A20	NULL
RNA	NULL
expression	NULL
in	NULL
the	NULL
panel	NULL
of	NULL
cell	NULL
lines	NULL
studied	NULL
in	NULL
this	NULL
paper	NULL
.	NULL

Lines	NULL
marked	NULL
ND	NULL
were	NULL
not	NULL
tested	NULL
for	NULL
the	NULL
indicated	NULL
protein	NULL
or	NULL
RNA	NULL
.	NULL

A20	NULL
expression	NULL
was	NULL
determined	NULL
by	NULL
Northern	NULL
blotting	NULL
,	NULL
except	NULL
for	NULL
Raji	NULL
,	NULL
IB4	NULL
,	NULL
and	NULL
BL36LCL	NULL
,	NULL
which	NULL
were	NULL
assayed	NULL
by	NULL
RNase	NULL
protection	NULL
.	NULL

Group	NULL
III	NULL
BL	NULL
cell	NULL
lines	NULL
and	NULL
LCLs	NULL
are	NULL
resistant	NULL
to	NULL
apoptosis	NULL
induced	NULL
by	NULL
cross-linking	NULL
surface	NULL
immunoglobulin	NULL
,	NULL
ionomycin	NULL
,	NULL
and	NULL
serum	NULL
depletion	NULL
relative	NULL
to	NULL
group	NULL
I	NULL
and	NULL
EBV-negative	NULL
BL	NULL
cell	NULL
lines	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
LCLs	NULL
are	NULL
sensitive	NULL
to	NULL
Fas-induced	NULL
apoptosis	NULL
,	NULL
whereas	NULL
group	NULL
III	NULL
BL	NULL
cell	NULL
lines	NULL
are	NULL
resistant	NULL
.	NULL

Group	NULL
I	NULL
BL	NULL
cell	NULL
lines	NULL
and	NULL
EBV-negative	NULL
BL	NULL
lines	NULL
do	NULL
not	NULL
express	NULL
Fas	NULL
and	NULL
are	NULL
therefore	NULL
resistant	NULL
to	NULL
Fas-induced	NULL
apoptosis	NULL
.	NULL

possible	NULL
that	NULL
there	NULL
is	NULL
further	NULL
heterogeneity	NULL
in	NULL
the	NULL
B-cell	NULL
preparation	NULL
with	NULL
consequent	NULL
heterogeneity	NULL
of	NULL
response	NULL
to	NULL
the	NULL
virus	NULL
,	NULL
but	NULL
there	NULL
is	NULL
no	NULL
evidence	NULL
for	NULL
this	NULL
.	NULL

Under	NULL
the	NULL
conditions	NULL
used	NULL
,	NULL
about	NULL
27	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
became	NULL
positive	NULL
for	NULL
EBNA-LP	NULL
expression	NULL
by	NULL
immunofluorescence	NULL
.	NULL

We	NULL
are	NULL
not	NULL
able	NULL
to	NULL
track	NULL
individual	NULL
cells	NULL
through	NULL
the	NULL
long	NULL
time	NULL
course	NULL
of	NULL
immortalization	NULL
,	NULL
so	NULL
we	NULL
can	NULL
not	NULL
tell	NULL
at	NULL
this	NULL
stage	NULL
which	NULL
of	NULL
the	NULL
cells	NULL
will	NULL
eventually	NULL
grow	NULL
out	NULL
.	NULL

Over	NULL
the	NULL
first	NULL
72	NULL
h	NULL
of	NULL
infection	NULL
,	NULL
when	NULL
most	NULL
of	NULL
the	NULL
changes	NULL
occur	NULL
,	NULL
there	NULL
is	NULL
relatively	NULL
little	NULL
cell	NULL
death	NULL
and	NULL
negligible	NULL
proliferation	NULL
,	NULL
so	NULL
the	NULL
changes	NULL
are	NULL
not	NULL
likely	NULL
to	NULL
be	NULL
accounted	NULL
for	NULL
voL	NULL
.	NULL

73	NULL
,	NULL
1999	NULL
EBV	NULL
+++	NULL
++	NULL
000	NULL
sp	NULL
__	NULL
=p	NULL
BN	NULL
WS	NULL
:	NULL
sech	NULL
ahd	NULL
,	NULL
I	NULL
]	NULL
97	NULL
-	NULL
97	NULL
Pm	NULL
__	NULL
___	NULL
<	NULL
4	NULL
p65	NULL
66	NULL
46	NULL
-	NULL
46	NULL
97	NULL
-so-	NULL
97	NULL
z	NULL
-	NULL
<	NULL
p50	NULL
66	NULL
46	NULL
46	NULL
97	NULL
66	NULL
o	NULL
te	NULL
hae	NULL
Tas	NULL
<	NULL
4	NULL
p52	NULL
P	NULL
97	NULL
46	NULL
-	NULL
66	NULL
46	NULL
30	NULL
EBV	NULL
++	NULL
+++	NULL
1	NULL
f	NULL
c	NULL
@	NULL
RNRq	NULL
<	NULL
3	NULL
-	NULL
am	NULL
dts	NULL
CELL	NULL
CYCLE	NULL
AND	NULL
APOPTOSIS	NULL
IN	NULL
EBV	NULL
INFECTION	NULL
-	NULL
4685	NULL
EBV	NULL
+	NULL
++	NULL
++	NULL
1	NULL
5	NULL
wh	NULL
o_	NULL
Sf	NULL
o	NULL
2	NULL
{	NULL
N	NULL
©	NULL
Size	NULL
op	NULL
<	NULL
mon	NULL
dC	NULL
T	NULL
,	NULL
46	NULL
<	NULL
4	NULL
cRel	NULL
~~~	NULL
m	NULL
«	NULL
«	NULL
IkBa	NULL
.	NULL

30	NULL
66	NULL
-	NULL
-an	NULL
&	NULL
®	NULL
Gn	NULL
a	NULL
GRGIB	NULL
46	NULL
-	NULL
ae	NULL
e	NULL
<	NULL
IkBB	NULL
30	NULL
-	NULL
nc	NULL
in	NULL
on	NULL
's	NULL
46	NULL
&	NULL
LMP-1	NULL
30	NULL
-	NULL
_-	NULL
<	NULL
«	NULL
BCL-2	NULL
FIG	NULL
.	NULL

7	NULL
.	NULL

Purified	NULL
B	NULL
cells	NULL
positively	NULL
selected	NULL
from	NULL
peripheral	NULL
blood	NULL
were	NULL
infected	NULL
with	NULL
EBV	NULL
in	NULL
a	NULL
time	NULL
course	NULL
(	NULL
hours	NULL
post	NULL
infection	NULL
)	NULL
,	NULL
and	NULL
aliquots	NULL
were	NULL
assayed	NULL
by	NULL
Western	NULL
blotting	NULL
for	NULL
the	NULL
proteins	NULL
indicated	NULL
.	NULL

+	NULL
,	NULL
present	NULL
;	NULL
-	NULL
,	NULL
absent	NULL
;	NULL
x	NULL
,	NULL
empty	NULL
lane	NULL
.	NULL

by	NULL
population	NULL
effects	NULL
involving	NULL
subgroups	NULL
of	NULL
cells	NULL
containing	NULL
the	NULL
individual	NULL
marker	NULL
proteins	NULL
;	NULL
but	NULL
since	NULL
we	NULL
have	NULL
not	NULL
yet	NULL
followed	NULL
the	NULL
proteins	NULL
studied	NULL
here	NULL
by	NULL
Western	NULL
blotting	NULL
by	NULL
immunofluorescence	NULL
(	NULL
most	NULL
of	NULL
the	NULL
antibodies	NULL
used	NULL
are	NULL
not	NULL
suitable	NULL
for	NULL
immunofluorescence	NULL
studies	NULL
)	NULL
,	NULL
it	NULL
has	NULL
not	NULL
been	NULL
possible	NULL
to	NULL
link	NULL
the	NULL
changes	NULL
directly	NULL
to	NULL
expression	NULL
of	NULL
EBV	NULL
proteins	NULL
in	NULL
individual	NULL
cells	NULL
.	NULL

It	NULL
is	NULL
also	NULL
important	NULL
to	NULL
remember	NULL
that	NULL
the	NULL
virus	NULL
preparation	NULL
is	NULL
very	NULL
likely	NULL
to	NULL
be	NULL
heterogeneous	NULL
,	NULL
since	NULL
there	NULL
is	NULL
no	NULL
opportunity	NULL
to	NULL
plaque	NULL
purify	NULL
EBV	NULL
(	NULL
there	NULL
is	NULL
no	NULL
plaque	NULL
assay	NULL
)	NULL
and	NULL
there	NULL
is	NULL
little	NULL
knowledge	NULL
of	NULL
the	NULL
infectivity	NULL
per	NULL
virus	NULL
particle	NULL
.	NULL

In	NULL
spite	NULL
of	NULL
these	NULL
reservations	NULL
,	NULL
the	NULL
results	NULL
we	NULL
have	NULL
described	NULL
are	NULL
highly	NULL
consistent	NULL
with	NULL
the	NULL
entry	NULL
of	NULL
the	NULL
cells	NULL
into	NULL
the	NULL
cell	NULL
cycle	NULL
and	NULL
prevention	NULL
of	NULL
apoptosis	NULL
as	NULL
a	NULL
consequence	NULL
of	NULL
virus	NULL
infection	NULL
.	NULL

Since	NULL
EBV	NULL
infects	NULL
resting	NULL
B	NULL
cells	NULL
,	NULL
the	NULL
cells	NULL
must	NULL
first	NULL
enter	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

It	NULL
is	NULL
clear	NULL
that	NULL
some	NULL
activation	NULL
of	NULL
the	NULL
resting	NULL
cell	NULL
occurs	NULL
as	NULL
a	NULL
result	NULL
of	NULL
the	NULL
binding	NULL
of	NULL
the	NULL
gp350	NULL
surface	NULL
glycoprotein	NULL
on	NULL
the	NULL
virus	NULL
particle	NULL
to	NULL
the	NULL
receptor	NULL
on	NULL
the	NULL
cell	NULL
,	NULL
CD21	NULL
(	NULL
72	NULL
,	NULL
75	NULL
)	NULL
.	NULL

Signal	NULL
transduction	NULL
from	NULL
this	NULL
results	NULL
in	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
CD19	NULL
and	NULL
some	NULL
effects	NULL
of	NULL
the	NULL
virus	NULL
infection	NULL
in	NULL
the	NULL
cell	NULL
can	NULL
be	NULL
prevented	NULL
with	NULL
inhibitors	NULL
of	NULL
various	NULL
protein	NULL
kinases	NULL
(	NULL
71	NULL
)	NULL
.	NULL

A	NULL
small	NULL
,	NULL
transient	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
has	NULL
also	NULL
been	NULL
demonstrated	NULL
to	NULL
result	NULL
from	NULL
virus	NULL
binding	NULL
(	NULL
75	NULL
)	NULL
,	NULL
and	NULL
we	NULL
have	NULL
shown	NULL
here	NULL
that	NULL
part	NULL
of	NULL
the	NULL
reduction	NULL
in	NULL
mobility	NULL
of	NULL
E2F-4	NULL
occurs	NULL
with	NULL
UV-inactivated	NULL
EBV	NULL
,	NULL
implying	NULL
that	NULL
viral	NULL
gene	NULL
expression	NULL
is	NULL
not	NULL
necessary	NULL
for	NULL
this	NULL
effect	NULL
.	NULL

Other	NULL
responses	NULL
to	NULL
EBV	NULL
infection	NULL
that	NULL
we	NULL
have	NULL
measured	NULL
in	NULL
this	NULL
study	NULL
all	NULL
required	NULL
viral	NULL
gene	NULL
expression	NULL
.	NULL

One	NULL
of	NULL
the	NULL
most	NULL
remarkable	NULL
aspects	NULL
of	NULL
the	NULL
data	NULL
is	NULL
that	NULL
the	NULL
changes	NULL
in	NULL
protein	NULL
profiles	NULL
are	NULL
so	NULL
clear	NULL
and	NULL
complete	NULL
in	NULL
the	NULL
time	NULL
course	NULL
studied	NULL
.	NULL

For	NULL
example	NULL
,	NULL
p27	NULL
virtually	NULL
disappears	NULL
by	NULL
72	NULL
h	NULL
after	NULL
infection	NULL
and	NULL
there	NULL
are	NULL
major	NULL
changes	NULL
in	NULL
the	NULL
phosphorylation	NULL
profiles	NULL
of	NULL
p130	NULL
and	NULL
pRb	NULL
which	NULL
at	NULL
first	NULL
sight	NULL
seem	NULL
to	NULL
be	NULL
inconsistent	NULL
with	NULL
only	NULL
about	NULL
27	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
becoming	NULL
positive	NULL
for	NULL
EBNA-LP	NULL
,	NULL
our	NULL
early	NULL
marker	NULL
for	NULL
virus	NULL
infection	NULL
.	NULL

Potential	NULL
explanations	NULL
for	NULL
this	NULL
include	NULL
more	NULL
than	NULL
27	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
being	NULL
infected	NULL
(	NULL
perhaps	NULL
there	NULL
are	NULL
large	NULL
variations	NULL
in	NULL
the	NULL
degree	NULL
of	NULL
immunofluorescence	NULL
upon	NULL
infection	NULL
)	NULL
or	NULL
activation	NULL
of	NULL
other	NULL
cells	NULL
by	NULL
those	NULL
that	NULL
have	NULL
achieved	NULL
viral	NULL
gene	NULL
expression	NULL
.	NULL

It	NULL
is	NULL
noticeable	NULL
that	NULL
the	NULL
cells	NULL
clump	NULL
together	NULL
after	NULL
the	NULL
addition	NULL
of	NULL
virus	NULL
,	NULL
giving	NULL
the	NULL
opportunity	NULL
for	NULL
cell-to-cell	NULL
communication	NULL
.	NULL

Alternatively	NULL
,	NULL
there	NULL
might	NULL
be	NULL
soluble	NULL
factors	NULL
secreted	NULL
as	NULL
a	NULL
consequence	NULL
of	NULL
early	NULL
viral	NULL
gene	NULL
expression	NULL
that	NULL
can	NULL
then	NULL
cause	NULL
changes	NULL
in	NULL
the	NULL
uninfected	NULL
cells	NULL
.	NULL

We	NULL
have	NULL
also	NULL
studied	NULL
regulation	NULL
of	NULL
apoptosis	NULL
in	NULL
EBV-negative	NULL
and	NULL
-positive	NULL
BL-derived	NULL
cell	NULL
lines	NULL
and	NULL
EBV-immortalized	NULL
LCLs	NULL
.	NULL

Phenotypically	NULL
distinct	NULL
BL	NULL
cell	NULL
lines	NULL
and	NULL
LCLs	NULL
are	NULL
dif-ferentially	NULL
sensitive	NULL
to	NULL
induction	NULL
of	NULL
apoptosis	NULL
by	NULL
some	NULL
agents	NULL
.	NULL

EBV	NULL
-negative	NULL
and	NULL
group	NULL
I	NULL
EBV-positive	NULL
BL	NULL
lines	NULL
are	NULL
relatively	NULL
sensitive	NULL
to	NULL
ionomycin	NULL
,	NULL
stimulation	NULL
via	NULL
surface	NULL
Ig	NULL
molecules	NULL
,	NULL
or	NULL
serum	NULL
deprivation	NULL
compared	NULL
to	NULL
group	NULL
III	NULL
BL	NULL
cell	NULL
lines	NULL
(	NULL
8	NULL
,	NULL
27	NULL
,	NULL
28	NULL
,	NULL
31	NULL
,	NULL
81	NULL
)	NULL
.	NULL

Additionally	NULL
,	NULL
although	NULL
both	NULL
group	NULL
III	NULL
BL	NULL
lines	NULL
and	NULL
LCLs	NULL
express	NULL
the	NULL
Fas	NULL
receptor	NULL
(	NULL
21	NULL
)	NULL
,	NULL
only	NULL
LCLs	NULL
are	NULL
sensitive	NULL
to	NULL
Fas-induced	NULL
apoptosis	NULL
(	NULL
EBV-negative	NULL
and	NULL
group	NULL
I	NULL
BL	NULL
lines	NULL
do	NULL
not	NULL
express	NULL
Fas	NULL
receptor	NULL
and	NULL
are	NULL
therefore	NULL
insensitive	NULL
to	NULL
Fas	NULL
ligation	NULL
)	NULL
.	NULL

Group	NULL
III	NULL
BL	NULL
cells	NULL
express	NULL
high	NULL
levels	NULL
of	NULL
BCL-2	NULL
,	NULL
whereas	NULL
group	NULL
I	NULL
and	NULL
EBV-negative	NULL
lines	NULL
do	NULL
not	NULL
,	NULL
and	NULL
it	NULL
has	NULL
been	NULL
concluded	NULL
that	NULL
this	NULL
contributes	NULL
to	NULL
the	NULL
resistance	NULL
of	NULL
group	NULL
III	NULL
BL	NULL
lines	NULL
to	NULL
apoptosis	NULL
induced	NULL
by	NULL
ionomycin	NULL
,	NULL
Ig	NULL
,	NULL
and	NULL
serum	NULL
withdrawal	NULL
(	NULL
27	NULL
,	NULL
28	NULL
)	NULL
.	NULL

However	NULL
,	NULL
control	NULL
of	NULL
apoptosis	NULL
is	NULL
thought	NULL
to	NULL
be	NULL
determined	NULL
by	NULL
the	NULL
relative	NULL
levels	NULL
of	NULL
pro-	NULL
and	NULL
antiapoptotic	NULL
BCL-2-related	NULL
proteins	NULL
,	NULL
and	NULL
in	NULL
those	NULL
experiments	NULL
the	NULL
endogenous	NULL
levels	NULL
of	NULL
other	NULL
BCL-2	NULL
family	NULL
proteins	NULL
were	NULL
not	NULL
measured	NULL
.	NULL

Indeed	NULL
,	NULL
BCL-2-independent	NULL
events	NULL
also	NULL
play	NULL
a	NULL
role	NULL
in	NULL
resistance	NULL
to	NULL
apoptosis	NULL
triggered	NULL
by	NULL
these	NULL
agents	NULL
in	NULL
some	NULL
BL	NULL
lines	NULL
(	NULL
44	NULL
)	NULL
,	NULL
and	NULL
the	NULL
resistance	NULL
of	NULL
group	NULL
III	NULL
BL	NULL
lines	NULL
to	NULL
Fas-induced	NULL
apoptosis	NULL
relative	NULL
to	NULL
LCLs	NULL
can	NULL
not	NULL
be	NULL
determined	NULL
by	NULL
BCL-2	NULL
,	NULL
since	NULL
both	NULL
these	NULL
groups	NULL
of	NULL
lines	NULL
express	NULL
equivalent	NULL
amounts	NULL
of	NULL
BCL-2	NULL
(	NULL
18	NULL
,	NULL
28	NULL
)	NULL
.	NULL

This	NULL
is	NULL
also	NULL
consistent	NULL
with	NULL
the	NULL
inability	NULL
of	NULL
BCL-2	NULL
expression	NULL
to	NULL
suppress	NULL
Fas-induced	NULL
apoptosis	NULL
in	NULL
some	NULL
systems	NULL
(	NULL
14	NULL
,	NULL
18	NULL
,	NULL
29	NULL
,	NULL
43	NULL
,	NULL
46	NULL
,	NULL
52	NULL
,	NULL
70	NULL
,	NULL
77	NULL
)	NULL
.	NULL

Some	NULL
of	NULL
the	NULL
proteins	NULL
known	NULL
to	NULL
be	NULL
induced	NULL
by	NULL
EBV	NULL
infection	NULL
,	NULL
such	NULL
as	NULL
E2F-1	NULL
and	NULL
c-Myc	NULL
,	NULL
are	NULL
able	NULL
to	NULL
induce	NULL
apoptosis	NULL
in	NULL
some	NULL
circumstances	NULL
.	NULL

The	NULL
time	NULL
course	NULL
of	NULL
changes	NULL
in	NULL
the	NULL
E2F-1	NULL
and	NULL
E2F-4	NULL
proteins	NULL
has	NULL
been	NULL
described	NULL
in	NULL
this	NULL
paper	NULL
,	NULL
and	NULL
our	NULL
analysis	NULL
of	NULL
the	NULL
expression	NULL
and	NULL
properties	NULL
of	NULL
Myc	NULL
family	NULL
proteins	NULL
during	NULL
EBV	NULL
infection	NULL
will	NULL
be	NULL
published	NULL
elsewhere	NULL
.	NULL

To	NULL
provide	NULL
4686	NULL
SPENDER	NULL
ET	NULL
AL	NULL
.	NULL

LCL3/	NULL
unlabelled	NULL
xb	NULL
LCL3/	NULL
unlabelled	NULL
non-specifc	NULL
P	NULL
Bo	NULL
9	NULL
©	NULL
ao	NULL
u	NULL
%	NULL
n	NULL
g	NULL
©	NULL
in	NULL
%	NULL
mow	NULL
4	NULL
Rot	NULL
§	NULL
ff	NULL
A	NULL
*	NULL
dido	NULL
q	NULL
qd	NULL
d	NULL
s	NULL
2	NULL
a	NULL
a	NULL
a	NULL
a	NULL
A	NULL
3	NULL
3	NULL
A	NULL
-	NULL
cam	NULL
am	NULL
<	NULL
-	NULL
supershifted	NULL
«	NULL
ag-	NULL
complexes	NULL
I	NULL
!	NULL

|	NULL
H	NULL
an	NULL
“	NULL
i	NULL
I	NULL
:	NULL
Kb	NULL
complexes	NULL
~~	NULL
<	NULL
li	NULL
.	NULL

probe	NULL
B	NULL
15000	NULL
7	NULL
10000	NULL
7	NULL
LMP-1	NULL
5000	NULL
--	NULL
I	NULL
I	NULL
U	NULL
I	NULL
I	NULL
I	NULL
0	NULL
24	NULL
48	NULL
72	NULL
96	NULL
120	NULL
144	NULL
15000	NULL
7	NULL
NF-kB	NULL
10000	NULL
7	NULL
activity	NULL
5000	NULL
7	NULL
J-	NULL
.	NULL

T	NULL
J	NULL
t	NULL
T	NULL
T	NULL
t	NULL
0	NULL
24	NULL
48	NULL
72	NULL
96	NULL
120	NULL
144	NULL
FIG	NULL
.	NULL

8	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Establishment	NULL
of	NULL
specificity	NULL
of	NULL
gel	NULL
retardation	NULL
assay	NULL
for	NULL
NF-	NULL
«	NULL
B	NULL
complexes	NULL
with	NULL
LCL3	NULL
cell	NULL
extracts	NULL
by	NULL
competition	NULL
with	NULL
100-fold	NULL
excess	NULL
of	NULL
unlabelled	NULL
NF-kB	NULL
oligonucleotide	NULL
or	NULL
a	NULL
control	NULL
oligonucleotide	NULL
of	NULL
unrelated	NULL
sequence	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
complexes	NULL
(	NULL
arrows	NULL
)	NULL
were	NULL
also	NULL
tested	NULL
in	NULL
supershift	NULL
assays	NULL
with	NULL
antibodies	NULL
to	NULL
p50	NULL
,	NULL
p52	NULL
,	NULL
RelB	NULL
,	NULL
cRel	NULL
,	NULL
and	NULL
p65	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
antibodies	NULL
sc-114	NULL
,	NULL
sc-848	NULL
,	NULL
sc-226	NULL
,	NULL
sc-70	NULL
,	NULL
and	NULL
sc-109	NULL
,	NULL
respectively	NULL
)	NULL
as	NULL
indicated	NULL
(	NULL
1	NULL
mg	NULL
per	NULL
assay	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Purified	NULL
B	NULL
cells	NULL
positively	NULL
selected	NULL
from	NULL
peripheral	NULL
blood	NULL
were	NULL
infected	NULL
with	NULL
EBV	NULL
in	NULL
a	NULL
time	NULL
course	NULL
(	NULL
hours	NULL
post	NULL
infection	NULL
)	NULL
,	NULL
and	NULL
aliquots	NULL
were	NULL
assayed	NULL
by	NULL
Western	NULL
blotting	NULL
for	NULL
LMP-1	NULL
.	NULL

The	NULL
LMP-1	NULL
signal	NULL
was	NULL
quantified	NULL
by	NULL
scanning	NULL
the	NULL
autoradiograph	NULL
,	NULL
and	NULL
the	NULL
results	NULL
are	NULL
plotted	NULL
in	NULL
arbitrary	NULL
units	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
the	NULL
same	NULL
time	NULL
course	NULL
of	NULL
infection	NULL
as	NULL
for	NULL
panel	NULL
B	NULL
and	NULL
used	NULL
in	NULL
a	NULL
gel	NULL
retardation	NULL
assay	NULL
for	NULL
NF-kB	NULL
performed	NULL
as	NULL
for	NULL
panel	NULL
A	NULL
.	NULL

The	NULL
active	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
indicated	NULL
by	NULL
the	NULL
amount	NULL
of	NULL
specifically	NULL
shifted	NULL
probe	NULL
,	NULL
was	NULL
quantified	NULL
by	NULL
scanning	NULL
the	NULL
autoradiograph	NULL
,	NULL
and	NULL
the	NULL
results	NULL
are	NULL
plotted	NULL
in	NULL
arbitrary	NULL
units	NULL
.	NULL

a	NULL
framework	NULL
for	NULL
investigation	NULL
of	NULL
the	NULL
control	NULL
of	NULL
apoptosis	NULL
in	NULL
LCLs	NULL
and	NULL
during	NULL
EBV	NULL
infection	NULL
,	NULL
we	NULL
studied	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
BCL-2	NULL
family	NULL
of	NULL
proteins	NULL
and	NULL
other	NULL
pro-	NULL
and	NULL
antiapoptotic	NULL
genes	NULL
.	NULL

Expression	NULL
of	NULL
BCL-2	NULL
and	NULL
A20	NULL
both	NULL
correlated	NULL
well	NULL
with	NULL
resistance	NULL
to	NULL
apoptosis	NULL
.	NULL

Attention	NULL
has	NULL
previously	NULL
focused	NULL
on	NULL
J.	NULL
Virou	NULL
.	NULL

BCL-2	NULL
in	NULL
this	NULL
context	NULL
,	NULL
but	NULL
our	NULL
results	NULL
and	NULL
several	NULL
recent	NULL
reports	NULL
of	NULL
effects	NULL
of	NULL
A20	NULL
in	NULL
lymphoid	NULL
and	NULL
epithelial	NULL
cells	NULL
indicate	NULL
that	NULL
A20	NULL
is	NULL
also	NULL
likely	NULL
to	NULL
be	NULL
important	NULL
.	NULL

It	NULL
is	NULL
well	NULL
established	NULL
that	NULL
the	NULL
A20	NULL
gene	NULL
can	NULL
be	NULL
activated	NULL
by	NULL
NF-	NULL
«	NULL
B	NULL
through	NULL
two	NULL
adjacent	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
sites	NULL
in	NULL
the	NULL
promoter	NULL
(	NULL
39	NULL
)	NULL
,	NULL
and	NULL
BCL-2	NULL
has	NULL
also	NULL
been	NULL
reported	NULL
to	NULL
be	NULL
induced	NULL
by	NULL
LMP-1	NULL
(	NULL
28	NULL
)	NULL
.	NULL

NF-kB	NULL
activity	NULL
,	NULL
measured	NULL
by	NULL
using	NULL
a	NULL
standard	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
identical	NULL
in	NULL
sequence	NULL
to	NULL
one	NULL
of	NULL
those	NULL
in	NULL
the	NULL
A20	NULL
promoter	NULL
,	NULL
showed	NULL
an	NULL
excellent	NULL
temporal	NULL
correlation	NULL
between	NULL
active	NULL
,	NULL
nuclear	NULL
NF-kB	NULL
and	NULL
LMP-1	NULL
expression	NULL
during	NULL
infection	NULL
,	NULL
indicating	NULL
that	NULL
LMP	NULL
is	NULL
likely	NULL
to	NULL
be	NULL
the	NULL
major	NULL
determinant	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
activity	NULL
in	NULL
the	NULL
LCL	NULL
cells	NULL
.	NULL

The	NULL
Namalwa	NULL
and	NULL
BL74	NULL
cell	NULL
lines	NULL
,	NULL
which	NULL
were	NULL
negative	NULL
for	NULL
A20	NULL
,	NULL
have	NULL
the	NULL
group	NULL
II	NULL
pattern	NULL
of	NULL
EBV	NULL
gene	NULL
expression	NULL
and	NULL
do	NULL
not	NULL
express	NULL
LMP-1	NULL
,	NULL
although	NULL
both	NULL
expressed	NULL
BCL-2	NULL
.	NULL

It	NULL
was	NULL
notable	NULL
in	NULL
the	NULL
Western	NULL
blots	NULL
of	NULL
BCL-2	NULL
family	NULL
protein	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
)	NULL
that	NULL
the	NULL
pattern	NULL
of	NULL
expression	NULL
of	NULL
BAX	NULL
detected	NULL
with	NULL
the	NULL
N20	NULL
antibody	NULL
was	NULL
quite	NULL
different	NULL
from	NULL
the	NULL
protein	NULL
expression	NULL
detected	NULL
with	NULL
the	NULL
P-19	NULL
antibody	NULL
,	NULL
which	NULL
has	NULL
also	NULL
been	NULL
described	NULL
as	NULL
detecting	NULL
human	NULL
BAX	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
.	NULL

The	NULL
protein	NULL
from	NULL
some	NULL
cell	NULL
lines	NULL
detected	NULL
by	NULL
P-19	NULL
also	NULL
showed	NULL
altered	NULL
migration	NULL
on	NULL
the	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
gel	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
)	NULL
.	NULL

We	NULL
considered	NULL
the	NULL
possibility	NULL
that	NULL
the	NULL
two	NULL
antibodies	NULL
might	NULL
be	NULL
detecting	NULL
hitherto-unknown	NULL
different	NULL
forms	NULL
of	NULL
BAX	NULL
in	NULL
these	NULL
cells	NULL
or	NULL
that	NULL
the	NULL
specificity	NULL
of	NULL
one	NULL
of	NULL
the	NULL
antibodies	NULL
(	NULL
probably	NULL
P-19	NULL
)	NULL
was	NULL
described	NULL
incorrectly	NULL
.	NULL

This	NULL
is	NULL
significant	NULL
because	NULL
a	NULL
considerable	NULL
amount	NULL
of	NULL
earlier	NULL
work	NULL
(	NULL
2	NULL
,	NULL
42	NULL
,	NULL
63	NULL
,	NULL
74	NULL
)	NULL
has	NULL
used	NULL
P-19	NULL
to	NULL
monitor	NULL
human	NULL
BAX	NULL
protein	NULL
levels	NULL
.	NULL

Upon	NULL
investigation	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
it	NULL
became	NULL
clear	NULL
that	NULL
the	NULL
P-19	NULL
antibody	NULL
cross-reacts	NULL
in	NULL
Western	NULL
blotting	NULL
experiments	NULL
with	NULL
another	NULL
protein	NULL
of	NULL
a	NULL
size	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
human	NULL
BAX	NULL
.	NULL

The	NULL
authenticity	NULL
of	NULL
the	NULL
N20	NULL
specificity	NULL
for	NULL
Bax	NULL
was	NULL
verified	NULL
by	NULL
showing	NULL
that	NULL
a	NULL
third	NULL
anti-BAX	NULL
antibody	NULL
(	NULL
13666E	NULL
)	NULL
)	NULL
gave	NULL
the	NULL
same	NULL
pattern	NULL
of	NULL
reactivity	NULL
as	NULL
N20	NULL
in	NULL
a	NULL
panel	NULL
of	NULL
relevant	NULL
cell	NULL
lines	NULL
and	NULL
the	NULL
Bax	NULL
protein	NULL
recognized	NULL
in	NULL
the	NULL
cell	NULL
extracts	NULL
was	NULL
the	NULL
same	NULL
size	NULL
as	NULL
the	NULL
protein	NULL
produced	NULL
by	NULL
transfection	NULL
of	NULL
a	NULL
Bax	NULL
cDNA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

It	NULL
therefore	NULL
seems	NULL
that	NULL
antibody	NULL
P-19	NULL
does	NULL
not	NULL
recognize	NULL
endogenous	NULL
human	NULL
Bax	NULL
.	NULL

We	NULL
have	NULL
,	NULL
however	NULL
,	NULL
repeated	NULL
the	NULL
experiments	NULL
in	NULL
the	NULL
study	NULL
in	NULL
this	NULL
laboratory	NULL
that	NULL
used	NULL
P-19	NULL
(	NULL
2	NULL
)	NULL
with	NULL
the	NULL
N20	NULL
antibody	NULL
and	NULL
confirmed	NULL
the	NULL
conclusions	NULL
of	NULL
the	NULL
study	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
first	NULL
two	NULL
viral	NULL
genes	NULL
known	NULL
to	NULL
be	NULL
expressed	NULL
upon	NULL
infection	NULL
are	NULL
EBNA-LP	NULL
and	NULL
EBNA-2	NULL
.	NULL

These	NULL
two	NULL
proteins	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
cooperate	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
cyclin	NULL
D2	NULL
RNA	NULL
,	NULL
which	NULL
is	NULL
an	NULL
early	NULL
marker	NULL
of	NULL
cell	NULL
cycle	NULL
entry	NULL
that	NULL
is	NULL
induced	NULL
after	NULL
infection	NULL
(	NULL
72	NULL
)	NULL
.	NULL

Although	NULL
EBNA-2	NULL
and	NULL
EBNA-LP	NULL
can	NULL
activate	NULL
transcription	NULL
of	NULL
various	NULL
promoters	NULL
,	NULL
it	NULL
is	NULL
not	NULL
yet	NULL
clear	NULL
whether	NULL
the	NULL
promoter	NULL
for	NULL
cyclin	NULL
D2	NULL
is	NULL
regulated	NULL
directly	NULL
by	NULL
these	NULL
pro-teins	NULL
.	NULL

Deletion	NULL
analysis	NULL
of	NULL
the	NULL
cyclin	NULL
D2	NULL
promoter	NULL
,	NULL
seeking	NULL
elements	NULL
that	NULL
may	NULL
control	NULL
its	NULL
response	NULL
to	NULL
serum	NULL
growth	NULL
factors	NULL
,	NULL
has	NULL
revealed	NULL
both	NULL
positive	NULL
and	NULL
negative	NULL
regulatory	NULL
regions	NULL
upstream	NULL
of	NULL
the	NULL
transcription	NULL
start	NULL
(	NULL
11	NULL
)	NULL
.	NULL

One	NULL
of	NULL
the	NULL
consequences	NULL
of	NULL
activation	NULL
of	NULL
edk	NULL
activity	NULL
is	NULL
phosphorylation	NULL
of	NULL
pocket	NULL
proteins	NULL
,	NULL
which	NULL
bind	NULL
and	NULL
regulate	NULL
the	NULL
EZF	NULL
complex	NULL
.	NULL

The	NULL
E2F	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
are	NULL
thought	NULL
to	NULL
be	NULL
major	NULL
determinants	NULL
of	NULL
cell	NULL
cycle	NULL
progression	NULL
,	NULL
and	NULL
different	NULL
E2F	NULL
family	NULL
members	NULL
and	NULL
complexes	NULL
with	NULL
various	NULL
pocket	NULL
proteins	NULL
are	NULL
characteristic	NULL
of	NULL
the	NULL
resting	NULL
and	NULL
cycling	NULL
cells	NULL
(	NULL
65	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
E2F-4-DP-1-p130	NULL
complexes	NULL
are	NULL
found	NULL
in	NULL
resting	NULL
cells	NULL
(	NULL
45	NULL
,	NULL
73	NULL
)	NULL
,	NULL
but	NULL
the	NULL
dominant	NULL
G	NULL
,	NULL
E2F	NULL
complex	NULL
in	NULL
cycling	NULL
cells	NULL
contains	NULL
E2F-1	NULL
with	NULL
DP-1	NULL
and	NULL
Rb	NULL
or	NULL
p107	NULL
.	NULL

Clearly	NULL
,	NULL
changes	NULL
in	NULL
the	NULL
E2F	NULL
profile	NULL
and	NULL
changes	NULL
in	NULL
cyclins	NULL
are	NULL
both	NULL
early	NULL
events	NULL
in	NULL
the	NULL
cell	NULL
cycle	NULL
entry	NULL
caused	NULL
by	NULL
EBV	NULL
infection	NULL
.	NULL

Since	NULL
only	NULL
the	NULL
RNA	NULL
of	NULL
cyclin	NULL
D2	NULL
had	NULL
been	NULL
measured	NULL
in	NULL
previous	NULL
experiments	NULL
(	NULL
72	NULL
)	NULL
and	NULL
little	NULL
study	NULL
had	NULL
been	NULL
made	NULL
of	NULL
the	NULL
EZ2F	NULL
proteins	NULL
(	NULL
12	NULL
)	NULL
,	NULL
it	NULL
was	NULL
unclear	NULL
whether	NULL
the	NULL
earliest	NULL
effects	NULL
of	NULL
EBNA-2	NULL
and	NULL
EBNA-LP	NULL
on	NULL
the	NULL
cell	NULL
cycle	NULL
entry	NULL
process	NULL
were	NULL
likely	NULL
to	NULL
be	NULL
mediated	NULL
voL	NULL
.	NULL

73	NULL
,	NULL
1999	NULL
through	NULL
changing	NULL
the	NULL
balance	NULL
of	NULL
E2F	NULL
complex	NULL
proteins	NULL
or	NULL
through	NULL
cyclin	NULL
D2	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
in	NULL
which	NULL
we	NULL
have	NULL
analyzed	NULL
the	NULL
time	NULL
course	NULL
of	NULL
changes	NULL
to	NULL
E2F	NULL
factors	NULL
,	NULL
pocket	NULL
proteins	NULL
,	NULL
cyclins	NULL
,	NULL
edks	NULL
,	NULL
and	NULL
cdk	NULL
inhibitors	NULL
,	NULL
the	NULL
induction	NULL
of	NULL
cyclin	NULL
D2	NULL
is	NULL
the	NULL
earliest	NULL
event	NULL
we	NULL
have	NULL
observed	NULL
that	NULL
is	NULL
dependent	NULL
on	NULL
viral	NULL
gene	NULL
expression	NULL
(	NULL
presumably	NULL
of	NULL
EBNA-2	NULL
and	NULL
EBNA-LP	NULL
)	NULL
.	NULL

Identification	NULL
of	NULL
the	NULL
initial	NULL
target	NULL
genes	NULL
in	NULL
the	NULL
cell	NULL
for	NULL
EBV	NULL
immortalizing	NULL
proteins	NULL
will	NULL
thus	NULL
now	NULL
focus	NULL
on	NULL
whether	NULL
the	NULL
cyclin	NULL
D2	NULL
promoter	NULL
can	NULL
be	NULL
activated	NULL
directly	NULL
by	NULL
EBNA-2	NULL
and	NULL
EBNA-LP	NULL
or	NULL
whether	NULL
there	NULL
may	NULL
be	NULL
other	NULL
intermediate	NULL
steps	NULL
.	NULL

There	NULL
is	NULL
no	NULL
consensus	NULL
binding	NULL
site	NULL
for	NULL
RBP-Jk	NULL
in	NULL
the	NULL
first	NULL
1,000	NULL
nucleotides	NULL
upstream	NULL
of	NULL
the	NULL
reported	NULL
transcription	NULL
starts	NULL
in	NULL
the	NULL
sequence	NULL
of	NULL
the	NULL
cyclin	NULL
D2	NULL
promoter	NULL
(	NULL
11	NULL
)	NULL
,	NULL
but	NULL
EBNA-2	NULL
is	NULL
known	NULL
to	NULL
be	NULL
able	NULL
to	NULL
activate	NULL
transcription	NULL
through	NULL
other	NULL
DNA	NULL
binding	NULL
proteins	NULL
;	NULL
by	NULL
analyzing	NULL
the	NULL
mechanism	NULL
of	NULL
induction	NULL
of	NULL
cyclin	NULL
D2	NULL
RNA	NULL
and	NULL
screening	NULL
for	NULL
other	NULL
genes	NULL
that	NULL
might	NULL
be	NULL
induced	NULL
soon	NULL
after	NULL
infection	NULL
,	NULL
we	NULL
hope	NULL
to	NULL
identify	NULL
the	NULL
direct	NULL
cell	NULL
targets	NULL
that	NULL
EBV	NULL
modulates	NULL
when	NULL
it	NULL
infects	NULL
human	NULL
B	NULL
cells	NULL
and	NULL
,	NULL
with	NULL
such	NULL
high	NULL
efficiency	NULL
,	NULL
causes	NULL
them	NULL
to	NULL
proliferate	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
V.	NULL
M.	NULL
Dixit	NULL
and	NULL
E.	NULL
Lam	NULL
for	NULL
plasmids	NULL
used	NULL
in	NULL
this	NULL
work	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Alfieri	NULL
,	NULL
C.	NULL
,	NULL
M.	NULL
Birkenbach	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1991	NULL
.	NULL

Early	NULL
events	NULL
in	NULL
Epstein-Barr	NULL
virus	NULL
infection	NULL
of	NULL
human	NULL
B	NULL
lymphocytes	NULL
.	NULL

Virology	NULL
181:595-608	NULL
.	NULL

(	NULL
Erratum	NULL
,	NULL
185:946	NULL
.	NULL
)	NULL

2	NULL
.	NULL

Allday	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
G.	NULL
J.	NULL
Inman	NULL
,	NULL
D.	NULL
H.	NULL
Crawford	NULL
,	NULL
and	NULL
P.	NULL
J.	NULL
Farrell	NULL
.	NULL

1995	NULL
.	NULL

DNA	NULL
damage	NULL
in	NULL
human	NULL
B	NULL
cells	NULL
can	NULL
induce	NULL
apoptosis	NULL
,	NULL
proceeding	NULL
from	NULL
G1/S	NULL
when	NULL
p53	NULL
is	NULL
transactivation	NULL
competent	NULL
and	NULL
G2/M	NULL
when	NULL
it	NULL
is	NULL
transactivation	NULL
defec-tive	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

14:4994-5005	NULL
.	NULL

3	NULL
.	NULL

Ashkenazi	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
V.	NULL
Dixit	NULL
.	NULL

1998	NULL
.	NULL

Death	NULL
receptors	NULL
:	NULL
signaling	NULL
and	NULL
modula-tion	NULL
.	NULL

Science	NULL
281:1305-1308	NULL
.	NULL

4	NULL
.	NULL

Askew	NULL
,	NULL
D.	NULL
S.	NULL
,	NULL
R.	NULL
A.	NULL
Ashmun	NULL
,	NULL
B.	NULL
C.	NULL
Simmons	NULL
,	NULL
and	NULL
J.	NULL
L.	NULL
Cleveland	NULL
.	NULL

1991	NULL
.	NULL

Constitutive	NULL
c-myc	NULL
expression	NULL
in	NULL
an	NULL
IL-3-dependent	NULL
myeloid	NULL
cell	NULL
line	NULL
suppresses	NULL
cell	NULL
cycle	NULL
arrest	NULL
and	NULL
accelerates	NULL
apoptosis	NULL
.	NULL

Oncogene	NULL
6:1915-1922	NULL
.	NULL

5	NULL
.	NULL

Beijersbergen	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
R.	NULL
M.	NULL
Kerkhoven	NULL
,	NULL
L.	NULL
Zhu	NULL
,	NULL
L.	NULL
Carlee	NULL
,	NULL
P.	NULL
M.	NULL
Voorhoeve	NULL
,	NULL
and	NULL
R.	NULL
Bernards	NULL
.	NULL

1994	NULL
.	NULL

E2F-4	NULL
,	NULL
a	NULL
new	NULL
member	NULL
of	NULL
the	NULL
E2F	NULL
gene	NULL
family	NULL
,	NULL
has	NULL
oncogenic	NULL
activity	NULL
and	NULL
associates	NULL
with	NULL
p107	NULL
in	NULL
vivo	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

8:2680-2690	NULL
.	NULL

6	NULL
.	NULL

Ben-Bassat	NULL
,	NULL
H.	NULL
,	NULL
N.	NULL
Goldblum	NULL
,	NULL
S.	NULL
Mitrani	NULL
,	NULL
T.	NULL
Goldblum	NULL
,	NULL
J.	NULL
M.	NULL
Yoffey	NULL
,	NULL
M.	NULL
M.	NULL
Cohen	NULL
,	NULL
Z.	NULL
Bentwich	NULL
,	NULL
B.	NULL
Ramot	NULL
,	NULL
E.	NULL
Klein	NULL
,	NULL
and	NULL
G.	NULL
Klein	NULL
.	NULL

1977	NULL
.	NULL

Establishment	NULL
in	NULL
continuous	NULL
culture	NULL
of	NULL
a	NULL
new	NULL
type	NULL
of	NULL
lymphocyte	NULL
from	NULL
a	NULL
``	NULL
Burkitt	NULL
like	NULL
``	NULL
malignant	NULL
lymphoma	NULL
(	NULL
line	NULL
D.G.-75	NULL
)	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
19:27-33	NULL
.	NULL

7	NULL
.	NULL

Boise	NULL
,	NULL
L.	NULL
H.	NULL
,	NULL
M.	NULL
Gonzalez-Garcia	NULL
,	NULL
C.	NULL
E.	NULL
Postema	NULL
,	NULL
L.	NULL
Ding	NULL
,	NULL
T.	NULL
Lindsten	NULL
,	NULL
L.	NULL
A.	NULL
Turka	NULL
,	NULL
X.	NULL
Mao	NULL
,	NULL
G.	NULL
Nunez	NULL
,	NULL
and	NULL
C.	NULL
B.	NULL
Thompson	NULL
.	NULL

1993.	NULL
bel-x	NULL
,	NULL
a	NULL
bel-2-related	NULL
gene	NULL
that	NULL
functions	NULL
as	NULL
a	NULL
dominant	NULL
regulator	NULL
of	NULL
apoptotic	NULL
cell	NULL
death	NULL
.	NULL

Cell	NULL
74	NULL
:	NULL
597-608	NULL
.	NULL

8	NULL
.	NULL

Bonnefoy-Berard	NULL
,	NULL
N.	NULL
,	NULL
L.	NULL
Genestier	NULL
,	NULL
M.	NULL
Flacher	NULL
,	NULL
and	NULL
J.	NULL
P.	NULL
Revillard	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
phosphoprotein	NULL
phosphatase	NULL
calcineurin	NULL
controls	NULL
calcium-dependent	NULL
apoptosis	NULL
in	NULL
B	NULL
cell	NULL
lines	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

24:325-329	NULL
.	NULL

9	NULL
.	NULL

Brimmell	NULL
,	NULL
M.	NULL
,	NULL
R.	NULL
Mendicla	NULL
,	NULL
J.	NULL
Mangion	NULL
,	NULL
and	NULL
G.	NULL
Packham	NULL
.	NULL

1998	NULL
.	NULL

BAX	NULL
frameshift	NULL
mutations	NULL
in	NULL
cell	NULL
lines	NULL
derived	NULL
from	NULL
human	NULL
haemopoctic	NULL
malignancies	NULL
are	NULL
associated	NULL
with	NULL
resistance	NULL
to	NULL
apoptosis	NULL
and	NULL
microsatellite	NULL
insta-bility	NULL
.	NULL

Oncogene	NULL
16:1803-1812	NULL
.	NULL

10	NULL
.	NULL

Brodeur	NULL
,	NULL
S.	NULL
,	NULL
G.	NULL
Cheng	NULL
,	NULL
D.	NULL
Baltimore	NULL
,	NULL
and	NULL
D.	NULL
Thorley-Lawson	NULL
.	NULL

1997	NULL
.	NULL

Localization	NULL
of	NULL
the	NULL
major	NULL
NF-kappa	NULL
B	NULL
activating	NULL
site	NULL
and	NULL
the	NULL
sole	NULL
TRAF3	NULL
binding	NULL
site	NULL
of	NULL
LMP-1	NULL
defines	NULL
two	NULL
distinct	NULL
signaling	NULL
motifs	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272	NULL
:	NULL
19777-19784	NULL
.	NULL

11	NULL
.	NULL

Brooks	NULL
,	NULL
A.	NULL
,	NULL
D.	NULL
Shiffman	NULL
,	NULL
C.	NULL
Chan	NULL
,	NULL
E.	NULL
Brooks	NULL
,	NULL
and	NULL
P.	NULL
Milner	NULL
.	NULL

1996	NULL
.	NULL

Functional	NULL
analysis	NULL
of	NULL
the	NULL
human	NULL
cyclin	NULL
D2	NULL
and	NULL
D3	NULL
promoters	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271	NULL
:	NULL
9090-9099	NULL
.	NULL

12	NULL
.	NULL

Cannell	NULL
,	NULL
E.	NULL
,	NULL
P.	NULL
Farrell	NULL
,	NULL
and	NULL
A.	NULL
Sinclair	NULL
.	NULL

1996	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
exploits	NULL
the	NULL
normal	NULL
cell	NULL
pathway	NULL
to	NULL
regulate	NULL
Rb	NULL
activity	NULL
during	NULL
the	NULL
immortalisation	NULL
of	NULL
primary	NULL
B	NULL
cells	NULL
.	NULL

Oncogene	NULL
13:1413-1421	NULL
.	NULL

13	NULL
.	NULL

Chittenden	NULL
,	NULL
T.	NULL
,	NULL
E.	NULL
A.	NULL
Harrington	NULL
,	NULL
R.	NULL
O'Connor	NULL
,	NULL
C.	NULL
Flemington	NULL
,	NULL
R.	NULL
J.	NULL
Lutz	NULL
,	NULL
G.	NULL
I.	NULL
Evan	NULL
,	NULL
and	NULL
B.	NULL
C.	NULL
Guild	NULL
.	NULL

1995	NULL
.	NULL

Induction	NULL
of	NULL
apoptosis	NULL
by	NULL
the	NULL
Bcl-2	NULL
homologue	NULL
.	NULL

Bak	NULL
.	NULL

Nature	NULL
374:733-736	NULL
.	NULL

14	NULL
.	NULL

Chiu	NULL
,	NULL
V.	NULL
K.	NULL
,	NULL
C.	NULL
M.	NULL
Walsh	NULL
,	NULL
C.	NULL
C.	NULL
Liu	NULL
,	NULL
J.	NULL
C.	NULL
Reed	NULL
,	NULL
and	NULL
W.	NULL
R.	NULL
Clark	NULL
.	NULL

1995	NULL
.	NULL

Bcl-2	NULL
blocks	NULL
degranulation	NULL
but	NULL
not	NULL
fas-based	NULL
cell-mediated	NULL
cytotoxicity	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

154:2023-2032	NULL
.	NULL

15	NULL
.	NULL

Cludts	NULL
,	NULL
L	NULL
,	NULL
and	NULL
P.	NULL
Farrell	NULL
.	NULL

1998	NULL
.	NULL

Multiple	NULL
functions	NULL
within	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
EBNA-3A	NULL
protein	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

72:1862-1869	NULL
.	NULL

16	NULL
.	NULL

Cory	NULL
,	NULL
S.	NULL
1995	NULL
.	NULL

Regulation	NULL
of	NULL
lymphocyte	NULL
survival	NULL
by	NULL
the	NULL
bel-2	NULL
gene	NULL
family	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

13:513-543	NULL
.	NULL

17	NULL
.	NULL

Craig	NULL
,	NULL
R.	NULL
W.	NULL
1995	NULL
.	NULL

The	NULL
bel-2	NULL
gene	NULL
family	NULL
.	NULL

Semin	NULL
.	NULL

Cancer	NULL
Biol	NULL
.	NULL

6:35-43	NULL
.	NULL

18	NULL
.	NULL

Debatin	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
and	NULL
P.	NULL
H.	NULL
Krammer	NULL
.	NULL

1995	NULL
.	NULL

Resistance	NULL
to	NULL
APO-1	NULL
(	NULL
CD95	NULL
)	NULL
CELL	NULL
CYCLE	NULL
AND	NULL
APOPTOSIS	NULL
IN	NULL
EBV	NULL
INFECTION	NULL
-	NULL
4687	NULL
induced	NULL
apoptosis	NULL
in	NULL
T-ALL	NULL
is	NULL
determined	NULL
by	NULL
a	NULL
BCL-2	NULL
independent	NULL
antiapoptotic	NULL
program	NULL
.	NULL

Leukemia	NULL
9:815-820	NULL
.	NULL

19	NULL
.	NULL

Devergne	NULL
,	NULL
O.	NULL
,	NULL
E.	NULL
Hatzivassiliou	NULL
,	NULL
K.	NULL
M.	NULL
Izumi	NULL
,	NULL
K.	NULL
M.	NULL
Kaye	NULL
,	NULL
M.	NULL
F.	NULL
Kleijnen	NULL
,	NULL
E.	NULL
Kieff	NULL
,	NULL
and	NULL
G.	NULL
Mosialos	NULL
.	NULL

1996	NULL
.	NULL

Association	NULL
of	NULL
TRAF1	NULL
,	NULL
TRAF2	NULL
,	NULL
and	NULL
TRAF3	NULL
with	NULL
an	NULL
Epstein-Barr	NULL
virus	NULL
LMP1	NULL
domain	NULL
important	NULL
for	NULL
B-lymphocyte	NULL
trans-formation	NULL
:	NULL
role	NULL
in	NULL
NF-B	NULL
activation	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16:7098-7108	NULL
.	NULL

20	NULL
.	NULL

Eliopoulos	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
L.	NULL
Young	NULL
.	NULL

1998	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
cJun	NULL
N-terminal	NULL
kinase	NULL
(	NULL
JNK	NULL
)	NULL
pathway	NULL
by	NULL
the	NULL
Epstein-Barr	NULL
virus-encoded	NULL
latent	NULL
membrane	NULL
protein	NULL
1	NULL
(	NULL
LMP1	NULL
)	NULL
.	NULL

Oncogene	NULL
16:1731-1742	NULL
.	NULL

21	NULL
.	NULL

Falk	NULL
,	NULL
M.	NULL
H.	NULL
,	NULL
B.	NULL
C.	NULL
Trauth	NULL
,	NULL
K.	NULL
M.	NULL
Debatin	NULL
,	NULL
C.	NULL
Klas	NULL
,	NULL
C.	NULL
D.	NULL
Gregory	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Rickinson	NULL
,	NULL
A.	NULL
Calender	NULL
,	NULL
G.	NULL
M.	NULL
Lenoir	NULL
,	NULL
J.	NULL
W.	NULL
Ellwart	NULL
,	NULL
P.	NULL
H.	NULL
Krammer	NULL
,	NULL
and	NULL
G.	NULL
Borakamm	NULL
.	NULL

1992	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
APO-1	NULL
antigen	NULL
in	NULL
Burkitt	NULL
lymphoma	NULL
cell	NULL
lines	NULL
correlates	NULL
with	NULL
a	NULL
shift	NULL
towards	NULL
a	NULL
lymphoblastoid	NULL
phenotype	NULL
.	NULL

Blood	NULL
79	NULL
:	NULL
3300-3306	NULL
.	NULL

22	NULL
.	NULL

Farrell	NULL
,	NULL
P.	NULL
1995	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
immortalizing	NULL
genes	NULL
.	NULL

Trends	NULL
Microbiol	NULL
.	NULL

3:105-109	NULL
.	NULL

23	NULL
.	NULL

Farrell	NULL
,	NULL
P.	NULL
1998	NULL
.	NULL

Signal	NULL
transduction	NULL
from	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
LMP-1	NULL
transforming	NULL
protein	NULL
.	NULL

Trends	NULL
Microbiol	NULL
.	NULL

6:175-177	NULL
.	NULL

24	NULL
.	NULL

Farrow	NULL
,	NULL
S.	NULL
N.	NULL
,	NULL
J.	NULL
H.	NULL
White	NULL
,	NULL
I	NULL
Martinou	NULL
,	NULL
T.	NULL
Raven	NULL
,	NULL
K.	NULL
T.	NULL
Pun	NULL
,	NULL
C.	NULL
J.	NULL
Grinham	NULL
,	NULL
J.	NULL
C.	NULL
Martinou	NULL
,	NULL
and	NULL
R.	NULL
Brown	NULL
.	NULL

1995	NULL
.	NULL

Cloning	NULL
of	NULL
a	NULL
bcl-2	NULL
homologue	NULL
by	NULL
interaction	NULL
with	NULL
adenovirus	NULL
E1B	NULL
19K	NULL
.	NULL

Nature	NULL
374:731-733	NULL
.	NULL

25	NULL
.	NULL

Finke	NULL
,	NULL
J.	NULL
,	NULL
M.	NULL
Rowe	NULL
,	NULL
B.	NULL
Kallin	NULL
,	NULL
I.	NULL
Ernberg	NULL
,	NULL
A.	NULL
Rosen	NULL
,	NULL
J.	NULL
Dillner	NULL
,	NULL
and	NULL
G.	NULL
Klein	NULL
.	NULL

1987	NULL
.	NULL

Monoclonal	NULL
and	NULL
polyclonal	NULL
antibodies	NULL
against	NULL
Epstein-Barr	NULL
virus	NULL
nuclear	NULL
antigen	NULL
5	NULL
(	NULL
EBNA-5	NULL
)	NULL
detect	NULL
multiple	NULL
protein	NULL
species	NULL
in	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
and	NULL
lymphoblastoid	NULL
cell	NULL
lines	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

61:3870-3878	NULL
.	NULL

26	NULL
.	NULL

Fries	NULL
,	NULL
K.	NULL
L.	NULL
,	NULL
W.	NULL
E.	NULL
Miller	NULL
,	NULL
and	NULL
N.	NULL
Raab-Traub	NULL
.	NULL

1996	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
latent	NULL
membrane	NULL
protein	NULL
1	NULL
blocks	NULL
p53-mediated	NULL
apoptosis	NULL
through	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
A20	NULL
gene	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

70:8653-8659	NULL
.	NULL

27	NULL
.	NULL

Gregory	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
C.	NULL
Dive	NULL
,	NULL
S.	NULL
Henderson	NULL
,	NULL
C.	NULL
A.	NULL
Smith	NULL
,	NULL
G.	NULL
T.	NULL
Williams	NULL
,	NULL
J.	NULL
Gordon	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Rickinson	NULL
.	NULL

1991	NULL
.	NULL

Activation	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
latent	NULL
genes	NULL
protects	NULL
human	NULL
B	NULL
cells	NULL
from	NULL
death	NULL
by	NULL
apoptosis	NULL
.	NULL

Nature	NULL
349:612-614	NULL
.	NULL

28	NULL
.	NULL

Henderson	NULL
,	NULL
S.	NULL
,	NULL
M.	NULL
Rowe	NULL
,	NULL
C.	NULL
Gregory	NULL
,	NULL
D.	NULL
Croom-Carter	NULL
,	NULL
F.	NULL
Wang	NULL
,	NULL
R.	NULL
Long-necker	NULL
,	NULL
E.	NULL
Kieff	NULL
,	NULL
and	NULL
A.	NULL
Rickinson	NULL
.	NULL

1991	NULL
.	NULL

Induction	NULL
of	NULL
bel-2	NULL
expression	NULL
by	NULL
Epstein-Barr	NULL
virus	NULL
latent	NULL
membrane	NULL
protein	NULL
1	NULL
protects	NULL
infected	NULL
B	NULL
cells	NULL
from	NULL
programmed	NULL
cell	NULL
death	NULL
.	NULL

Cell	NULL
65:1107-1115	NULL
.	NULL

28a.Hollyoake	NULL
,	NULL
M.	NULL
,	NULL
A.	NULL
Stithler	NULL
,	NULL
P.	NULL
J.	NULL
Farrell	NULL
,	NULL
J.	NULL
Gordon	NULL
,	NULL
and	NULL
A.	NULL
J.	NULL
Sinclair	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
normal	NULL
cell	NULL
cycle	NULL
activation	NULL
program	NULL
is	NULL
exploited	NULL
during	NULL
the	NULL
infection	NULL
of	NULL
quiescent	NULL
B	NULL
lymphocytes	NULL
by	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

55:4784-4787	NULL
.	NULL

29	NULL
.	NULL

Itoh	NULL
,	NULL
N.	NULL
,	NULL
Y.	NULL
Tsujimoto	NULL
,	NULL
and	NULL
S.	NULL
Nagata	NULL
.	NULL

1993	NULL
.	NULL

Effect	NULL
of	NULL
bel-2	NULL
on	NULL
Fas	NULL
antigen-mediated	NULL
cell	NULL
death	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

151:621-627	NULL
.	NULL

30	NULL
.	NULL

Izumi	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1997	NULL
.	NULL

The	NULL
EBV	NULL
oncogene	NULL
product	NULL
LMP-1	NULL
engages	NULL
the	NULL
TRADD	NULL
protein	NULL
to	NULL
mediate	NULL
B	NULL
lymphocyte	NULL
growth	NULL
transformation	NULL
and	NULL
activate	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
94:12592-12597	NULL
.	NULL

31	NULL
.	NULL

Kelly	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
K.	NULL
A.	NULL
Knox	NULL
.	NULL

1995	NULL
.	NULL

Differential	NULL
regulatory	NULL
effects	NULL
of	NULL
cAMP-elevating	NULL
agents	NULL
on	NULL
human	NULL
normal	NULL
and	NULL
neoplastic	NULL
B	NULL
cell	NULL
functional	NULL
response	NULL
following	NULL
ligation	NULL
of	NULL
surface	NULL
immunoglobulin	NULL
and	NULL
CD40	NULL
.	NULL

Cell	NULL
.	NULL

Immunol	NULL
.	NULL

166	NULL
:	NULL
93-102	NULL
.	NULL

32	NULL
.	NULL

Kempkes	NULL
,	NULL
B.	NULL
,	NULL
D.	NULL
Spitkovsky	NULL
,	NULL
P.	NULL
Jansen-Durr	NULL
,	NULL
J.	NULL
W.	NULL
Ellwart	NULL
,	NULL
E.	NULL
Kremmer	NULL
,	NULL
H.	NULL
J.	NULL
Delecluse	NULL
,	NULL
C.	NULL
Rottenberger	NULL
,	NULL
G.	NULL
W.	NULL
Bornkamm	NULL
,	NULL
and	NULL
W.	NULL
Hammerschmidt	NULL
.	NULL

1995	NULL
.	NULL

B-cell	NULL
proliferation	NULL
and	NULL
induction	NULL
of	NULL
early	NULL
G1-regulating	NULL
proteins	NULL
by	NULL
Epstein-Barr	NULL
virus	NULL
mutants	NULL
conditional	NULL
for	NULL
EBNAZ	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

14	NULL
:	NULL
88-96	NULL
.	NULL

33	NULL
.	NULL

Kiefer	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
M.	NULL
J.	NULL
Braver	NULL
,	NULL
V.	NULL
C.	NULL
Powers	NULL
,	NULL
J.	NULL
J.	NULL
Wu	NULL
,	NULL
S.	NULL
R.	NULL
Umansky	NULL
,	NULL
L.	NULL
D.	NULL
Tomei	NULL
,	NULL
and	NULL
P.	NULL
J.	NULL
Barr	NULL
.	NULL

1995	NULL
.	NULL

Modulation	NULL
of	NULL
apoptosis	NULL
by	NULL
the	NULL
widely	NULL
distributed	NULL
Bcl-2	NULL
homologue	NULL
Bak	NULL
.	NULL

Nature	NULL
374:736-739	NULL
.	NULL

34	NULL
.	NULL

Kieser	NULL
,	NULL
A.	NULL
,	NULL
E.	NULL
Kilger	NULL
,	NULL
O.	NULL
Gires	NULL
,	NULL
M.	NULL
Ueffing	NULL
,	NULL
W.	NULL
Kolch	NULL
,	NULL
and	NULL
W.	NULL
Hammerschmidt	NULL
.	NULL

1997	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
latent	NULL
membrane	NULL
protein-1	NULL
triggers	NULL
AP-1	NULL
activity	NULL
via	NULL
the	NULL
c-Jun	NULL
N-terminal	NULL
kinase	NULL
cascade	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

16:6478-6485	NULL
.	NULL

35	NULL
.	NULL

Kilger	NULL
,	NULL
E.	NULL
,	NULL
A.	NULL
Kieser	NULL
,	NULL
M.	NULL
Baumann	NULL
,	NULL
and	NULL
W.	NULL
Hammerschmidt	NULL
.	NULL

1998	NULL
.	NULL

Epstcin-Barr	NULL
virus-mediated	NULL
B-cell	NULL
proliferation	NULL
is	NULL
dependent	NULL
upon	NULL
latent	NULL
membrane	NULL
protein	NULL
1	NULL
,	NULL
which	NULL
simulates	NULL
an	NULL
activated	NULL
CD40	NULL
receptor	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

17:1700-1709	NULL
.	NULL

36	NULL
.	NULL

King	NULL
,	NULL
W.	NULL
,	NULL
A.	NULL
L.	NULL
Thomas-Powell	NULL
,	NULL
N.	NULL
Raab-Traub	NULL
,	NULL
M.	NULL
Hawke	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1980	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
RNA	NULL
.	NULL

V.	NULL
Viral	NULL
RNA	NULL
in	NULL
a	NULL
restringently	NULL
infected	NULL
,	NULL
growth-transformed	NULL
cell	NULL
line	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

36:506-518	NULL
.	NULL

37	NULL
.	NULL

Klein	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
L.	NULL
Dombos	NULL
.	NULL

1973	NULL
.	NULL

Relationship	NULL
between	NULL
the	NULL
sensitivity	NULL
of	NULL
EBV-carrying	NULL
lymphoblastoid	NULL
lines	NULL
to	NULL
superinfection	NULL
and	NULL
the	NULL
inducibility	NULL
of	NULL
the	NULL
resident	NULL
viral	NULL
genome	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
11:327-337	NULL
.	NULL

38	NULL
.	NULL

Krikos	NULL
,	NULL
A.	NULL
,	NULL
C.	NULL
Laherty	NULL
,	NULL
and	NULL
V.	NULL
Dixit	NULL
.	NULL

1992	NULL
.	NULL

Transcriptional	NULL
activation	NULL
of	NULL
the	NULL
tumor	NULL
necrosis	NULL
factor	NULL
inducible	NULL
zinc	NULL
finger	NULL
protein	NULL
A20	NULL
is	NULL
mediated	NULL
by	NULL
«	NULL
B	NULL
elements	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267:17971-17976	NULL
.	NULL

39	NULL
.	NULL

Laherty	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
H.	NULL
M.	NULL
Hu	NULL
,	NULL
A.	NULL
W.	NULL
Opipari	NULL
,	NULL
F.	NULL
Wang	NULL
,	NULL
and	NULL
V.	NULL
M.	NULL
Dixit	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
LMP1	NULL
gene	NULL
product	NULL
induces	NULL
A20	NULL
zinc	NULL
finger	NULL
protein	NULL
expression	NULL
by	NULL
activating	NULL
nuclear	NULL
factor	NULL
kappa	NULL
B.	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267:24157-24160	NULL
.	NULL

40	NULL
.	NULL

Lenoir	NULL
,	NULL
G.	NULL
,	NULL
M.	NULL
Vuillaume	NULL
,	NULL
and	NULL
C.	NULL
Bonnardel	NULL
.	NULL

1985	NULL
.	NULL

The	NULL
use	NULL
of	NULL
lymphoma-tous	NULL
and	NULL
lymphoblastoid	NULL
cell	NULL
lines	NULL
in	NULL
the	NULL
study	NULL
of	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
,	NULL
p.	NULL
309-318	NULL
.	NULL

In	NULL
G.	NULL
Lenoir	NULL
,	NULL
G.	NULL
O'Conor	NULL
,	NULL
and	NULL
C.	NULL
Olweny	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Burkitt	NULL
's	NULL
lym-phoma	NULL
:	NULL
a	NULL
human	NULL
cancer	NULL
model	NULL
.	NULL

IARC	NULL
Publications	NULL
,	NULL
Lyon	NULL
,	NULL
France	NULL
.	NULL

41	NULL
.	NULL

Mann	NULL
,	NULL
K.	NULL
P.	NULL
,	NULL
D.	NULL
Staunton	NULL
,	NULL
and	NULL
D.	NULL
A.	NULL
Thorley-Lawson	NULL
.	NULL

1985	NULL
.	NULL

Epstein-Barr	NULL
virus-encoded	NULL
protein	NULL
found	NULL
in	NULL
plasma	NULL
membrane	NULL
in	NULL
transformed	NULL
cells	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

55:710-720	NULL
.	NULL

4688	NULL
42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

60	NULL
.	NULL

61	NULL
.	NULL

62	NULL
.	NULL

63	NULL
.	NULL

64	NULL
.	NULL

SPENDER	NULL
ET	NULL
AL	NULL
.	NULL

Meijerink	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
T.	NULL
F.	NULL
Smetsers	NULL
,	NULL
A.	NULL
W.	NULL
Sloetjes	NULL
,	NULL
E.	NULL
H.	NULL
Linders	NULL
,	NULL
and	NULL
E.	NULL
J.	NULL
Mensink	NULL
.	NULL

1995	NULL
.	NULL

Bax	NULL
mutations	NULL
in	NULL
cell	NULL
lines	NULL
derived	NULL
from	NULL
hematological	NULL
ma-lignancies	NULL
.	NULL

Leukemia	NULL
9:1828-1832	NULL
.	NULL

Memon	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
M.	NULL
B.	NULL
Moreno	NULL
,	NULL
D.	NULL
Petrak	NULL
,	NULL
and	NULL
C.	NULL
M.	NULL
Zacharchuk	NULL
.	NULL

1995	NULL
.	NULL

Bcl-2	NULL
blocks	NULL
glucocorticoid	NULL
but	NULL
not	NULL
Fas-	NULL
or	NULL
activation-induced	NULL
apoptosis	NULL
in	NULL
a	NULL
T	NULL
cell	NULL
hybridoma	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

155:4644-4652	NULL
.	NULL

Milner	NULL
,	NULL
A.	NULL
E.	NULL
,	NULL
G.	NULL
D.	NULL
Johnson	NULL
,	NULL
and	NULL
C.	NULL
D.	NULL
Gregory	NULL
.	NULL

1992	NULL
.	NULL

Prevention	NULL
of	NULL
programmed	NULL
cell	NULL
death	NULL
in	NULL
Burkitt	NULL
lymphoma	NULL
cell	NULL
lines	NULL
by	NULL
bel-2-dependent	NULL
and	NULL
-independent	NULL
mechanisms	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
52:636-644	NULL
.	NULL

Moberg	NULL
,	NULL
K.	NULL
,	NULL
M.	NULL
Starz	NULL
,	NULL
and	NULL
J.	NULL
Lees	NULL
.	NULL

1996	NULL
.	NULL

E2F-4	NULL
switches	NULL
from	NULL
p130	NULL
to	NULL
p107	NULL
and	NULL
pRb	NULL
in	NULL
response	NULL
to	NULL
cell	NULL
cycle	NULL
reentry	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16:1436-1449	NULL
.	NULL

Moreno	NULL
,	NULL
M.	NULL
B.	NULL
,	NULL
S.	NULL
A.	NULL
Memon	NULL
,	NULL
and	NULL
C.	NULL
M.	NULL
Zacharchuk	NULL
,	NULL
1996	NULL
.	NULL

Apoptosis	NULL
signaling	NULL
pathways	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
:	NULL
differential	NULL
activity	NULL
of	NULL
Bel-2	NULL
and	NULL
IL-1	NULL
beta-converting	NULL
enzyme	NULL
family	NULL
protease	NULL
inhibitors	NULL
on	NULL
glucocorticoid-	NULL
and	NULL
Fas-mediated	NULL
cytotoxicity	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

157:3845-3849	NULL
.	NULL

Mosialos	NULL
,	NULL
G.	NULL
,	NULL
M.	NULL
Birkenbach	NULL
,	NULL
R.	NULL
Yalamanchili	NULL
,	NULL
T.	NULL
VanArsdale	NULL
,	NULL
C.	NULL
Ware	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
transforming	NULL
protein	NULL
LMP1	NULL
engages	NULL
signaling	NULL
proteins	NULL
for	NULL
the	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptor	NULL
family	NULL
.	NULL

Cell	NULL
80	NULL
:	NULL
389-399	NULL
.	NULL

Oltvai	NULL
,	NULL
Z.	NULL
N.	NULL
,	NULL
and	NULL
S.	NULL
J.	NULL
Korsmeyer	NULL
.	NULL

1994	NULL
.	NULL

Checkpoints	NULL
of	NULL
ducling	NULL
dimers	NULL
foil	NULL
death	NULL
wishes	NULL
.	NULL

Cell	NULL
79:189-192	NULL
.	NULL

Oltvai	NULL
,	NULL
Z.	NULL
N.	NULL
,	NULL
C.	NULL
L.	NULL
Milliman	NULL
,	NULL
and	NULL
S.	NULL
J.	NULL
Korsmeyer	NULL
.	NULL

1993	NULL
.	NULL

Bcl-2	NULL
heterodimerizes	NULL
in	NULL
vivo	NULL
with	NULL
a	NULL
conserved	NULL
homolog	NULL
,	NULL
Bax	NULL
,	NULL
that	NULL
accelerates	NULL
programmed	NULL
cell	NULL
death	NULL
.	NULL

Cell	NULL
74:609-619	NULL
.	NULL

Opipari	NULL
,	NULL
A.	NULL
,	NULL
M.	NULL
Boguski	NULL
,	NULL
and	NULL
V.	NULL
Dixit	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
A20	NULL
cDNA	NULL
induced	NULL
by	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
encodes	NULL
a	NULL
novel	NULL
type	NULL
of	NULL
zinc	NULL
finger	NULL
protein	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

265:14705-14708	NULL
.	NULL

Opipari	NULL
,	NULL
A.	NULL
,	NULL
Jr.	NULL
,	NULL
H.	NULL
M.	NULL
Hu	NULL
,	NULL
R.	NULL
Yabkowitz	NULL
,	NULL
and	NULL
V.	NULL
M.	NULL
Dixit	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
A20	NULL
zinc	NULL
finger	NULL
protein	NULL
protects	NULL
cells	NULL
from	NULL
tumor	NULL
necrosis	NULL
factor	NULL
cytotoxicity	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267:12424-12427	NULL
.	NULL

Owen-Schaub	NULL
,	NULL
L.	NULL
B.	NULL
,	NULL
R.	NULL
Radinsky	NULL
,	NULL
E.	NULL
Kruzel	NULL
,	NULL
K.	NULL
Berry	NULL
,	NULL
and	NULL
S.	NULL
Yonehara	NULL
.	NULL

1994	NULL
.	NULL

Anti-Fas	NULL
on	NULL
nonhematopoietic	NULL
tumors	NULL
:	NULL
levels	NULL
of	NULL
Fas/APO-1	NULL
and	NULL
bel-2	NULL
are	NULL
not	NULL
predictive	NULL
of	NULL
biological	NULL
responsiveness	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

54	NULL
:	NULL
1580-1586	NULL
.	NULL

Packham	NULL
,	NULL
G.	NULL
,	NULL
M.	NULL
Brimmell	NULL
,	NULL
and	NULL
J.	NULL
Cleveland	NULL
.	NULL

1997	NULL
.	NULL

Mammalian	NULL
cells	NULL
express	NULL
two	NULL
differently	NULL
localized	NULL
Bag-1	NULL
isoforms	NULL
generated	NULL
by	NULL
alternative	NULL
translation	NULL
initiation	NULL
.	NULL

Biochem	NULL
.	NULL

J	NULL
.	NULL

328:808-813	NULL
.	NULL

Packham	NULL
,	NULL
G.	NULL
,	NULL
J.	NULL
Labti	NULL
,	NULL
B	NULL
.	NULL

Fee	NULL
,	NULL
J.	NULL
Gawn	NULL
,	NULL
E.	NULL
Coustan-Smith	NULL
,	NULL
D.	NULL
Campana	NULL
,	NULL
L.	NULL
Douglas	NULL
,	NULL
V.	NULL
Kidd	NULL
,	NULL
S.	NULL
Ghosh	NULL
,	NULL
and	NULL
J.	NULL
Cleveland	NULL
.	NULL

1997	NULL
.	NULL

Fas	NULL
activates	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
induces	NULL
apoptosis	NULL
in	NULL
T	NULL
cell	NULL
lines	NULL
by	NULL
signaling	NULL
pathways	NULL
distinct	NULL
from	NULL
those	NULL
activated	NULL
by	NULL
TNF-	NULL
«	NULL
.	NULL

Cell	NULL
Death	NULL
Differ	NULL
.	NULL

4:130-139	NULL
.	NULL

Pagano	NULL
,	NULL
M.	NULL
,	NULL
S.	NULL
Tam	NULL
,	NULL
A.	NULL
Theodoras	NULL
,	NULL
P.	NULL
Beer-Romero	NULL
,	NULL
G.	NULL
Sal	NULL
,	NULL
V.	NULL
Chau	NULL
,	NULL
P.	NULL
Yew	NULL
,	NULL
G.	NULL
Dracetta	NULL
,	NULL
and	NULL
M.	NULL
Rolfe	NULL
.	NULL

1995	NULL
.	NULL

Role	NULL
of	NULL
the	NULL
ubiquitin-proteasome	NULL
pathway	NULL
in	NULL
regulating	NULL
abundance	NULL
of	NULL
the	NULL
cyclin	NULL
dependent	NULL
kinase	NULL
inhibitor	NULL
p27	NULL
.	NULL

Science	NULL
269:682-685	NULL
.	NULL

Parker	NULL
,	NULL
G.	NULL
,	NULL
R.	NULL
Touitou	NULL
,	NULL
and	NULL
M.	NULL
Allday	NULL
.	NULL

Submitted	NULL
for	NULL
publication	NULL
.	NULL

Pulvertaft	NULL
,	NULL
R.	NULL
1965	NULL
.	NULL

A	NULL
study	NULL
of	NULL
malignant	NULL
tumours	NULL
in	NULL
Nigeria	NULL
in	NULL
short	NULL
term	NULL
tissue	NULL
culture	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Pathol	NULL
.	NULL

18:261-273	NULL
.	NULL

Reed	NULL
,	NULL
J	NULL
.	NULL

1997	NULL
.	NULL

Double	NULL
identity	NULL
for	NULL
proteins	NULL
of	NULL
the	NULL
Bcl-2	NULL
family	NULL
.	NULL

Nature	NULL
387	NULL
:	NULL
773-776	NULL
.	NULL

Reed	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
T.	NULL
Miyashita	NULL
,	NULL
S.	NULL
Takayama	NULL
,	NULL
H.	NULL
G.	NULL
Wang	NULL
,	NULL
T.	NULL
Sato	NULL
,	NULL
S.	NULL
Krajewski	NULL
,	NULL
C.	NULL
Aime-Sempe	NULL
,	NULL
S.	NULL
Bodrug	NULL
,	NULL
S.	NULL
Kitada	NULL
,	NULL
and	NULL
M.	NULL
Hanada	NULL
.	NULL

1996	NULL
.	NULL

BCL-2	NULL
family	NULL
proteins	NULL
:	NULL
regulators	NULL
of	NULL
cell	NULL
death	NULL
involved	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
cancer	NULL
and	NULL
resistance	NULL
to	NULL
therapy	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
.	NULL

Biochem	NULL
.	NULL

60:23-32	NULL
.	NULL

Reynolds	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
T.	NULL
Yang	NULL
,	NULL
L.	NULL
Qian	NULL
,	NULL
J.	NULL
D.	NULL
Jenkinson	NULL
,	NULL
P.	NULL
Zhou	NULL
,	NULL
A.	NULL
Eastman	NULL
,	NULL
and	NULL
R.	NULL
W.	NULL
Craig	NULL
.	NULL

1994	NULL
.	NULL

Mcl-1	NULL
,	NULL
a	NULL
member	NULL
of	NULL
the	NULL
Bcl-2	NULL
family	NULL
,	NULL
delays	NULL
apoptosis	NULL
induced	NULL
by	NULL
c-Myc	NULL
overexpression	NULL
in	NULL
Chinese	NULL
hamster	NULL
ovary	NULL
cells	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

54:6348-6352	NULL
.	NULL

Rickinson	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1996	NULL
.	NULL

Epstein-Barr	NULL
Virus	NULL
,	NULL
p.	NULL
2397-2446	NULL
.	NULL

In	NULL
B.	NULL
N.	NULL
Fields	NULL
,	NULL
P.	NULL
M.	NULL
Knipe	NULL
,	NULL
and	NULL
P.	NULL
M.	NULL
Howley	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Fields	NULL
virology	NULL
.	NULL

Lippin-cott-Raven	NULL
,	NULL
Philadelphia	NULL
,	NULL
Pa.	NULL
Rowe	NULL
,	NULL
M.	NULL
,	NULL
D.	NULL
T.	NULL
Rowe	NULL
,	NULL
C.	NULL
D.	NULL
Gregory	NULL
,	NULL
L.	NULL
S.	NULL
Young	NULL
,	NULL
P.	NULL
J.	NULL
Farrell	NULL
,	NULL
H.	NULL
Rupani	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Rickinson	NULL
.	NULL

1987	NULL
.	NULL

Differences	NULL
in	NULL
B	NULL
cell	NULL
growth	NULL
phenotype	NULL
reflect	NULL
novel	NULL
patterns	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
latent	NULL
gene	NULL
expression	NULL
in	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
cells	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

62743-2751	NULL
.	NULL

Saegusa	NULL
,	NULL
M.	NULL
,	NULL
Y.	NULL
Takano	NULL
,	NULL
M.	NULL
Hashimura	NULL
,	NULL
Y.	NULL
Shoji	NULL
,	NULL
and	NULL
I.	NULL
Okayasu	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
possible	NULL
role	NULL
of	NULL
bel-2	NULL
expression	NULL
in	NULL
the	NULL
progression	NULL
of	NULL
tumors	NULL
of	NULL
the	NULL
uterine	NULL
cervix	NULL
.	NULL

Cancer	NULL
76:2297-2303	NULL
.	NULL

Sandberg	NULL
,	NULL
M.	NULL
,	NULL
W.	NULL
Hammerschmidt	NULL
,	NULL
and	NULL
B.	NULL
Sugden	NULL
.	NULL

1997	NULL
.	NULL

Characterization	NULL
65	NULL
.	NULL

66	NULL
.	NULL

67	NULL
.	NULL

68	NULL
.	NULL

69	NULL
.	NULL

70	NULL
.	NULL

71	NULL
.	NULL

72	NULL
.	NULL

73	NULL
.	NULL

74	NULL
.	NULL

75	NULL
.	NULL

76	NULL
.	NULL

77	NULL
.	NULL

78	NULL
.	NULL

79	NULL
.	NULL

80	NULL
.	NULL

81	NULL
.	NULL

82	NULL
.	NULL

83	NULL
.	NULL

84	NULL
.	NULL

85	NULL
.	NULL

86	NULL
.	NULL

J.	NULL
Virou	NULL
.	NULL

of	NULL
LMP1	NULL
's	NULL
association	NULL
with	NULL
TRAF1	NULL
,	NULL
TRAF2	NULL
,	NULL
and	NULL
TRAF3	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

71	NULL
:	NULL
4649-4656	NULL
.	NULL

Sardet	NULL
,	NULL
C.	NULL
,	NULL
L.	NULL
LeCam	NULL
,	NULL
E.	NULL
Fabrizio	NULL
,	NULL
and	NULL
M.	NULL
Vidal	NULL
.	NULL

1997	NULL
.	NULL

E2Fs	NULL
and	NULL
the	NULL
retinoblastoma	NULL
protein	NULL
family	NULL
,	NULL
p.	NULL
1-57	NULL
.	NULL

In	NULL
M.	NULL
Yaniv	NULL
and	NULL
J.	NULL
Ghysdael	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Oncogenes	NULL
as	NULL
transcriptional	NULL
regulators	NULL
.	NULL

Birkhauser	NULL
Verlag	NULL
,	NULL
Basel	NULL
,	NULL
Switzer-land	NULL
.	NULL

Sarma	NULL
,	NULL
V.	NULL
,	NULL
Z.	NULL
Lin	NULL
,	NULL
L.	NULL
Clark	NULL
,	NULL
B.	NULL
M.	NULL
Rust	NULL
,	NULL
M.	NULL
Tewari	NULL
,	NULL
R.	NULL
J.	NULL
Noelle	NULL
,	NULL
and	NULL
V.	NULL
M.	NULL
Dixit	NULL
.	NULL

1995	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
B-cell	NULL
surface	NULL
receptor	NULL
CD40	NULL
induces	NULL
A20	NULL
,	NULL
a	NULL
novel	NULL
zinc	NULL
finger	NULL
protein	NULL
that	NULL
inhibits	NULL
apoptosis	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:12343-12346	NULL
.	NULL

Sato	NULL
,	NULL
T.	NULL
,	NULL
M.	NULL
Hanada	NULL
,	NULL
S.	NULL
Bodrug	NULL
,	NULL
S.	NULL
Irie	NULL
,	NULL
N.	NULL
Iwama	NULL
,	NULL
L.	NULL
H.	NULL
Boise	NULL
,	NULL
C.	NULL
B.	NULL
Thompson	NULL
,	NULL
E.	NULL
Golemis	NULL
,	NULL
L.	NULL
Fong	NULL
,	NULL
H.	NULL
G.	NULL
Wang	NULL
,	NULL
and	NULL
J.	NULL
C.	NULL
Reed	NULL
.	NULL

1994	NULL
.	NULL

Interactions	NULL
among	NULL
members	NULL
of	NULL
the	NULL
Bcl-2	NULL
protein	NULL
family	NULL
analyzed	NULL
with	NULL
a	NULL
yeast	NULL
two-hybrid	NULL
system	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91:9238-9242	NULL
.	NULL

Sedlak	NULL
,	NULL
T.	NULL
W.	NULL
,	NULL
Z.	NULL
N.	NULL
Oltvai	NULL
,	NULL
E.	NULL
Yang	NULL
,	NULL
K.	NULL
Wang	NULL
,	NULL
L.	NULL
H.	NULL
Boise	NULL
,	NULL
C.	NULL
B.	NULL
Thompson	NULL
,	NULL
and	NULL
S.	NULL
J.	NULL
Korsmeyer	NULL
.	NULL

1995	NULL
.	NULL

Multiple	NULL
Bcl-2	NULL
family	NULL
members	NULL
demonstrate	NULL
selective	NULL
dimerizations	NULL
with	NULL
Bax	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92:7834-7838	NULL
.	NULL

Sheaff	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
M.	NULL
Groudine	NULL
,	NULL
M.	NULL
Gordon	NULL
,	NULL
J.	NULL
M.	NULL
Roberts	NULL
,	NULL
and	NULL
B.	NULL
E.	NULL
Clurman	NULL
.	NULL

1997	NULL
.	NULL

Cyclin	NULL
E-CDK2	NULL
is	NULL
a	NULL
regulator	NULL
of	NULL
p27Kip1	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

11:1464-1478	NULL
.	NULL

Shima	NULL
,	NULL
Y.	NULL
,	NULL
N.	NULL
Nishimoto	NULL
,	NULL
A.	NULL
Ogata	NULL
,	NULL
Y.	NULL
Fujii	NULL
,	NULL
K.	NULL
Yoshizaki	NULL
,	NULL
and	NULL
T.	NULL
Kishimoto	NULL
.	NULL

1995	NULL
.	NULL

Myeloma	NULL
cells	NULL
express	NULL
Fas	NULL
antigen/APO-1	NULL
(	NULL
CD95	NULL
)	NULL
but	NULL
only	NULL
some	NULL
are	NULL
sensitive	NULL
to	NULL
anti-Fas	NULL
antibody	NULL
resulting	NULL
in	NULL
apoptosis	NULL
.	NULL

Blood	NULL
85:757-764	NULL
.	NULL

Sinclair	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
and	NULL
P.	NULL
J.	NULL
Farrell	NULL
.	NULL

1995	NULL
.	NULL

Host	NULL
cell	NULL
requirements	NULL
for	NULL
efficient	NULL
infection	NULL
of	NULL
quiescent	NULL
primary	NULL
B	NULL
lymphocytes	NULL
by	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

69:5461-5468	NULL
.	NULL

Sinclair	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
I	NULL
Palmero	NULL
,	NULL
G.	NULL
Peters	NULL
,	NULL
and	NULL
P.	NULL
J.	NULL
Farrell	NULL
.	NULL

1994	NULL
.	NULL

EBNA-2	NULL
and	NULL
EBNA-LP	NULL
cooperate	NULL
to	NULL
cause	NULL
GO	NULL
to	NULL
G1	NULL
transition	NULL
during	NULL
immortalization	NULL
of	NULL
resting	NULL
human	NULL
B	NULL
lymphocytes	NULL
by	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

13:3321-3328	NULL
.	NULL

Smith	NULL
,	NULL
E.	NULL
,	NULL
G.	NULL
Leone	NULL
,	NULL
J.	NULL
Degregori	NULL
,	NULL
L.	NULL
Jakoi	NULL
,	NULL
and	NULL
J.	NULL
Nevins	NULL
.	NULL

1996	NULL
.	NULL

The	NULL
accumulation	NULL
of	NULL
an	NULL
E2F-p130	NULL
transcriptional	NULL
repressor	NULL
distinguishes	NULL
a	NULL
Gp	NULL
cell	NULL
state	NULL
from	NULL
a	NULL
G	NULL
;	NULL
cell	NULL
state	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16:6965-6976	NULL
.	NULL

Strobel	NULL
,	NULL
T.	NULL
,	NULL
L.	NULL
Swanson	NULL
,	NULL
S.	NULL
Korsmeyer	NULL
,	NULL
and	NULL
S.	NULL
Cannistra	NULL
.	NULL

1997	NULL
.	NULL

Radiation-induced	NULL
apoptosis	NULL
is	NULL
not	NULL
enhanced	NULL
by	NULL
expression	NULL
of	NULL
either	NULL
p53	NULL
or	NULL
BAX	NULL
in	NULL
SW626	NULL
ovarian	NULL
cancer	NULL
cells	NULL
.	NULL

Oncogene	NULL
14:2753-2758	NULL
.	NULL

Sugano	NULL
,	NULL
N.	NULL
,	NULL
W.	NULL
Chen	NULL
,	NULL
M.	NULL
Roberts	NULL
,	NULL
and	NULL
N.	NULL
Cooper	NULL
.	NULL

1997	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
binding	NULL
to	NULL
CD21	NULL
activates	NULL
the	NULL
initial	NULL
viral	NULL
promoter	NULL
via	NULL
NF-kappa	NULL
B	NULL
induc-tion	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

186:731-737	NULL
.	NULL

Takada	NULL
,	NULL
K.	NULL
,	NULL
K.	NULL
Horinouchi	NULL
,	NULL
Y.	NULL
Ono	NULL
,	NULL
T.	NULL
Aya	NULL
,	NULL
T.	NULL
Osato	NULL
,	NULL
M.	NULL
Takahashi	NULL
,	NULL
and	NULL
S.	NULL
Hayasaka	NULL
.	NULL

1991	NULL
.	NULL

An	NULL
Epstein-Barr	NULL
virus-producer	NULL
line	NULL
Akata	NULL
:	NULL
establishment	NULL
of	NULL
the	NULL
cell	NULL
line	NULL
and	NULL
analysis	NULL
of	NULL
viral	NULL
DNA	NULL
.	NULL

Virus	NULL
Genes	NULL
5:147-156	NULL
.	NULL

Takayama	NULL
,	NULL
S.	NULL
,	NULL
T.	NULL
Sato	NULL
,	NULL
S.	NULL
Krajewski	NULL
,	NULL
K.	NULL
Kochel	NULL
,	NULL
S.	NULL
Irie	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Millan	NULL
,	NULL
and	NULL
J.	NULL
C.	NULL
Reed	NULL
.	NULL

1995	NULL
.	NULL

Cloning	NULL
and	NULL
functional	NULL
analysis	NULL
of	NULL
BAG-1	NULL
:	NULL
a	NULL
novel	NULL
Bcl-2-binding	NULL
protein	NULL
with	NULL
anti-cell	NULL
death	NULL
activity	NULL
.	NULL

Cell	NULL
80:279-284	NULL
.	NULL

Vairo	NULL
,	NULL
G.	NULL
,	NULL
D.	NULL
Livingston	NULL
,	NULL
and	NULL
D.	NULL
Ginsberg	NULL
.	NULL

1995	NULL
.	NULL

Functional	NULL
interaction	NULL
between	NULL
E2F-4	NULL
and	NULL
p130	NULL
:	NULL
evidence	NULL
for	NULL
distinct	NULL
mechanisms	NULL
underlying	NULL
growth	NULL
suppression	NULL
by	NULL
different	NULL
retinoblastoma	NULL
protein	NULL
family	NULL
members	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

9:869-881	NULL
.	NULL

Van	NULL
der	NULL
Sman	NULL
,	NULL
J.	NULL
,	NULL
N.	NULL
S.	NULL
B.	NULL
Thomas	NULL
,	NULL
and	NULL
E.	NULL
Lam	NULL
.	NULL

Modulation	NULL
of	NULL
E2F	NULL
complexes	NULL
during	NULL
G	NULL
,	NULL
to	NULL
S	NULL
phase	NULL
transition	NULL
in	NULL
human	NULL
primary	NULL
B	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
in	NULL
press	NULL
.	NULL

Vlach	NULL
,	NULL
J.	NULL
,	NULL
S.	NULL
Hennecke	NULL
,	NULL
and	NULL
B.	NULL
Amati	NULL
.	NULL

1997	NULL
.	NULL

Phosphorylation-dependent	NULL
degradation	NULL
of	NULL
the	NULL
cyclin-dependent	NULL
kinase	NULL
inhibitor	NULL
p27	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

16	NULL
:	NULL
5334-5344	NULL
.	NULL

Wang	NULL
,	NULL
H.	NULL
,	NULL
R.	NULL
J	NULL
.	NULL

Grand	NULL
,	NULL
A.	NULL
E.	NULL
Milner	NULL
,	NULL
R.	NULL
J.	NULL
Armitage	NULL
,	NULL
J.	NULL
Gordon	NULL
,	NULL
and	NULL
C.	NULL
D.	NULL
Gregory	NULL
.	NULL

1996	NULL
.	NULL

Repression	NULL
of	NULL
apoptosis	NULL
in	NULL
human	NULL
B-lymphoma	NULL
cells	NULL
by	NULL
CD40-ligand	NULL
and	NULL
Bcl-2	NULL
:	NULL
relationship	NULL
to	NULL
the	NULL
cell-cycle	NULL
and	NULL
role	NULL
of	NULL
the	NULL
retinoblastoma	NULL
protein	NULL
.	NULL

Oncogene	NULL
13:373-379	NULL
.	NULL

Wilson	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
G.	NULL
Miller	NULL
.	NULL

1979	NULL
.	NULL

Recovery	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
from	NULL
non-producer	NULL
neonatal	NULL
human	NULL
lymphoid	NULL
cell	NULL
transformants	NULL
.	NULL

Virology	NULL
95:351-358	NULL
.	NULL

Yang	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
S.	NULL
J.	NULL
Korsmeyer	NULL
.	NULL

1996	NULL
.	NULL

Molecular	NULL
thanatopsis	NULL
:	NULL
a	NULL
discourse	NULL
on	NULL
the	NULL
BCL2	NULL
family	NULL
and	NULL
cell	NULL
death	NULL
.	NULL

Blood	NULL
88:386-401	NULL
.	NULL

Yang	NULL
,	NULL
E.	NULL
,	NULL
J.	NULL
Zha	NULL
,	NULL
J.	NULL
Jockel	NULL
,	NULL
L.	NULL
H.	NULL
Boise	NULL
,	NULL
C.	NULL
B.	NULL
Thompson	NULL
,	NULL
and	NULL
S.	NULL
J.	NULL
Korsmeyer	NULL
.	NULL

1995	NULL
.	NULL

Bad	NULL
,	NULL
a	NULL
heterodimeric	NULL
partner	NULL
for	NULL
Bcl-XL	NULL
and	NULL
Bel-2	NULL
,	NULL
displaces	NULL
Bax	NULL
and	NULL
promotes	NULL
cell	NULL
death	NULL
.	NULL

Cell	NULL
80:285-291	NULL
.	NULL

Yin	NULL
,	NULL
X.	NULL
,	NULL
Z.	NULL
Oltvai	NULL
,	NULL
and	NULL
S.	NULL
Korsmeyer	NULL
.	NULL

1994	NULL
.	NULL

BH1	NULL
and	NULL
BH2	NULL
domains	NULL
of	NULL
Bcl-2	NULL
are	NULL
required	NULL
for	NULL
inhibition	NULL
of	NULL
apoptosis	NULL
and	NULL
heterodimerization	NULL
with	NULL
Bax	NULL
.	NULL

Nature	NULL
369:321-323	NULL
.	NULL

Zha	NULL
,	NULL
H.	NULL
,	NULL
C.	NULL
Aime-Sempe	NULL
,	NULL
T.	NULL
Sato	NULL
,	NULL
and	NULL
J.	NULL
C.	NULL
Reed	NULL
.	NULL

1996	NULL
.	NULL

Proapoptotic	NULL
protein	NULL
Bax	NULL
heterodimerizes	NULL
with	NULL
Bcl-2	NULL
and	NULL
homodimerizes	NULL
with	NULL
Bax	NULL
via	NULL
a	NULL
novel	NULL
domain	NULL
(	NULL
BH3	NULL
)	NULL
distinct	NULL
from	NULL
BH1	NULL
and	NULL
BH2	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271:7440-7444	NULL
.	NULL

